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Abstract
Skeletal muscle atrophy is a hallmark of many pathologies and is associated with disease
prognosis, quality of life, and mortality. Specifically, lack of contractile activity of the muscle can
result in disuse-associated atrophy. Disuse-induced atrophy is a common phenomenon in
intensive care unit (ICU) patients and significantly impacts patient prognosis and ability to
transition of out of intensive care. However, effective therapeutics to mitigate disuse-associated
atrophy do not exist, clearly demonstrating the scientific and clinical need to further understand
mechanisms contributing to disuse atrophy. In particular, a significant portion of the scientific
literature has utilized male models, yet there is increasing evidence that ICU-associated muscle
atrophy may affect females more, demonstrating the necessity to investigate myopathies in both
sexes. Mitochondrial aberrations have recently been implicated as a potential therapeutic target
to mitigate atrophy. However, to my knowledge mitochondrial aberrations and mitochondrially
targeted therapeutics for disuse atrophy have not been investigated in both sexes. Therefore, the
purpose of this dissertation was to investigate mitochondrial alterations during the development
of disuse atrophy and how biological sex influences the rate of muscle pathologies as well as
overall mechanisms contributing to muscle atrophy. To accomplish this, I completed a series of
studies using a hindlimb unloading model of disuse in male and female mice. For study 1, male
and female mice were hindlimb unloaded for 0 hrs, 24 hrs, 48 hrs, 72 hrs, or 168 hrs to induce
muscle atrophy, after designated time points hindlimb muscles were harvested for measures of
mitochondrial quality. I find males exhibit mitochondrial stress before the onset of disuse atrophy,
whereas females protect mitochondrial quality during disuse atrophy. Yet, females appear to
experience disuse atrophy faster compared to males. In study 2, I utilized two separate strains of
mice that targeted different components of mitochondrial quality. One strain of mice
overexpressed the transcriptional coactivator PGC1α, resulting in increased mitochondrial
content. The other strain of mice overexpressed mitochondrially-targeted catalase gene (MCAT).
Male and female mice of both strains were hindlimb unloaded for 168 hrs to induce disuse atrophy.

While neither intervention mitigated muscle loss in male mice, MCAT females appeared to
alleviate muscle loss compared to their WT counterparts, particularly in the atrophy-prone soleus
muscle. In study 3 I investigated the potential influence of sex hormones on the development of
muscle atrophy. C2C12 myotubes were treated with various atrophic stimuli and incubated with
physiological concentrations of testosterone, estrogen, progesterone or estrogen combined with
progesterone. Overall, sex hormones appear protective against atrophic stimuli; however the
degree of protection and mechanisms contributing to protections vary depending on the atrophic
stimulus. More so, estrogen and progesterone can have opposite effects on cellular signaling
cascades, depending on the atrophic stimulus. Taken together, this dissertation provides
evidence for sex-mediated differences in the progression and development of disuse muscle
atrophy and clearly demonstrates the need to investigate myopathies and potential muscle
therapeutics in male and female organisms; clearly it is time for more muscle biologists to start
“talk[ing] about sex”.
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Chapter I: Introduction
Skeletal muscle is among the most metabolically active organs in the human body and
has significant implications for health and longevity. During many chronic diseases, muscle
wasting is a concurrent pathology and a significant predictor of mortality and morbidity(1, 2).
Nutritional interventions are ineffective treatments (3, 4) and overall there are not currently
effective treatments for muscle atrophies. Therefore, a critical need remains to understand
mechanisms contributing to atrophic pathologies. Muscle loss presents differently between males
and females in many different pathologies (5-10). However, most research investigating muscle
wasting only investigates these pathologies using male models (11-15), resulting in a significant
chasm in the literature examining mechanisms contributing to muscle pathologies within females.
Currently, mitochondrial degeneration is believed to be a predominant mechanism for the
development of muscle atrophy (16-18). Whereby excessive generation of reactive oxygen
species induces mitochondrial dysfunction, and subsequent catabolism(16, 17). Our laboratory
recently demonstrated that mitochondrial deterioration occurs before the development of muscle
wasting in cancer-cachexia (19). Therefore, mitochondrial dysfunction may be a common
mechanism contributing to the development of muscle atrophies. Mitochondrial characteristics
differ between sexes (20-22), yet there is noticeable lack of literature investigating sexual
dimorphisms in relation to these muscle pathologies. As such, for this dissertation I have
compared muscle alterations between sexes during disuse atrophy. The central hypothesis of my
dissertation is males and females will exhibit different mitochondrial mechanisms contributing to
the development of disuse atrophy.
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Chapter II: Review of Literature
Megan E. Rosa-Caldwell, Nicholas P. Greene
Muscle makes up ~47-60% of lean body mass in men and women and is one of the
greatest contributors to whole body energy expenditure (1). Therefore, maintaining skeletal
muscle health is critical to maintaining health and longevity throughout the lifetime. Various
pathological conditions, such as prolonged periods of disuse, cancer cachexia, burn injuries, and
others cause dramatic muscle atrophy, which in turn relates to a decrease in overall quality of life
and increased mortality (2). Specifically, disuse atrophy, a common occurrence with prolonged
bed rest, casting and space-flight, develops rapidly and significantly increases mortality and
morbidity in these populations (2, 3). This is particularly true in Intensive Care Unit (ICU) patients,
where greater muscle loss is associated with increased ICU-treatment time and mortality (4-7).
Interestingly, these disuse-induced pathologies appear to discriminate between biological
sexes, with females tending to have faster onset of muscle loss compared to males (8) which has
been postulated to correspond to increased mortality in female ICU patients (9). However, until
recently, investigations into disuse pathologies have primarily been conducted in only one sex(1020) despite the influence of biological sex in many diseases (21-26). However, the differences
and similarities between males and females during atrophic pathologies is not currently codified.
Therefore, the purpose of this review is to examine the current literature on various physiological
processes between males and females potentially contributing to muscle health, including:
general muscle phenotype, response to catabolic and anabolic stimuli, hormonal contributions to
muscle health, as well as mitochondrial profiles.
a. Muscle Phenotypes between Males and Females
The maintenance of muscle size relies on a delicate balance between protein synthesis
and degradation, whereby an increased protein synthesis:degration ratio results in muscle
hypertrophy and decreased synthesis:degration ratio results in muscle atrophy. Many diseases
are associated with reduced health outcomes with muscle loss(27, 28). Recent works have
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established mechanisms contributing to these muscle pathologies are different depending on the
disease, making effective treatment options difficult. For example, cancer is also known to cause
marked muscle and body fat loss, with body weight losses being strongly associated with
mortality. However, this particular form of atrophy appears to be related to the inflammatory action
of the tumor-host interactions (29-32), whereas disuse atrophy does not typically display this
classical inflamed phenotype (33). Until recently, it was thought that processes contributing to
muscle loss were not sex specific. However, recent works have begun to establish differences
between males and females on responsiveness to atrophic and hypertrophic stimuli. In this
section I will focus specifically on sex differences in overall muscle phenotype and how these
differences may contribute to differential sensitivity to catabolic and anabolic factors as well as
highlight areas for further research (Figure 1).
i.

Fiber Type Differences between Males and Females and Susceptibility for Disuse
Atrophy
Data have begun to demonstrate muscle composition differences between males and

females. Females tend to rely more oxidative metabolism compared to males (34),
correspondingly, females also have greater relative content of Type I muscle fibers compared to
males within the same muscle (35, 36). Works have previously established different muscle
pathologies differently affect different muscle fibers (37), with cancer cachexia more strongly
influencing glycolytic fibers compared to oxidative(38-40) and disuse atrophy preferentially
selecting for oxidative fibers (14, 33, 41). Although it is not completely understood why disuse
atrophy more radically impacts oxidative fibers, the differential content of fibers between males
and females may be an important consideration for future research investigating sex as a
biological variable with muscle atrophies.
ii.

Disuse Muscle Loss between Males and Females
While muscle loss occurs in both males and females across a variety of pathologies,

different pathologies appear to differentially affect males and females(8, 9, 42-46). For example,
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during aging-induced atrophy, females experience a greater shift towards smaller fibers compared
to males (47). However, during inflammation-based muscle pathologies, such as cancer cachexia,
males tend to have greater muscle losses and subsequent side effects compared to females (4345, 48). Overall, suggesting that males and females exhibit differing muscle atrophy responses
depending on the precise stimuli. Specific to disuse atrophy, female mice have been shown to
exhibit a greater percent loss of soleus mass compared to males during hindlimb unloading (49),
suggesting females may be particularly susceptible to disuse atrophy compared to males.
However, it is not currently clear if this is due to a higher percentage of disuse-susceptible Type
I fibers in females or innate differences in muscle physiology. Clinically, recent works suggest
females are more likely to succumb to Intensive Care Unit (ICU)-associated muscle weakness(8),
potentially leading to more ICU-associated deaths (9). Taken together, these data clearly suggest
different responses to atrophic stimuli between males and females and highlight the need for
further research investigating mechanisms for muscle wasting across a variety of pathologies.
iii.

Sex Difference in Anabolic and Catabolic Factors
As the maintenance of muscle mass depends on the balance of anabolic and catabolic

factors, here I will briefly describe known differences between males and females on mediators
of protein synthesis and degradation. Briefly, one of the major mediators of protein synthesis is
the mammalian target of rapamycin (mTOR). Activation of mTOR by anabolic stimuli (resistance
exercise, insulin, amino acids etc.) results in phosphorylation of 4EBP-1 and S6K1 proteins,
allowing for mRNA translation and subsequent protein synthesis (50). In general, most studies
have found that males and females have similar mTOR activation and subsequent protein
synthesis with anabolic stimuli such as food consumption or resistance exercise (51-55).
However, there still remains some controversy on sex differences with regards to anabolic
processes. For example, some literature has suggested increased protein synthesis measured
by fractional myofibrillar synthesis rates in females compared to males with whey ingestion (56)
whereas others have found males to have greater increases in muscle protein synthesis
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compared to females after weeks of sprint interval training (57). Regardless, the current literature
tends to favor no sex-mediated differences on mTOR activation and subsequent protein synthesis
(51-55).
Conversely, recent evidence suggests potential sex differences in satellite cell activation
and proliferation. Briefly, satellite cells are myogenic stem cells, activated during regenerative
stimuli, such as resistance exercise or muscle damage (58). Once activated, satellite cells
proliferate to form new myonuclei and facilitate muscle hypertrophy or regeneration, depending
on the specific stimuli (58). A more through overview of satellite cell activation and proliferation
has been reviewed elsewhere (58). Male satellite cells appear to have more mRNA related to
differentiation and hypertrophy such as Myogenin and MyoD compared to females (59) and
appear to also have greater proliferative capacity compared to females (60, 61). For example, it
was recently found that young male mice tend to have greater numbers of satellite cells compared
to female mice (61), satellite cells derived from male poultry also have greater proliferation in vitro
(60). These differences may in part be due to differences in testosterone-mediated satellite cell
proliferation (62). For example, in vitro culture of satellite cells treated with serum from castrated
males demonstrate reduced proliferation compared to serum from uncastrated males (63). In vivo
loss of testosterone in various mammalian species results in reduced satellite cell content and
reduced muscle size (64, 65). Furthermore, adding supplemental testosterone in males mitigates
these aberrations and can result in greater overall satellite cell content compared to control
animals (64-66). This hypothesis of testosterone mediated satellite cell proliferation is further
corroborated by research finding testosterone treatment in female mice produced an increase in
the number of myonuclei (67). Taken together, the aggregate of these studies strongly suggest
testosterone mediates greater satellite cell content in males, possibly allowing for greater muscle
size. However, we should note there has been recent controversy on the necessity of satellite
cells for maintenance of muscle mass and hypertrophy (68-70). Such controversies are beyond
the scope of this review article, for further information, the reader is directed to excellent reviews
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on this topic (58, 71). Overall based on the current literature, females and males do not appear to
have clinically meaningful differences in mTOR activation and subsequent protein synthesis in
response to anabolic stimuli, however males do appear to have greater satellite cell content and
proliferative capacity compared to females.
Catabolic factors and signaling mechanisms also play a large role in the overall muscle
size. Broadly speaking, the two primary protein degradative pathways include: ubiquitinproteasome and autophagy pathways (72). Briefly, the ubiquitin-proteasome system involves
tagging old or misfolded proteins with small ubiquitin proteins; these ubiquitin-tagged proteins are
then transferred to the proteome for degradation (73). This system is regulated by various ligases
(referred to as E1, E2, and E3 ligases) that facilitate activation of the ubiquitin, transfer of the
ubiquitin to the target protein,

and finally the attachment of ubiquitin to the target protein

respectively (73).The ubiquitin-tagged protein is then shuttled to the proteasome for degradation
and recycling of amino acids (73). MuRF1 and Atrogin1 are important E3 ligases within the
ubiquitin-proteasome pathway and are activated across a variety of catabolic muscle pathologies
(73-75). Similarly, the autophagic degradative pathway serves to remove damaged or old proteins
(76). Autophagy-related genes (Atgs) are the primary regulators of this pathway. Broadly
speaking, catabolic stimuli signal to ULK1 protein to initiate autophagosomal formation, which is
initiated by the Beclin (Atg6) protein (77). Autophagosomal formation is facilitated by the activation
of the LC3I to LC3II conversation induced by Atg4 (77). Concurrently, the p62 (SQSTM1) cargo
protein brings the proteins tagged for autophagosomal degradation to the autophagosome.
Finally, the autophagosome binds with a lysosome for lysosomal degradation of the protein (77).
A more through overview of these process has been reviewed elsewhere (73, 77).
Recent works have begun to tease out the nuances in possible differences of these
pathways between males and females. In general, it appears that both of these processes are at
least partially mediated by biological sex, as prior works have found mRNAs related to these
processes are differentially expressed between males and females (78). Specifically females

9
overall tend to have lower basal ubiquitin-proteasome activity compared to males, which is
thought to be partially mediated by estrogen signaling (79, 80). This lowered ubiquitin-proteasome
activity appears to result in differential FOXO3a-Ubiquitin signaling during disuse atrophy, with
females showing less FOXO3a content compared to males, yet greater ubiquitinated protein
content (49). Potential reasons or mechanism for this differential signaling during disuse have yet
to be elucidated. While females tend to have less ubiquitin-proteasome activity compared to
males, females tend to have greater autophagy-related protein degradation compared to males
(81, 82). Current literature suggests greater protein content of autophagy regulators of autophagy
initiation and resolution compared to males (81, 82), overall suggesting males and females may
preferentially favor different protein catabolic pathways.
Specific to disuse atrophy, both males and females have potent inductions of degradative
pathways with disuse (83, 84, 10, 12, 85-93). However, these responses may be partially
mediated by biological sex. For example, male rats and mice undergoing hindlimb unload have
increased Atrogin1 and MuRF1 induction in the early stages of disuse (~2-10 fold depending on
length of unloading and tissue) (10, 12, 85-90). Comparatively, females potentially have an
augmented response compared to males, with some studies reporting as much as 20-40 fold
increases in MuRF1 and Atrogin1 respectively(83, 84), though others have noted only 2-4 fold
greater Atrogin1 and MuRF1 mRNA in hindlimb casted females (91). Taken together, these
studies may suggest similar degradative pathways in males and females during disuse atrophy,
however in females, degradative pathways such as ubiquitin-proteasome may be relatively
greater compared to males. However, to our knowledge, this hypothesis has not been directly
tested and may warrant further study. Similarly, autophagy is also known to be activated during
disuse atrophies in both human and animal models (91, 92, 94). However, potential sex
differences in autophagy induction during disuse atrophy have not been directly evaluated
between sexes.
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Finally, males and females may differ in regulators of protein catabolism, specifically
myostatin sensitivity. Myostatin, a protein within the TGF-β family, can greatly impact muscle size,
with increased myostatin activity contributing to reduced muscle size in multiple models of muscle
catabolism (95, 96, 97). While myostatin will affect both sexes, females appear to be more
responsive to myostatin withdrawal, with inhibition of myostatin causing greater muscle
hypertrophy in females compare to males (98). However, myostatin action in both sexes still
remains perplexing as recent works have found disuse atrophy to increase myostatin content in
females but not males (49). This may be partially due to myostatin-androgen receptor reciprocity.
Prior works have found myostatin translation and secretion moderated by androgen receptor
translocation to the nucleus with androgen binding (99, 100). Speculatively, this interaction
between androgen receptor activity and myostatin synthesis may serve to counter balance
androgen hypertrophic action. This hypothesize would align with noted differences in myostatin
content between males and females during disuse atrophy, however, more works are needed to
fully elucidated these complicated interactions.
Overall, the current literature appears to suggest multiple differences in muscle physiology
between males and females, as well as a few similarities between the biological sexes. Males
and females appear to have similar inductions of protein synthetic pathways with anabolic stimuli
and both have large inductions of catabolic pathways with disuses, however the relative strength
of these inductions may warrant further research. Females tend to have more oxidative Type I
fibers compared to males (34-36), which may predispose females to greater muscle losses with
disuse atrophy. Females tend to have less satellite cells (60, 61), which may be partially mediated
by testosterone-activation of ARs on the satellite cells (64-66). Females also tend to have less
basal ubiquitin-proteasome activity and greater autophagy activity compared to males (79-82).
Finally, females appear to have differential regulation of myostatin activity and subsequent
alterations to muscle physiology (49, 98). Taken together the aggregate of these data suggest
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differential interactions between muscle pathologies and biological sex and warrant further
research that may necessitate personalized medical treatments based on biological sex.

b. Hormonal Interactions
One significant difference between males and females that likely contributes to dimorphic
responses between sexes during muscle pathologies is differing circulating hormones. The
process of synthesizing these hormones begins at the gonadotropic cells in the anterior pituitary
gland of the brain. Gonadotropes facilitate signaling to sex organs for the synthesis of sex
hormones. Different genetic expression within the gonadotropes at the anterior pituitary gland
vary in mammals depending on age and menstrual/estrous cycling status. Among females greater
activation of gonadotrope signaling to sex organs is present during proestrus (corresponding to
increased estrogen and progesterone synthesis) compared to diestrus (101). In general, sex
hormones exert beneficial effects on muscle mass maintenance and function (102-104), however
their specific impacts on skeletal muscle may have specificity to the sex of the organism. While it
is unlikely that hormones solely mediate differences in muscle health, it is likely that hormonal
interactions have at least some influence on muscle quality and health. For the purpose of this
review, I will focus primarily on the three primary sex-related hormones: testosterone, estrogen,
and progesterone (Figure 2).
i.

Testosterone as a mediator of muscle growth
Testosterone is currently one of the most popular supplements in the United States, with

sales of testosterone supplements increasing 500% between 1993 and 2000(105), and continuing
to grow. Men tend to have greater testosterone than women, with a normative range of ~ 82-257
ng/dL for young men and .8-10ng/dL for young women (106). Testosterone is an androgenic
hormone that works through the action of androgen receptors (AR) on various tissues to facilitate
protein anabolism. Specifically, part of this anabolic response involves AR translocation to the
nucleus to act as a transcription factor to increase myotube and muscle protein synthesis (107,
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108). Previous work has demonstrated testosterone can work specifically through ARs to
contribute to increased protein synthesis (107, 108). In human primary myotubes from men,
recent work has clarified the pathways for testosterone action (107). Specifically, it has been
demonstrated that testosterone action can activate mTOR through androgen-mediated action of
androgen receptor to activate PI3k/Akt signaling (107). AR receptor content varies based on the
type of tissue, and in muscle by the fiber type (109). Interestingly, AR activation seems to favor a
shift towards slow twitch fibers, with AR-knockout mice demonstrating a shift towards Type II
fibers (99). In animal models, removing testosterone in male mice by castration induces a noted
decrease in muscle size (99, 110, 111). Whereas, when testosterone is given to those with low
levels of testosterone, such as men with hypogonadism or older male mice, there appears to be
increased muscle mass (110, 112). In females, testosterone also appears to have anabolic
effects, for example postmenopausal women given an acute treatment with testosterone exhibit
increased fractional protein synthesis rates (113). However, that same study found greater FSR
in older females compared to young (113) as such, it unclear if increasing protein synthesis rates
alone necessitates a phenotypic change in the muscle in this population.
Whereas AR content appears necessary for appropriate muscle fiber size, it does not
appear sufficient to induce muscle hypertrophy; for example resistance exercise training does not
appear to impact the number of AR (114). Additionally, free testosterone in the blood has little
relationship to changes in lean body mass or strength (114, 115). Finally, there does not appear
to be sex differences in the number of ARs or sensitivity to anabolic stimuli (63, 116), suggesting
that sex differences in androgenic activity are likely due to higher concentrations of androgens in
the blood.
During multiple muscle pathologies, hypogonadism and associated testosterone
concentrations are known to be lowered and hypothesized to partially contribute to muscle loss
(117-121). For example, men with spinal cord injury, demonstrate generally lower testosterone
levels compared to non-injured controls (122). However, testosterone supplementation in these

13
populations has shown promise for mitigating this muscle loss in men (119, 120). Hypogonadism
also commonly accompanies cancer cachexia (117, 118), and recent works have begun to
evaluate the sufficiency of drugs with androgen-like binding and testosterone itself as
pharmacological agents for the treatment of cancer cachexia in men (123, 124). Finally,
testosterone supplementation appears to limit glucocorticoid-induced muscle atrophies in male
mice (121). However, despite these promising findings in other muscle pathologies, testosterone
status does not appear to influence muscle mass recovery from hindlimb unloading, in that
androgen supplementation in these populations does not mitigate muscle losses (125, 126).
Therefore, while the presence of testosterone appears to be a necessary component for muscle
mass and quality in males, the precise relationships between testosterone status and muscle
quality appear dependent on the specific muscle pathology. Overall, it does not appear
testosterone treatment is necessarily effective for mitigating disuse-induced muscle loss in males.
However, mechanisms for these discrepancies between different muscle pathologies remain
under investigated and warrant further research.
ii.

Estrogen as a Mediator of Muscle Growth
Estrogen (also sometimes referred to as estradiol) is primarily associated as a female sex

hormone whose concentration varies throughout the course of the menstrual (human) or estrous
(murine) cycle. Specifically, women tend to have increased estradiol and progesterone during the
luteal phase of menstrual cycle (250 µg estradiol/day and 25 mg progesterone/day during the
luteal phase v. 36 µg estradiol/day and 1 mg progesterone/day during the follicular phase,
respectively) (127). In female mice, estradiol and progesterone appear to peak at 40-60 pg/ml
and 25-30 ng/ml respectively during proestrus and 7-10 pg/ml and 5ng/ml during diestrus (128132). Each of these phases affects energy utilization and bioenergetics (133). Estrogen overall
appears to exert a hypertrophic effect (134), which is at least partially mediated by increased
sensitivity of IGF-1 in satellite cells (135). Estrogen also affects mitochondrial health (136, 137),
whereby estrogen removal in ovariectomized rats decreases mitochondrial O2 consumption and
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efficiency (136, 138), overall suggesting estrogen plays an important role for cellular and likely
muscular health in females.
While the specific role of estrogen on muscle size and quality is still controversial, in
general, deficiency of estrogen is likely detrimental to muscle function in both males and females
(1). Generally, ovariectomized young mice and postmenopausal women have smaller muscles
compared to functional uterus controls (1), suggesting estrogen plays a role in muscle size, at
least in females. Estrogen also may be important for protection from atrophic stimuli.

For

example, during inflammation-induced atrophy, estrogen diminishes IL-6 secretion from the liver
and appears to blunt atrophy (139). This finding strongly suggests protective effects of estrogen
and may partially account for differences seen been males and females during pathologies such
as cancer cachexia, whereby cycling females do not experience cachexia compared to acyclic
females who do undergo cachexia (140). Estrogen-based treatments have begun to be
investigated for various muscular dystrophies (141-144), specifically the use of tamoxifen, a drug
developed for estrogen-dependent breast cancer. Finally, loss of estrogen receptors delays
muscle regeneration and differentiation after injury (145). Overall, the aggregate of the literature
appears to suggest estrogen is a necessary component of muscle size, with reduction or
elimination of estrogen causing reduced muscle size and regenerative capacity. However, it
should be noted one study suggested activation of estrogen receptors in males to cause muscle
atrophy through increased ubiquitin-specific peptidase 19 content and potential augmented
activation of the ubiquitin-protease system(80), and recent work suggests that estrogen treatment
in males can alter MHC gene expression as measured through microarray analysis in cardiac
tissue (146). Therefore, more research may be necessary to understand the intricacies of
estrogen’s precise effects on muscle in both males and females.
Specific to disuse muscle atrophy, estrogen treatment and/or supplementation has shown
mixed efficacy on protections against disuse-induced muscle pathologies. For example,
ovariectomized mice showed delayed recovery from disuse-induced atrophy, and greater muscle
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loss (measured by cross sectional area) compared to ovariectomized mice with estrogen
replacement (104), suggesting that estrogen may a necessary component to mitigate the intensity
of muscle atrophy. However, other work shows estrogen treatment in female mice to have little
effect on muscular deteriorations with disuse (147), suggesting estrogen treatment in females is
not sufficient to counteract disuse atrophy, Contrastingly, estrogen-based treatments (including
both estrogen and estrogen-receptor agonists) have shown some protections against disuse
atrophy in male mice and rats (148-151). Further demonstrating the necessity to investigate
potential treatments against muscle pathologies in both male and female models.
Overall the current literature appears to suggest estrogen is a major mediator of muscle
quality, with loss of estrogen associated with decreases in muscle quality. Supplementation of
estrogen may increase muscle size in animals, however more research using both male and
female models are necessary to understand the full influence of estrogen on muscle quality and
size.
iii.

Progesterone and Muscle Health
Similar to estrogen, progesterone also is associated as a female sex hormone, with

massive increases in progesterone concentrations during the luteal phase of the menstrual cycle.
However, compared to estrogen, progesterone has not been studied as extensively in relation to
muscle quality. One of the early investigations of progesterone found progesterone treatment on
myotubes increased hydrogen peroxide (ROS) emission from the mitochondria (152), which the
authors interpreted as pathological. However, based on this study it is not clear whether this
emission is necessarily pathological, as small amounts of ROS production may benefit
mitochondrial and muscle health as seen in exercise studies where blunting ROS response blunts
exercise adaptations (153). Recently, is has been suggested that mitochondria contain a
progesterone receptor that can directly mediate and increase mitochondrial respiration and
efficiency (154, 155). This increased respiration in the muscle may allow for the increased ATP
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production necessary to develop and maintain muscle mass. However, to our knowledge this
relationship has not been directly tested in mammalian species.
With specific regard to muscle hypertrophy high feed efficiency broiler chickens have been
found to have higher mitochondrial efficiency which appears to be mediated by progesterone
action (156). Further suggesting mitochondrial health to be a major mediator of muscle size and
quality and this quality is at least partially mediated by progesterone action. Additionally, in cattle,
feed efficiency can be increased ~20% by supplementation with progesterone (157), and
progesterone treatment in mice and humans can stimulate cardiac and skeletal muscle protein
synthesis (108, 158). However, to our knowledge, no work has directly investigated the role of
progesterone on disuse or other muscle atrophies.

Based on works demonstrating

progesterone’s hypertrophic capacity, progesterone treatment may be an additional treatment
target for pharmacological interventions for the prevention of muscle atrophies. However more
works are needed to thoroughly understand progesterone’s mechanism of action for regulation of
muscle quality.
iv.

Estrous Cycle in Relation to Muscle Pathologies
Recent literature is beginning to examine the influence of estrous/menstrual cycle on

various pathologies and treatments in females. Currently, the aggregation of literature suggests
estrous cycle can influence some pathologies. For example, female mice are more sensitive to
the effects of antidepressants during proestrus (159, 160) and other pathologies such as
autoimmune diseases, are thought to be mediated by estrogen and the estrous/menstrual cycle
(161, 162), suggesting hormonal status may influence some disease pathologies. Specific to
muscle pathologies, recent work has strongly suggested estrous cycle may influence
development of cancer cachexia in female mice, whereby it is hypothesized cancer cachexia may
influence estrous cycling and result in muscle wasting (140, 163). For example, in female Apcmin/+
mice, 100% of acyclic females become cachectic as opposed to essentially no cycling females
becoming cachetic (140). This acyclicity appears to occur in ~38% of female Apcmin/+ mice (140),
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however mechanisms for this cessation are not yet fully understood. These works suggest the
presence or absence of the estrous cycle influences muscle maintenance in cancer cachexia,
however these differences develop over the course of weeks. With the relatively short time frame
of many disuse studies (~3-14 days) (10, 11, 92, 164), and the accelerated development of
atrophy therein, it is unlikely that the presence or absence of cycling dramatically influences the
progression of disuse atrophy. However, this hypothesis has not been directly investigated,
therefore more research directly investigating the influence of estrous cycle during disuse atrophy
is likely warranted.
Taken together, the aggregate of the current literature suggests hormones can
significantly influence overall muscle health and size. With loss of testosterone or estrogen
dramatically influencing muscle size in males and females respectively (1, 104, 117-122, 134,
145). However, the potential for supplementation or pharmacological activation of these specific
receptors has mixed results depending on the sex of the model organism and muscle pathology
(125, 126, 119-121, 123, 124, 141-144). These data imply the necessity of research using both
male and female organisms to more fully elucidate the influences of these hormones on muscle
pathologies and potential treatment efficacy. Finally, progesterone, the traditionally classified
female hormone has recently emerged as a potential regulator of mitochondrial and muscular
health (154-156). These recent findings warrant further research on the potential mechanisms of
progesterone during muscle pathologies and possible therapeutic applications of progesterone
during various muscle pathologies.
c. Mitochondrial differences between males and females
Mitochondrial quality has been a recently proposed mediator of muscle size and function
(108). Females in general tend to preferentially oxidize fat as the primary energy substrate (34,
165, 166), aligning with a greater relative content of Type I fibers (35, 36). Therefore, suggesting
females’ higher reliance on mitochondrial oxidative phosphorylation for ATP synthesis. To date,
multiple studies have found mitochondrial function, morphology and content to differ between
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males and females. Indeed, animal and human studies across multiple tissues have found higher
mitochondrial content per gram of tissue and greater transcription factors associated with
mitochondrial biogenesis in females compared to males (165, 167-170). Female gastrocnemius
muscles have greater mitochondrial content and mtDNA per gram of tissue compared to males
as well as more ATPase, TFAM protein, and mitochondrial complexes (168). These differences
appear to correspond to greater mitochondrial activities (167). Additionally, in other tissues, such
as the liver, females have greater mitochondrial content, and respiratory capacity (169, 170).
Taken together, these data demonstrate some aspects of mitochondrial quality, appear inherently
different between males and females, which may contribute to differential progressions of
mitochondrially-related pathologies including muscle atrophies (Figure 3).
i.

Sex Differences in Mitochondrial Aberrations during Catabolic Stimuli
Recent data suggests that mitochondrial alterations during catabolic stimuli appear to

discriminate between males and females. During arthritis induced disuse, females experience a
large decline in subsarcolemmal mitochondrial density compared to males (35, 46). Additionally,
females have greater reductions in the mitochondrial translation protein TFAM compared to males
with aging associated muscle wasting (171) and female mitochondria tend to make less ATP
compared to males during energetic stress such as glucose deprivation in vitro (172). Overall
demonstrating that females and males have different mitochondrial responses to cellular stress,
emphasizing the need to further understand how female muscle differs from male, both during
basal and stressed conditions. Recent research examining primary cells from males and females
have demonstrated sexual dimorphisms on measures of mitochondrial function (172, 173), clearly
demonstrating sex differences are not solely hormone mediated and need to be further
investigated using in vivo and in vitro methods. Overall, while it is generally well known that
females have differing mitochondrial profiles compared to males, both at baseline and during
differing pathologies, it is not directly clear how these differences may influence overall phenotypic
and clinical outcomes.
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ii.

Mitochondrial Aberrations during Disuse Atrophy
Research throughout the past 25 years has demonstrated disuse atrophy increases

reactive oxygen species (ROS) and peroxide species production (13, 15-19, 174). Because
mitochondria are the primary generators of ROS, efforts to increase mitochondrial quality and
function are being investigated as a therapeutic modality for disuse atrophy. For example, multiple
studies have investigated the therapeutic potential of antioxidant treatments such as vitamin E
supplementation. However the results of these studies have been mixed with some data showing
vitamin E supplementation to be protective (20, 175) whereas others have not seen any protective
effects of supplementation (12, 13). Additionally, because alterations in PGC-1α, mitochondrial
quality, and oxidative phosphorylation have been noted as substantial contributors to disuse
muscle wasting (14, 91, 176), efforts to improve these markers have been investigated as
possible therapeutic agents. Overexpression of PGC-1α in C2C12 myotubes inhibits protein
degradative pathways (177). In vivo, genetic overexpression of PGC-1α in male mice mitigates
some phenotypic characteristics of disuse atrophy(12), whereas local transfection of PGC-1α in
the tibialis anterior of female mice mitigates some measures of oxidative stress associated with
reloading after disuse (178). Additionally, mitochondrially targeted antioxidant treatment has
shown some promise in female rats for the prevention of disuse atrophies (91).
However, despite these promising findings, no current clinical treatments have yet been
developed based on these findings. This may be partially due to the disparity in pre-clinical
research in female models. Females generally have more mitochondria (168) while it may be
appealing to conclude females are inherently protected against mitochondrial-related pathologies
such as muscle wasting, to date this hypothesis has not been directly tested in disuse pathologies.
More so, greater mitochondrial content does not necessarily translate to greater mitochondrial
and cellular health, as we and others have demonstrated that genetic induction of mitochondrial
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biogenesis via PGC-1α overexpression, does not protect against, and may exacerbate, other
muscle pathologies such as insulin resistance (179-181). Additionally, greater mitochondrial
content per gram of tissue weight also presents the opportunity for greater ROS production during
pathological stimuli. ROS production is thought to occur primarily through complex III within the
mitochondria (182), and some evidence suggests females may have greater complex III activity
compared to males (183). Overall suggesting that mitochondrial differences between males and
females may potentially explain differences noted between males and females during disuse
pathologies.
iii.

Mitochondria and Sex Hormones
It is becoming more and more accepted that the mitochondria also contain receptors

specific to classical sex hormones that may influence sexual dimorphisms in mitochondrial-related
pathologies. For example, estrogen receptors (specifically ERβ) have been found in the
mitochondrial membrane across multiple tissues (184-190). The ERβ is currently thought to
increase transcription of nuclear- and mitochondrial- encoded proteins involved in oxidative
function and of NRF-1 and COX complexes (191), leading to overall increased mitochondrial
oxidation and potentially improved function (192, 193). ERβ and ERα total content do not currently
appear to differ between males and females (194, 195), thereby suggesting ER-mediated
differences between males and females are likely the result of differences in plasma hormone
circulation as opposed to receptor action. Androgen rectors have in some studies been noted on
the mitochondria, however this has been limited to mitochondria present in mobile sperm (196),
as such, the influence ARs may have on mitochondrial and cellular function is likely limited (191).
Recently, progesterone action has been hypothesized to alter mitochondrial oxidative function. It
has been established since the 1990s that during the luteal phase of the female menstrual cycle
(when progesterone peaks) energy expenditure and mitochondrial respiration increase (197-199).
However, recent works have established the presence of a progesterone receptor specific to the
mitochondrial membrane (PR-M) (154, 155). This PR-M appears to facilitate increased cellular
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respiration within the mitochondria (154, 155), overall suggesting progesterone may greatly
influence overall mitochondrial and muscular health. However, the potential direct and indirect
effects of hormonal actions and mitochondrial quality during muscle atrophies requires further
investigation.
In aggregate, the current literature suggests inherent differences between males and females
on both mitochondrial content and function (165, 167-170). These differences may at least
partially contribute to differential mitochondrial alterations during muscle pathologies and
subsequent muscle loss (35, 46, 171). However, many of these differences in disuse specific
muscle loss have yet to be investigated as well as global differences in mitochondrial function
during pathologies. As such, more research on mitochondrial-specific alterations during muscle
pathologies between males and females is necessary to develop more effective therapeutics for
mitochondria-related pathologies.
d. Conclusions
Skeletal muscle size and quality remain one of the largest mediators of overall quality of
life and mortality across a variety of pathologies. Clearly, males have been preferentially
researched in pre-clinical models, resulting in a relative dearth of research on muscle pathologies
in females. However, the current research demonstrates males and females are clearly different
on many aspects of muscular health and physiology including: muscle fiber composition, anabolic
and catabolic pathways, hormonal interactions and mitochondrial content and function. These
differences can greatly influence the development and progression of various muscle atrophies,
including disuse atrophy. However, specific studies investigating how any of these processes are
differentially regulated between males and females in relation to muscle loss are lacking,
specifically disuse studies. This lack of data has clear therapeutic implications; less than half of
pharmacological agents move to Phase 3 clinical trails (200), often due to lack of efficacy in
human models. Part of this lack of efficacy in human models is likely partially attributable to lack
of female model organisms in pre-clinical and Phase I trials. If we are to fulfil the promise of
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individualized medicine the scientific community has sought since President Barack Obama’s
pledge to the “All of Us” individualized Medicine Campaign in 2015 (201, 202), we need to start
seriously investigating one of the basic aspects of an individual’s genome, biological sex. Only
then can we truly begin to adequately begin the long process of developing individualized
medicine for patients.
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e. Figures

Figure 1: Summary of current literature of sex differences and similarities of muscle phenotype
in males and females.
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Figure 2: Summary of the current literature of classical sex hormones and their influence on
muscle size.
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Figure 3: Summary of current data on mitochondrial differences between males and females as
well as mitochondrial interventions for disuse atrophy.
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Chapter III: Proposal
a. Specific Aims: Mitochondrial contributions to disuse atrophy: let’s talk about sex
Skeletal muscle is among the most metabolically active organs in the human body and
has significant implications for health and longevity. During many chronic diseases, muscle
wasting is a concurrent pathology and a significant predictor of mortality and morbidity (1, 2).
Nutritional interventions are ineffective treatments (3, 4) and overall there are not currently
effective treatments for muscle atrophies. Therefore, a critical need remains to understand
mechanisms contributing to atrophic pathologies. Muscle loss presents differently between males
and females in many different pathologies (5-10) and we have evidence demonstrating a clear
sexual dimorphism in the progression of disuse muscle wasting in mice, with females displaying
signs of atrophy within 24hrs of disuse whereas males do not atrophy until 48-72hrs of disuse.
However, most research investigating muscle wasting only investigates these pathologies using
male models (11-15), resulting in a significant chasm in the literature examining mechanisms
contributing to muscle pathologies within females.
Currently, mitochondrial degeneration is believed to be a predominant mechanism for the
development of muscle atrophy (16-18). Whereby excessive generation of reactive oxygen
species induces mitochondrial dysfunction, and subsequent catabolism(16, 17). Our laboratory
recently demonstrated that mitochondrial deterioration occurs before the development of muscle
wasting in cancer-cachexia(19), and we have data suggesting a similar mechanism during disuse
atrophy. Therefore, mitochondrial dysfunction may be a common mechanism contributing
to the development of muscle atrophies. Mitochondrial characteristics differ between sexes
(20-22), yet there is noticeable lack of literature investigating sexual dimorphisms in relation to
these muscle pathologies. As such, I propose to compare muscle alterations between sexes
during disuse atrophy. The central hypothesis of my proposal is males and females will
exhibit different mitochondrial mechanisms contributing to the development of disuse
atrophy (Figure 1).
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Specific Aim 1: Define metabolic and mitochondrial quality alterations during the
development and progression of disuse muscle atrophy in male and female mice. To
complete this aim, I will use hindlimb unloading to induce disuse atrophy in male and female
C57BL/6J mice. Mice will be unloaded for 0-7 days with tissues collected for analysis of muscle
wasting and mitochondrial and metabolic alterations. Wasting will be determined by muscle size
and cross-sectional area(19). Mitochondrial quality will be determined by 1.) fluorescent
electroporated pMitoTimer (19) 2.) mitochondrial respiratory function and ROS production in
permeabilized fibers (19, 23) 3.) mRNA and protein content of mitochondrial quality control
regulators (19, 24-26).
Specific Aim 2: Identify the sufficiency of increased mitochondrial quality or antioxidant
function to mitigate disuse pathologies and if these responses differ by sex. To complete
this aim I will hindlimb unload transgenic mice overexpressing either PGC-1α or MCAT genes,
increasing mitochondrial content and antioxidant capacities respectively (24, 27-29). Male and
female mice will be unloaded for 7 days. Sufficiency to mitigate muscle wasting will be determined
by: 1.) muscle size and cross sectional area, 2.) fluorescent electroporated pMitoTimer and 3.)
mRNA and protein content of mitochondrial quality control regulators.
Specific Aim 3: Elucidate the influence of sex-specific hormonal interactions on
mechanisms contributing to disuse muscle atrophy. I will differentiate C2C12 myoblasts into
myotubes and electro-stimulate and contract myotubes serving as a “healthy muscle” control. I
will then halt electrostimulation and contraction to induce disuse atrophy. After halting
electrostimulation, myotubes will then be incubated with media containing physiological
concentrations of traditional sex-related hormones, simulating sex in vitro. After a period of
“disuse”, outcome variables will include: 1.) myotube size, 2.) mitochondrial stress measured by
fluorescent dyes and 3.) mRNA and protein content related to mitochondrial quality control
regulators.
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This will be the first study to directly investigate dimorphic effects of disuse muscle atrophy
between sexes using both in vivo and in vitro models. These experiments will greatly enhance
our understanding of muscle physiology and mechanisms contributing to deteriorations in muscle
health. More so, as personalized medicine and treatments becomes the expectation within
modern medicine, this proposal will provide foundational work for the personalized treatment of
muscle atrophies. I have extensive experience with the proposed models and techniques.
Therefore, I am uniquely qualified as the optimal candidate to test the primary research
hypothesis.
b. Significance
i.

Muscle wasting contributes to mortality and increasing health care costs.
Skeletal muscle is among the largest and most metabolically active organs in the human

body and a major mediator of overall quantity and quality of live. During many chronic diseases,
such as cancer, HIV, chronic kidney disease, liver failure, and long periods of disuse (e.g.
Intensive Care Unit (ICU) treatment) (1) muscle atrophy is a concurrent pathology and a
significant predictor of mortality and morbidity (30). Specifically, reduced muscle strength is
associated with mortality and length of hospital stay in ICU patients (31-36) as well as 30% higher
healthcare costs (33, 37), contributing to almost 82 billion dollars spent on ICU care (38). Frailty
develops rapidly during ICU stays, with 7 days of best rest resulting in 17.5% reduction in muscle
fiber cross-sectional area (39). Other studies have also found muscle atrophy with as little as 3
days of disuse (40, 41) and we have preliminary evidence demonstrating muscle wasting within
1-2 days of disuse in mice (Figure 2). However, mechanisms contributing to muscle wasting
remain elusive, specifically preliminary events initiating muscle atrophy. Due to the rapid
occurrence and progression of muscle wasting, a clear need remains to understand early (patho)
physiological alterations underlying disuse-associated wasting and methods to mitigate this
wasting.
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ii.

Muscle wasting pathologies present differently between males and females.
Muscle wasting is a large determinant of mortality across multiple conditions. However,

sex specific differences occur during the development of these pathologies and are diseasespecific (42-46). For example, males tend to have greater muscle loss and mortality compared to
females during the progression of various cancers (44-46), suggesting female sex is protective
during these conditions. However, during disuse atrophies, such as extended bed rest, there is
evidence females are more likely to experience ICU-associated muscle weakness (43). Moreover,
recent evidence suggests females have higher 30-day mortality compared to males in the ICU
(42). We also have preliminary evidence suggesting differential progression of muscle wasting
during the development of disuse atrophy (Figure 2) whereby female mice display mass loss
within 1 day of disuse whereas males do not atrophy until 2 or more days of disuse. As muscle
wasting is already demonstrably implicated in ICU-associated mortality and reduced quality of life,
early events initiating muscle atrophies and how they differ by sex represent a novel and
significant approach presenting new opportunities for the development of efficacious
therapeutics for muscle pathologies.
iii.

Females have greater content of muscle fibers susceptible to disuse.
Previous work has suggested Type I fibers are highly susceptible to disuse muscle

atrophies (14, 47), whereas they are protected during cancer induced atrophies (19). We have
also demonstrated protection of oxidative fibers during cancer cachexia (19) as well as rapid
deteriorations in oxidative muscles, with 7 days of disuse causing ~40% reduction in slow-twitch
soleus muscles compared to ~15% reduction in mixed fiber gastrocnemius muscles (Figure 2).
Females have greater proportions of oxidative Type I fibers compared to males, this relationship
is conserved across a variety of mammalian species including humans (8, 48-50). The different
muscle fiber-type profiles may largely contribute to significant losses in muscle mass within 1 day
of disuse in female mice compared to male (Figure 2), therefore different muscle fiber types
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and their related characteristics may contribute to differential responses to disuse atrophy
between sexes.
iv.

Mitochondrial alterations during disuse are different between sexes.
During ATP production mitochondria produce small amounts of reactive oxygen species

(ROS) which are normally quickly neutralized by antioxidant mechanisms (16, 17, 51).
Mitochondrial ROS production exceeding the capabilities of neutralizing antioxidants, resulting in
mitochondrial dysfunction, and increased protein degradation: synthesis ratios have been
hypothesized as potential mechanism for the development of muscle wasting(16, 17). We have
evidence suggesting this mitochondrial degeneration occurs before muscle wasting in male mice
(Figures 2,3). More so, we have primary evidence suggesting increasing mitochondrial content
by overexpression of the transcriptional coactivator PGG-1α can limit muscle loss during disuse
(Figure 4). Taken together, our preliminary data establishes accelerated development of
metabolic and mitochondrial stresses during muscle atrophy between sexes. Therefore,
understanding the differences in development of disuse muscle atrophy between biological sexes
is critical to develop efficacious therapeutic strategies.
v.

Significance of proposal.
Muscle wasting is one of the largest contributors to reduced quality of life and mortality

across a variety of pathologies (1, 30-36) and contributes to 30% higher health care costs (33,
37) . Pathological muscle atrophy presents differently between males and females across a
variety of diseases (5-10). We already have preliminary data demonstrating during disuse
atrophy: 1.) female mice atrophy sooner than males, specifically females will atrophy within 24
hrs of disuse whereas males do not atrophy until 48-72hrs and 2.) mitochondrial degeneration
occurs within 24 hrs of disuse in males, preceding significant muscle loss, and 3.) increasing
mitochondrial content appears protective against disuse-induced muscle loss.

However,

more in-depth investigation is required to further understand physiological processes and
mechanisms that may contribute to sex differences during muscle pathologies; therefore, the
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purpose of this proposal is to investigate mitochondrial alterations during the development of
disuse atrophy and how biological sex influences the rate of muscle pathologies as well as overall
mechanisms contributing to muscle atrophy. The central hypothesis of my proposal is males
and females will exhibit different mitochondrial mechanisms contributing to the
development of disuse atrophy. This will be the first study to directly investigate how muscle
atrophy differentially progresses between males and females using both in vivo and in vitro
methodologies. As the use of individualized medicine becomes ever more desired and feasible
(52, 53), biomedical science needs to take into account one of the primary factors contributing
to individual differences: sex. If biomedical science is to appropriately develop effective
individualized medicine, knowledge of mechanisms contributing to pathologies in both males and
females is imperative. This proposal provides the foundation for this promise of individualized
medicine (53) by investigating muscle alterations during the development of disuse muscle
atrophy. This research proposal will have large implications for future clinical trials and
development of effective therapeutics for both male and females, and therefore is highly
significant.
c.

Innovation
To date, no studies have sufficiently examined sex differences in the progression of disuse

muscle wasting and mechanisms contributing to this response. This proposal will be one of the
first to directly investigate not only initiating events in the development of disuse atrophy, but how
these early events and development of muscle atrophy differ between sexes. This proposal will
utilize both in vivo and in vitro models to directly investigate how biological sex and mitochondrial
quality contribute to early events and eventual progression of muscle wasting. Allowing for
strong conclusions on the impact of biological sex on the pathogenesis of muscle
atrophies. More so, this will be one of the first studies to simulate sex in vitro providing
foundational protocols and techniques for further research investigating similarities and
differences between males and females. These innovative methods and techniques will allow for
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investigation of the primary research hypothesis as well as the development of new protocols that
will help to further our understanding of muscle biology as well as the broader field of biomedical
sciences. This research will also be one of the first studies to provide foundational evidence
for individualized treatments of muscle pathologies for males and females, helping to
facilitate the promise of individualized medicine the scientific community has sought since
President Barack Obama’s pledge to the “All of Us” individualized Medicine Campaign in 2015
(53, 54). Specifically, I have the technical expertise in conjunction with a demonstrated record of
scientific productivity, and therefore the optimal candidate for this research proposal.
d. Approach [Overall Approach]
In order to test the central hypothesis, I used a combination of animal and cell culture
methods. These experiments were designed to test the specific research hypothesis by
investigating multiple aspects of the primary research hypothesis including: 1.) differences in
muscle metabolism in the development of disuse atrophy between males and females 2.)
sufficiency of improved mitochondrial content or ROS neutralizing capacities as a potential
therapeutic against disuse atrophy and 3.) the influence of sex hormones on differential
responses to disuse atrophy. Therefore, I proposed the following Specific Aims:
i.

Specific Aim 1: Define metabolic and mitochondrial quality alterations during the
progression of disuse muscle atrophy in male and female mice.
To test this aim, I used a commonly used model of disuse, hindlimb unloading (14, 41,

47), to investigate initial muscle alterations and subsequent progression of disuse atrophy. At 8
wks of age, C57BL/6J male and female mice underwent electric pulse-mediated gene transfer of
pMitoTimer in the flexor digitorum brevis (FDB) muscle as we have previously performed (19).
After 2 wks of recovery, mice were then individually housed and unloaded for 0,1,2,3, or 7 days
to induce muscle atrophy (Figure 2,3). At each of the designated time points, mice were humanely
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euthanized, and tissues collected for various outcome measures of muscle and mitochondrial
quality (Figure 5).
Induction of disuse atrophy: Disuse atrophy was induced through hindlimb unloading as
previously described (55), this model has been previously validated to induce disuse atrophy (56).
Model confirmation: Model confirmation was established by hindlimb muscle weights and tibialis
anterior muscle cross sectional area of SDH positive (indicative of oxidative phenotype) and SDH
negative (indicative of glycolytic phenotype). Our laboratory previously has successfully
recapitulating many features of disuse atrophy in human males using this model such as ~3-7%
loss of lean mass within days of unloading (57-62) (Figure 2).
Mitochondrial quality: Mitochondrial quality was assessed by analysis of fluorescent imaging of
pMitoTimer, mitochondrial function and ROS production from permeabilized myofibers, and
analysis of various measures of mitochondrial quality control mechanisms (19).
Analysis of pMitoTimer: FDB muscles were fixed and whole-mounted on microscope slides
immediately upon harvest. The exogenous gene becomes incorporated into the muscle tissue
and changes from green to red fluorescent emission spectra upon mitochondrial damage. Red
and green fluorescence was quantified with a Nikon TiS fluorescent microscope located in our
laboratory with controlled and standardized acquisition parameters. pMitoTimer was
subsequently analyzed for ratio of Red/Green fluorescence and number of pure red puncta using
a specially designed Matlab program (gift from Dr. Zhen Yan) as previously reported by our
laboratory (19).
Mitochondrial function and ROS production in permeabilized fibers: Mitochondrial function and
ROS emission was measured as we have previously described (19). Whole mitochondria
contained in permeabilized muscle fibers are preferred to isolated mitochondria as it does not
preferentially select for healthier mitochondria (63) or alter the mitochondrial network, making this
method superior to isolation methods which both select for healthier mitochondria and destroy the
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intact mitochondrial network. Mitochondrial oxygen consumption of permeabilized fibers was
measured as previously described (64). Due to COVID-19 global pandemic, only mitochondrial
function was measured in male tissues.
Mitochondrial quality control and metabolic mechanisms: I assessed mitochondrial quality control
mechanisms, including: biogenesis, fusion, fission, mitophagy and mitochondrial translation using
RT-qPCR and immunoblotting methods as we have previously described (19, 24-26) Additionally,
mRNA and protein content of metabolic markers of different energy systems were measured as I
have previously described(25).
Histology. Staining for succinate dehydrogenase (SDH) was performed as I have previously
described (19, 26) to determine the influence of oxidative capacity on muscle fiber atrophy.
Specifically, I compared muscle cross-sectional area in SDH+ v. SDH- fibers to determine the
relative influence of muscle oxidative capacity on the development of muscle atrophy as we have
previously performed (19).
Statistics and sample size determination. Using power calculation software, with an anticipated
effect size of ~0.5, I anticipated ~10 animals/condition was necessary for a power of 0.80. To
compare differences within each sex a one-way ANOVA with a Tukey post-hoc was used to
determine differences between groups. Additionally, to determine how the progression of disuse
differs between sexes, I used trend analysis as previously described (65) to determine how
various measures of muscle and mitochondrial function change during 7 days of muscle wasting
between both sexes.
Anticipated results and interpretation of findings. I anticipated that disuse atrophy would progress
differently between males and females. I further anticipated males and females will demonstrate
differences in muscle fiber and mitochondrial quality during the progression of disuse atrophy. I
interpret these differences as evidence altering mechanisms of action in disuse muscle atrophy
between biological sexes and provide foundational evidence for the development of
individualized therapeutics.
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Potential problems and contingency plans. I was mentored on this project by an emerging leader
in the field of mitochondrial alterations and muscle atrophies, who has extensive experience with
the proposed methods and techniques. More so, the animal work and a majority of initial sample
preparation has already been completed for this Aim, as such I do not anticipate major problems
with the completion of Aim 1. There is a possibility we do not find differences in muscle
physiological characteristics between sexes during disuse atrophy; this would suggest that
mitochondrial differences may not underlie differential progressions of disuse atrophy. However,
this information would still provide valuable data on muscle alterations during disuse and
demonstrate aspects of muscle physiology that do not differ by sex.
ii.

Specific Aim 2: Identify the sufficiency of increased mitochondrial content or
antioxidant capacity to mitigate disuse pathologies and if these responses differ by
sex.
To test this aim, I used two transgenic mouse models, the MCK-PGC-1α mouse and the

MCAT mouse. The MCK- PGC-1α mouse has muscle specific overexpression of the
transcriptional co-activator PGC-1α, facilitated by the MCK promotor that specifically targets the
sequence for PGC-1α in the muscle, a known regulator of mitochondrial content and quality
control mechanisms (24). The MCAT mouse has genetic overexpression of the mitochondrial
catalase enzyme, allowing for greater antioxidant handling capacities for the mitochondria (2729). Similar to Aim 1, animals were transfected with MitoTimer at 8wks of age, suspended at
10wks of age and muscle collected at 11wks (Figure 5).
Mitochondrial quality. Mitochondrial quality were assessed by analysis of fluorescent imaging of
pMitoTimer and analysis of various measures of mitochondrial quality control mechanisms (19)
similar to Specific Aim 1.
Statistics and sample size determination. Each transgenic study (PGC-1α and MCAT) was
analyzed by a 2X2 ANOVA with independent factors of condition (CON v. HU) and animal (WT v.
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Transgenic).

Using power calculation software, with an anticipated effect size of ~0.5, I

anticipated ~7-10 animals/condition/sex (total of ~130 animals total) were e necessary for a power
of 0.80. Males and females will be analyzed through paired analyses.
Anticipated results and interpretation of findings. I anticipated that increasing mitochondrial
content be at least partially protective against disuse atrophy. However, due to muscle
mitochondrial content differences between males and females (8, 48-50), I anticipated that males
will benefit more from increased mitochondrial content. However, I anticipated females will benefit
more from increased antioxidant capacity than increased mitochondrial content, since females
may exhibit a ceiling effect on mitochondrial content and potential protections associated with
mitochondrial content. These findings are interpreted as evidence for differential mechanisms in
the development of disuse atrophy between sexes and provide rationale for

individualized

treatments for males and females to combat muscle pathologies.
Potential problems and contingency plans. I had successfully maintained these colonies the last
12 months and as such, did not anticipate problems with animal breeding. Overall, I also have
extensive experience with the proposed experiments, and do not therefore anticipate significant
problems with completing Aim 2. However, if I encounter technical difficulties such as equipment
failures my advisor Dr. Nic Greene has collaborators across the University of Arkansas campus
with similar instruments and equipment to successfully complete most of the components of Aim
2. The notable exception would be if the Leica Cryostat malfunctions or becomes unusable,
histological assessment that requires tissue cutting (SDH staining) would not have been possible.
However, as an alternative plan to investigate the influence of oxidative phenotype on muscle
atrophy, I could have analyzed SDH enzymatic activity through a commercial ELISA kit (Abcam
Cat# ab228560) in gastrocnemius muscle. Then I would have statistically regressed SDH activity
on muscle size. The gastrocnemius muscle would have been used due to its mixed fiber
composition (66) which should allow for the range necessary for appropriate regression analysis
of muscle phenotype and atrophy.

53
iii.

Specific Aim 3: Elucidate the influence of sex-specific hormonal interactions on
mechanisms contributing to disuse muscle atrophy.
I attempted to recapitulate “healthy” muscle using electrical stimulation (E-Stim) and

stretching to simulate the excitation contraction coupling seen in typical in vivo muscle. I would
have then halted E-Stim and stretch to induce muscle “atrophy” in vitro for 24-48 hrs. At the
initiation of “atrophy” I would have incubated myotubes with physiological concentrations of
traditional sex-related hormones including: testosterone, progesterone and estrogen, simulating
sex in vitro.
Myotube electrostimulation and contraction and atrophy: I attempted to simulate “healthy” control
muscle using similar methods as previously described (67-76). Briefly, C2C12 murine myoblasts
would have been differentiated for 5 days to myotubes. Myotubes were then E-stimmed at 11.5
V for 2 ms pulses and 1Hz for 24 hrs. Concurrently, cells also underwent 5% stretch and
relaxation cycles. The E-stim protocol was chosen as a generally low frequency protocol that
elicits adaptations without large hypertrophic adaptations (73, 74). 5% stretch was chosen as a
low intensity intervention that produces modest gains in myotube size (67-69), without significant
damage that higher intensity (such as 10%) stretch protocols induce (69). 24hrs was chosen
because prior research has found 24hrs of either stretch or E-Stim to induce measurable
adaptations in vitro (67, 70, 73, 74).

To my knowledge no one has yet combined both E-Stim

and stretch in one in vitro protocol, because I do not want to induce a hyper-physiological effect I
opted for conservative protocols for both E-Stim and stretch. After 24hrs of E-stim and stretch,
simulating a “healthy” control muscle, myotubes would have had E-Stim and stretch halted to
simulate disuse atrophy. “Atrophy” will be allowed to develop for 24-48hrs (Figure 7).
Hormone Interventions: To test the effects of hormonal interactions on the development of disuse
“atrophy”, at the initiation of “disuse” myotubes were incubated with physiologically relevant
concentrations of traditional sex hormones: testosterone, estrogen, and progesterone. To
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simulate the estrous cycle in vitro, cells were treated with concentrations of progesterone and
estrogen combined that are typical of the proestrus (peak hormones) portion of the cycle.
Additionally, to delineate specific differences between progesterone and estrogen action, cells will
also be individually treated with progesterone and estrogen. Incubations will be for ~24hrs, as
our preliminary data suggested 24hrs is sufficient to induce muscle atrophy in female mice (Figure
2). Additionally, because female mice only stay in one stage of the estrous cycle for ~24hrs(77),
this incubation time will allow for more physiologically relevant analysis of hormonal factors on
muscle disuse. Outcome variables will include: 1.) myotube size, 2.) mitochondrial stress
measured by fluorescent dye and 3.) mRNA and protein content related to mitochondrial quality
control regulators.
Myotube size: myotube size will serve as a surrogate measure of muscle wasting and will be
measured using Nikon TiS microscope and associated software. Myotube size will be measured
pre-“atrophy” and post-“atrophy”.
Mitochondrial stress. Mitochondrial stress were measured by JC1 as I have previously completed
(78). JC1 measures mitochondrial polarization.
Mitochondrial quality control regulators. mRNA and protein content were measured as in Aim 1
and 2.
Anticipated results and interpretation of findings: I anticipated that differences in muscle atrophy
in vitro will be at least partially mediated by biological sex, where male and female hormones will
demonstrate different mechanisms contributing to atrophy. Specifically, I expected partial
protections for mitochondrial quality and subsequent atrophy with female hormones as opposed
to male, as both progesterone and estrogen have been found to be mitochondrial protective(79,
80). I interpret differences in muscle atrophy in vitro as evidence that hormonal differences
between sexes at least partially mediate differential etiologies and progressions of disuse muscle
atrophy.
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Potential problems and contingency plans: Due to technological issues and global pandemics, I
was not able to fully complete Specific Aim 3 of this proposal. The C-stretch unit had technical
difficulties that the instrument required servicing by the manufacturer and once the unit returned
there was limited research capacity due to the global pandemic of COVID-19. However, to
investigate the impacts of sex hormones on muscle atrophy, I completed experiments to
investigate how sex hormones influence development of in vitro muscle atrophy using
glucocorticoid-induced and cancer cachexia-induced muscle atrophy. Although not directly
related to disuse muscle atrophy, these experiments still provided evidence for hormonal
influence during the progression of muscle atrophies and offers rationale for future investigations
on the impacts of sex hormones during disuse atrophy.
e. Summary.
Muscle wasting, and its associated comorbidities represent a significant malady for
millions. Therefore, a significant need remains to investigate underlying metabolic mechanisms
contributing to these pathologies. This research proposal will be the first to elucidate the sexual
dimorphisms in progression of disuse atrophy and provide foundational evidence for
individualized treatments of disuse-induced muscle pathologies. I have extensive experience with
the proposed methods and techniques detailed in this proposal as well as a clear history of
scientific productivity and trajectory for a career in scientific excellence and therefore the optimal
candidate to execute this research proposal.
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f.

Figures

Figure 1: Pictorial description of my primary hypothesis

Figure 2: Preliminary data I have collected demonstrating a sex dimorphic response in the
percent difference of body and muscle weight loss during the progression of cachexia. Stars
indicate statistical difference between sexes at the same time point (p<0.05). Different letters
represent statistically different changes in mass from control within the same sex (p<0.05). Both
groups demonstrated linear trends for gastrocnemius and soleus tissues (p<0.05). (Preliminary
data, not published)
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Figure 3: Preliminary data I have collected mitochondrial alterations occur before muscle wasting
in male mice. Specifically, pMitoTimer Red/Green ratio, a measure of mitochondrial oxidative
stress, increased at 1 day of disuse. This alteration occurred prior to muscle loss, which occurred
at 2 days of disuse.

Figure 4: Preliminary data I have collected in WT and mice overexpressing mitochondrial specific
catalase (MCAT). Overall, MCAT mice appear to have a blunted response to wasting in the
gastrocnemius muscle compared to WT animals.
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Figure 5: Pictorial description of animal protocol. At 8wks of age, animals will be hindlimb
unloaded for 0 (con), 1, 2, 3, or 7 days. Outcome variables will be measured at each timepoint.

Figure 6: Pictorial description of Specific Aim2
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Figure 7: Pictorial description of Specific Aim 3. Where by C2C12 myotubes will be E-Stimmed
and stretched to simulate “healthy” control muscle in vitro. After which E-Stim and stretch will be
halted to induce disuse “atrophy” and cells will be treated with physiological concentrations of
traditional sex hormones to determine the relative influence of sex hormones on the development
of disuse atrophy.

60
g. References
1.
Leitner LM, Wilson RJ, Yan Z, Godecke A. Reactive Oxygen Species/Nitric Oxide
Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases. Antioxid Redox
Signal. 2017;26(13):700-17.
2.
Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, et al. Impact of
sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg.
2012;16(8):1478-86.
3.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and
classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95.
4.
Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and
metabolic pathways. Cell Metab. 2012;16(2):153-66.
5.
Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually
dimorphic manner. Cancer Res. 2011;71(5):1710-20.
6.
Angelini C, Tasca E, Nascimbeni AC, Fanin M. Muscle fatigue, nNOS and muscle fiber
atrophy in limb girdle muscular dystrophy. Acta Myol. 2014;33(3):119-26.
7.
Fanin M, Nascimbeni AC, Angelini C. Gender difference in limb-girdle muscular dystrophy:
a muscle fiber morphometric study in 101 patients. Clin Neuropathol. 2014;33(3):179-85.
8.
Callahan DM, Bedrin NG, Subramanian M, Berking J, Ades PA, Toth MJ, et al. Age-related
structural alterations in human skeletal muscle fibers and mitochondria are sex specific:
relationship to single-fiber function. J Appl Physiol (1985). 2014;116(12):1582-92.
9.
Callahan DM, Miller MS, Sweeny AP, Tourville TW, Slauterbeck JR, Savage PD, et al.
Muscle disuse alters skeletal muscle contractile function at the molecular and cellular levels in
older adult humans in a sex-specific manner. J Physiol. 2014;592(20):4555-73.
10.
Callahan DM, Tourville TW, Miller MS, Hackett SB, Sharma H, Cruickshank NC, et al.
Chronic disuse and skeletal muscle structure in older adults: sex-specific differences and
relationships to contractile function. Am J Physiol Cell Physiol. 2015;308(11):C932-43.
11.
Sun H, Gong Y, Qiu J, Chen Y, Ding F, Zhao Q. TRAF6 inhibition rescues
dexamethasone-induced muscle atrophy. Int J Mol Sci. 2014;15(6):11126-41.
12.
Wang DT, Yin Y, Yang YJ, Lv PJ, Shi Y, Lu L, et al. Resveratrol prevents TNF-alphainduced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes. Int
Immunopharmacol. 2014;19(2):206-13.

61
13.
Oki K, Halievski K, Vicente L, Xu Y, Zeolla D, Poort J, et al. Contractile dysfunction in
muscle may underlie androgen-dependent motor dysfunction in spinal bulbar muscular atrophy.
J Appl Physiol (1985). 2015;118(7):941-52.
14.
Gao Y, Arfat Y, Wang H, Goswami N. Muscle Atrophy Induced by Mechanical Unloading:
Mechanisms and Potential Countermeasures. Front Physiol. 2018;9.
15.
Dalla Libera L, Ravara B, Gobbo V, Tarricone E, Vitadello M, Biolo G, et al. A transient
antioxidant stress response accompanies the onset of disuse atrophy in human skeletal muscle.
J Appl Physiol (1985). 2009;107(2):549-57.
16.
Powers SK, Smuder A, Judge A. Oxidative stress and disuse muscle atrophy: cause or
consequence? Curr Opin Clin Nutr Metab Care. 2012;15(3):240-5.
17.
Powers SK. Can antioxidants protect against disuse muscle atrophy? Sports Med.
2014;44 Suppl 2:S155-65.
18.
Hyatt H, Deminice R, Yoshihara T, Powers SK. Mitochondrial dysfunction induces muscle
atrophy during prolonged inactivity: A review of the causes and effects. Arch Biochem Biophys.
2019;662:49-60.
19.
Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Brown LA, Perry RA, et al.
Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer
cachexia in tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2017;8(6):926-38.
20.
Karakelides H, Irving BA, Short KR, O'Brien P, Nair KS. Age, obesity, and sex effects on
insulin sensitivity and skeletal muscle mitochondrial function. Diabetes. 2010;59(1):89-97.
21.
Colom B, Alcolea MP, Valle A, Oliver J, Roca P, Garcia-Palmer FJ. Skeletal muscle of
female rats exhibit higher mitochondrial mass and oxidative-phosphorylative capacities compared
to males. Cell Physiol Biochem. 2007;19(1-4):205-12.
22.
Colom B, Oliver J, Garcia-Palmer FJ. Sexual Dimorphism in the Alterations of Cardiac
Muscle Mitochondrial Bioenergetics Associated to the Ageing Process. J Gerontol A Biol Sci Med
Sci. 2015;70(11):1360-9.
23.
Smith IJ, Godinez GL, Singh BK, McCaughey KM, Alcantara RR, Gururaja T, et al.
Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilationinduced diaphragm dysfunction. FASEB J. 282014. p. 2790-803.
24.
Greene NP, Lee DE, Brown JL, Rosa ME, Brown LA, Perry RAJ, et al. Mitochondrial
quality control, driven by PGC-1α, is dysregulated by Western Diet-induced obesity and partially
restored by moderate physical activity in mice. Physiological Reports. 2015;3:e12470.
25.
Rosa-Caldwell ME, Lee DE, Brown JL, Brown LA, Perry JRA, Greene ES, et al. Moderate
Physical Activity Promotes Basal Hepatic Autophagy in Diet-Induced Obese Mice. Applied
Physiology, Nutrition, and Metabolism. 2016.

62
26.
Rosa-Caldwell ME, Brown JL, Lee DE, Blackwell TA, Turner KW, Brown LA, et al.
Autophagy activation, not peroxisome proliferator-activated receptor gamma coactivator 1alpha,
may mediate exercise-induced improvements in glucose handling during diet-induced obesity.
Exp Physiol. 2017;102(9):1194-207.
27.
Dai DF, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, et al.
Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging.
Circulation. 2009;119(21):2789-97.
28.
Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, et al. Extension
of murine life span by overexpression of catalase targeted to mitochondria. Science.
2005;308(5730):1909-11.
29.
Olsen RH, Johnson LA, Zuloaga DG, Limoli CL, Raber J. Enhanced hippocampusdependent memory and reduced anxiety in mice over-expressing human catalase in
mitochondria. J Neurochem. 2013;125(2):303-13.
30.
Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr.
2010;91(4):1123s-7s.
31.
Ali NA, O'Brien JM, Jr., Hoffmann SP, Phillips G, Garland A, Finley JC, et al. Acquired
weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med.
2008;178(3):261-8.
32.
Sharshar T, Bastuji-Garin S, Stevens RD, Durand MC, Malissin I, Rodriguez P, et al.
Presence and severity of intensive care unit-acquired paresis at time of awakening are associated
with increased intensive care unit and hospital mortality. Crit Care Med. 2009;37(12):3047-53.
33.
Hermans G, Van Mechelen H, Clerckx B, Vanhullebusch T, Mesotten D, Wilmer A, et al.
Acute outcomes and 1-year mortality of intensive care unit-acquired weakness. A cohort study
and propensity-matched analysis. Am J Respir Crit Care Med. 2014;190(4):410-20.
34.
Mueller N, Murthy S, Tainter CR, Lee J, Richard K, Fintelmann FJ, et al. Can Sarcopenia
Quantified by Ultrasound of the Rectus Femoris Muscle Predict Adverse Outcome of Surgical
Intensive Care Unit Patients and Frailty? A Prospective, Observational Cohort Study. Ann Surg.
2016;264(6):1116-24.
35.
Baldwin MR, Reid MC, Westlake AA, Rowe JW, Granieri EC, Wunsch H, et al. The
feasibility of measuring frailty to predict disability and mortality in older medical intensive care unit
survivors. J Crit Care. 2014;29(3):401-8.
36.
Bagshaw SM, Stelfox HT, Johnson JA, McDermid RC, Rolfson DB, Tsuyuki RT, et al.
Long-term association between frailty and health-related quality of life among survivors of critical
illness: a prospective multicenter cohort study. Crit Care Med. 2015;43(5):973-82.

63
37.
van Vugt JLA, Buettner S, Levolger S, Coebergh van den Braak RRJ, Suker M, Gaspersz
MP, et al. Low skeletal muscle mass is associated with increased hospital expenditure in patients
undergoing cancer surgery of the alimentary tract. PLoS One. 2017;12(10).
38.
Halpern NA, Pastores SM. Critical Care Medicine Beds, Use, Occupancy, and Costs in
the United States: A Methodological Review. Crit Care Med. 2015;43(11):2452-9.
39.
Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute
skeletal muscle wasting in critical illness. Jama. 2013;310(15):1591-600.
40.
Rudrappa SS, Wilkinson DJ, Greenhaff PL, Smith K, Idris I, Atherton PJ. Human Skeletal
Muscle Disuse Atrophy: Effects on Muscle Protein Synthesis, Breakdown, and Insulin
Resistance—A Qualitative Review. Front Physiol. 2016;7.
41.
Baldwin KM, Haddad F, Pandorf CE, Roy RR, Edgerton VR. Alterations in muscle mass
and contractile phenotype in response to unloading models: role of transcriptional/pretranslational
mechanisms. Front Physiol. 2013;4:284.
42.
Lipes J, Mardini L, Jayaraman D. Sex and mortality of hospitalized adults after admission
to an intensive care unit. Am J Crit Care. 2013;22(4):314-9.
43.
De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et
al. Paresis acquired in the intensive care unit: a prospective multicenter study. Jama.
2002;288(22):2859-67.
44.
Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in
patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of
computed tomography image analysis. Am J Clin Nutr. 2010;91(4):1133s-7s.
45.
Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, et al. Gender disparities in metastatic
colorectal cancer survival. Clin Cancer Res. 2009;15(20):6391-7.
46.
Wallengren O, Iresjo BM, Lundholm K, Bosaeus I. Loss of muscle mass in the end of life
in patients with advanced cancer. Support Care Cancer. 2015;23(1):79-86.
47.
Thomason DB, Herrick RE, Surdyka D, Baldwin KM. Time course of soleus muscle myosin
expression during hindlimb suspension and recovery. J Appl Physiol (1985). 1987;63(1):130-7.
48.
Haizlip KM, Harrison BC, Leinwand LA. Sex-Based Differences in Skeletal Muscle Kinetics
and Fiber-Type Composition. Physiology (Bethesda). 2015;30(1):30-9.
49.
English AW, Eason J, Schwartz G, Shirley A, Carrasco DI. Sexual dimorphism in the rabbit
masseter muscle: myosin heavy chain composition of neuromuscular compartments. Cells
Tissues Organs. 1999;164(4):179-91.

64
50.
Eason JM, Schwartz GA, Pavlath GK, English AW. Sexually dimorphic expression of
myosin heavy chains in the adult mouse masseter. J Appl Physiol (1985). 2000;89(1):251-8.
51.
Alleman RJ, Katunga LA, Nelson MA, Brown DA, Anderson EJ. The "Goldilocks Zone"
from a redox perspective-Adaptive vs. deleterious responses to oxidative stress in striated
muscle. Front Physiol. 2014;5:358.
52.
Ginsburg GS, Phillips KA. Precision Medicine: From Science to Value. Health Aff
(Millwood). 2018;37(5):694-701.
53.
Kichko K, Marschall P, Flessa S. Personalized Medicine in the U.S. and Germany:
Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical
Standard. J Pers Med. 2016;6(2).
54.
NIH. National Institutes of Health: All of Us Research Program
https://allofus.nih.gov/.

[Available from:

55.
Washington TA, White JP, Davis JM, Wilson LB, Lowe LL, Sato S, et al. Skeletal muscle
mass recovery from atrophy in IL-6 knockout mice. Acta Physiol (Oxf). 2011;202(4):657-69.
56.
Globus RK, Morey-Holton E. Hindlimb unloading: rodent analog for microgravity. J Appl
Physiol (1985). 2016;120(10):1196-206.
57.
Marzuca-Nassr GN, Vitzel KF, Murata GM, Marquez JL, Curi R. Experimental Model of
HindLimb Suspension-Induced Skeletal Muscle Atrophy in Rodents. Methods Mol Biol.
2019;1916:167-76.
58.
Dirks ML, Wall BT, van de Valk B, Holloway TM, Holloway GP, Chabowski A, et al. One
Week of Bed Rest Leads to Substantial Muscle Atrophy and Induces Whole-Body Insulin
Resistance in the Absence of Skeletal Muscle Lipid Accumulation. Diabetes. 2016;65(10):286275.
59.
Dirks ML, Smeets JSJ, Holwerda AM, Kouw IWK, Marzuca-Nassr GN, Gijsen AP, et al.
Dietary feeding pattern does not modulate the loss of muscle mass or the decline in metabolic
health during short-term bed rest. Am J Physiol Endocrinol Metab. 2019;316(3):E536-e45.
60.
Tanner RE, Brunker LB, Agergaard J, Barrows KM, Briggs RA, Kwon OS, et al. Agerelated differences in lean mass, protein synthesis and skeletal muscle markers of proteolysis
after bed rest and exercise rehabilitation. J Physiol. 2015;593(Pt 18):4259-73.
61.
English KL, Mettler JA, Ellison JB, Mamerow MM, Arentson-Lantz E, Pattarini JM, et al.
Leucine partially protects muscle mass and function during bed rest in middle-aged adults. Am J
Clin Nutr. 2016;103(2):465-73.
62.
Ferrando AA, Stuart CA, Brunder DG, Hillman GR. Magnetic resonance imaging
quantitation of changes in muscle volume during 7 days of strict bed rest. Aviat Space Environ
Med. 1995;66(10):976-81.

65
63.
Picard M, Taivassalo T, Ritchie D, Wright KJ, Thomas MM, Romestaing C, et al.
Mitochondrial structure and function are disrupted by standard isolation methods. PLoS One.
2011;6(3):e18317.
64.
Min K, Kwon OS, Smuder AJ, Wiggs MP, Sollanek KJ, Christou DD, et al. Increased
mitochondrial emission of reactive oxygen species and calpain activation are required for
doxorubicin-induced cardiac and skeletal muscle myopathy. J Physiol. 2015;593(8):2017-36.
65.
Myers JL, Well AD, Lorch RFJ. Research Design and Statistical Analysis. 3 ed. New York,
NY: Routledge; 2010.
66.
Armstrong RB, Phelps RO. Muscle fiber type composition of the rat hindlimb. Am J Anat.
1984;171(3):259-72.
67.
Gao S, Carson JA. Lewis lung carcinoma regulation of mechanical stretch-induced protein
synthesis in cultured myotubes. Am J Physiol Cell Physiol. 2016;310(1):C66-79.
68.
Carson JA, Booth FW. Effect of serum and mechanical stretch on skeletal alpha-actin
gene regulation in cultured primary muscle cells. Am J Physiol. 1998;275(6):C1438-48.
69.
Simpson DG, Majeski M, Borg TK, Terracio L. Regulation of cardiac myocyte protein
turnover and myofibrillar structure in vitro by specific directions of stretch. Circ Res.
1999;85(10):e59-69.
70.
Vandenburgh H, Kaufman S. In vitro model for stretch-induced hypertrophy of skeletal
muscle. Science. 1979;203(4377):265-8.
71.
Tarum J, Folkesson M, Atherton PJ, Kadi F. Electrical pulse stimulation: an in vitro
exercise model for the induction of human skeletal muscle cell hypertrophy. A proof-of-concept
study. Exp Physiol. 2017;102(11):1405-13.
72.
Danilov K, Sidorenko S, Milovanova K, Klimanova E, Kapilevich LV, Orlov SN. Electrical
pulse stimulation decreases electrochemical Na(+) and K(+) gradients in C2C12 myotubes.
Biochem Biophys Res Commun. 2017;493(2):875-8.
73.
Evers-van Gogh IJ, Alex S, Stienstra R, Brenkman AB, Kersten S, Kalkhoven E. Electric
Pulse Stimulation of Myotubes as an In Vitro Exercise Model: Cell-Mediated and Non-CellMediated Effects. Sci Rep. 2015;5:10944.
74.
Lambernd S, Taube A, Schober A, Platzbecker B, Gorgens SW, Schlich R, et al.
Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting proinflammatory signalling pathways. Diabetologia. 2012;55(4):1128-39.
75.
Fujita H, Nedachi T, Kanzaki M. Accelerated de novo sarcomere assembly by electric
pulse stimulation in C2C12 myotubes. Exp Cell Res. 2007;313(9):1853-65.

66
76.
Matthews VB, Astrom MB, Chan MH, Bruce CR, Krabbe KS, Prelovsek O, et al. Brainderived neurotrophic factor is produced by skeletal muscle cells in response to contraction and
enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia.
2009;52(7):1409-18.
77.
Gonzalez G. Determining the Stage of the Estrous Cycle in Female Mice by Vaginal
Smear. Cold Spring Harb Protoc. 2016;2016(8).
78.
Rosa-Caldwell M, Brown J, Lee D, Washington T, Greene N. Tumor Derived Factors
Induce Muscle Mitochondria Hyperpolarization and Subsequent Superoxide Production. MSSE
Conference Proceedings. 2018.
79.
Cavalcanti-de-Albuquerque JP, Salvador IC, Martins EL, Jardim-Messeder D, Werneckde-Castro JP, Galina A, et al. Role of estrogen on skeletal muscle mitochondrial function in
ovariectomized rats: a time course study in different fiber types. J Appl Physiol (1985).
2014;116(7):779-89.
80.
Bottje W, Kong BW, Reverter A, Waardenberg AJ, Lassiter K, Hudson NJ. Progesterone
signalling in broiler skeletal muscle is associated with divergent feed efficiency. BMC Syst Biol.
2017;11(1):29.

67
Chapter IV: Manuscript from Specific Aim I
Mitochondrial Aberrations during the Progression of Disuse Atrophy Differentially Affect
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a. Abstract
Disuse decreases muscle size and is predictive of mortality across multiple pathologies.
Detriments to mitochondrial function are hypothesized to underlie this pathology. However, little
data exists on early mechanisms contributing to onset of these pathologies, nor is it known how
they differ between sexes. The purpose of this study was to investigate sex differences in
mitochondrial quality during the progression of disuse-induced muscle atrophy. 100 C57BL/6J
mice (50 male, 50 female) were hindlimb unloaded to induce disuse atrophy for 0(con), 24, 48,
72, or 168hrs. At designated time-points, EDL, gastrocnemius and soleus muscles were collected
for analysis of mitochondrial quality control markers. Disuse developed rapidly in both males and
females. Disuse resulted in aberrations to many markers of mitochondrial quality control in all
muscle collected; however the most robust alterations appeared to occur in the soleus muscle.
Interestingly, there appeared to be a robust dichotomy in autophagic and mitophagy responses
to disuse atrophy between males and females. In conclusion, disuse negatively affects
mitochondria differentially between sexes during development of muscle wasting and may
contribute to divergent clinical manifestations of atrophy.
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b. Introduction
Muscle is one of the largest contributors to whole body energy metabolism (1),
consequently deteriorations in muscular health can have significant implications for whole body
health. Muscle atrophy is a common occurrence across a variety of pathologies and has
substantial influence on quality of life and longevity (2). Specifically, disuse-induced muscle loss
is a frequent occurrence with spaceflight, casting of limbs, and prolonged bed rest (2). This
prolonged lack of muscle contractile activity has significant implications for patients (2, 3). Of note,
disuse-induced muscle atrophy is strongly associated with mortality in ICU patients (4-7).
However, to date, precise mechanisms contributing to this muscle loss and subsequent mortality
are not fully understood.
Until recently, the breadth of muscle pathology research has predominantly been
conducted using male models (8-18). Yet, recent works have begun to establish the importance
of biological sex in relation to muscle pathologies (19). Clinically, many muscle pathologies
present differently between males and females (20-25). For example, females tend to have
improved clinical outcomes and longevity compared to males during cancer progression (26-28).
Conversely, during disuse atrophy, females tend to experience Intensive Care Unit (ICU) frailty at
higher rates compared to males (29), which appears to correspond to increased ICU mortality in
females (30). Yet, preclinical models establishing mechanistic differences between males and
females during muscle pathologies are limited, which likely limits ability to develop effective
therapeutics for the prevention of muscle pathologies.
Current literature strongly implicates the role of mitochondrial function and quality on
maintenance of overall muscle health. Whereby, appropriate oxidative phosphorylation and ATP
production allow for muscle mass maintenance and overall metabolic health (31). However,
during pathological conditions, works have clearly demonstrated mitochondrial aberrations such
as: increased reactive oxygen species production (ROS), decreased ATP production, and

69
alterations to mitochondrial quality control mechanisms (11, 13-17, 32). We recently showed
mitochondrial degeneration and ROS production precede muscle loss in mice during development
of cancer cachexia (33), strongly suggesting mitochondrial mechanisms as an early alteration
during the progression and development of cancer-induced muscle atrophy. Indeed, recent works
have observed mitochondrial aberrations in the early phases of disuse atrophy (34). However,
whether these mitochondrial mechanisms are conserved between males and females remains to
be investigated.
Different muscle pathologies differentially affect various muscle fibers (35). For example,
inflammatory wasting such as cancer cachexia strongly affects glycolytic fibers (33, 35), whereas
disuse atrophy classically affects oxidative fibers (34, 35). Yet, if disuse atrophy differentially
affects fibers from males and females has not been fully investigated. Females are known to have
more oxidative fibers, corresponding to increased fat metabolism (24, 25, 36). There, it is possible
that males and females have different responses to disuse atrophy, possibly due to different fiber
type distributions, however to our knowledge this has not been fully investigated.
Overall, the aggregate of the literature clearly suggests alterations in muscle mitochondrial
and metabolic health may underlie numerous muscle pathologies. However, the role of
mitochondrial degeneration during the development of disuse-induced muscle atrophy is not
currently well-defined. Furthermore, how mitochondrial degeneration develops between biological
sexes during disuse-induced atrophy is unknown. Therefore, the purpose of this study was to
examine differential and conserved responses to mitochondrial quality control in male and female
mice during the development and progression of disuse-induced atrophy.
c.

Methods
i.

Animals and Interventions
All animal interventions were approved by The University of Arkansas Institutional Animal

Care and Use Committee. 100 C57BL6/J mice (50 males and 50 females, Jackson Laboratories,
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000664) were randomly assigned to different periods of disuse atrophy (0hrs [CON], 24hrs, 48hrs,
72hrs, or 168hrs with ~10 animals/group). At 8 weeks of age animals underwent electroporation
of the flexor digitorum brevis muscle with pMitoTimer as we have previously described (33).
Briefly, animals were anesthetized with 2% isoflurane mixed with oxygen. Upon anesthesia, 10
µL of of hyaluronidase solution (0.36mg/ml dissolved in sterile saline) was injected into the right
FDB of each mouse. After one hour animals were re-anesthetized and the right FDBs were
injected with 20 µg of pMitoTimer dissolved in 10 µL sterile saline. Animals were allowed to
recover for 15 minutes, then the FDB underwent electroporation with 10 pulses at 75 V/cm, 1Hz
and 20ms/pulse. The FDB muscle was chosen for this analysis for a few reasons. 1.) Due to the
anatomy of the muscle, it can be whole mounted directly on a microscope slide and analyzed
within an hour of tissue harvest. 2.) the FDB is responsive to atrophic stimuli (37-41)and 3.) Due
to the nature of the model the FDB was concurrently unloaded along with other hindlimb muscles.
After 2 weeks of recovery, disuse atrophy was induced at 10 weeks of age using hindlimb
unloading model as previously described (14, 42, 43). Animals’ tails were first sterilized using
ethanol wipes and iodine swabsticks. After which, tails were coated with benzoin solution to
increase adhesiveness of the animals’ tail. Athletic tape was then gently wrapped around the
animals’ tails, a specialized hook was then connected to the athletic tape. Fishing string was then
wrapped around the hook and looped through a custom designed pulley system to allow for
unloading of the hindlimb legs and animal mobility around a specially designed cage. Animals
had full use of forelimbs and were able to move around the cage. Animals were suspended at
~30-45 degree angle. Animals were monitored daily to ensure unloading of hindlimb as well as
signs of tail necrosis, or distress.
ii.

Mitochondrial Respiration
Mitochondrial respiration was performed as we and others have previously described (33,

44). Briefly, soleus and gastrocnemius muscles were excised from live animals and then carefully
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separated into individual muscle fibers (entire soleus and a portion of the mixed fibers from the
gastrocnemius). Fibers were then treated with saponin to permeabilize pores in the fiber
membrane. Mitochondrial oxygen consumption of the fibers was then measured. Mitochondria
were primed with malate and glutamate to measure ADP-stimulated (state 3) and ADP-depleted
(state 4) respiration. Results are reported as the ratio of state 3 to state 4 respiratory control ratio
(RCR) and normalized to dry tissue weight. The soleus and gastrocnemius were chosen to
compare the effect of disuse atrophy on highly oxidative muscles compared to mixed muscles.
Due to COVID-19 pandemic, only male data is available for this outcome.
iii.

Reactive Oxygen Species Assay
Reactive oxygen species was measured at harvest of animals; however, due to COVID-

19 global pandemic and subsequent laboratory shutdowns, this data is not available for the
dissertation. However, this data will be in the eventual manuscript. Reactive oxygen species
(ROS) production was measured as previously described (33, 44, 45). Briefly, permeabilized
fibers from soleus and gastrocnemius muscle were treated with Amplex Red Hydrogen Peroxide.
Amplex Red reacts in a 1:1 ratio with H2O2 to produce resorufin, a red fluorescent product. Red
florescence was quantified as a measure of ROS production in the soleus and plantaris muscles.
The gastrocnemius muscle was chosen because of its mixed fiber type composition and the
soleus was chosen because of its predominantly oxidative fiber composition. These two muscles
were chosen to contrast mixed fiber and oxidative fiber muscles.
iv.

Histological Analysis

pMitoTimer: pMitoTimer was analyzed as we have previously described (33). Briefly, animal flexor
digitorum brevis (FDB) muscles were excised at tissue harvest and fixed in 4%
paraformaldehyde/PBS solution for 20 minutes. After which, FDBs were washed for 5 minutes in
PBS and mounted on a gelatin coated slide. Slides were then analyzed for red and green
fluorescence using FITC and TRITC filters on a Nikon Ti‐S inverted epiflourescent microscope
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(Melville, NY) with LED‐based light source with tightly controlled acquisition parameters (33, 46).
All slides were analyzed at time of harvest for the ratio of Red/Green fluorescence, whereby
greater Red/Green ratios are indicative of increased mitochondrial stress (46). Slides were also
measured for red puncta, a marker for completely degenerated mitochondria (46).
Succinate Dehydrogenase Stain: Succinate dehydrogenase (SDH) stain was completed in 10 µm
sections of the tibialis anterior muscle as we have previously described (33, 47, 48). Muscle fibers
were dichotomized into either SDH positive (SDH+) or SDH negative (SDH-) fibers. Fiber cross
sectional area for SDH+ and SDH- fibers was assessed as we have previously described (33).
Periodic acid–Schiff stain: Periodic acid–Schiff stain (PAS) stain was completed in 10 µm sections
of the tibialis anterior muscle using similar methods as previously described (49). Images were
analyzed for area of stain using Nikon NIS-Elements Basic Research Software (Nikon Instruments
Inc., Melville, NY). All images for each animal were averaged and expressed as percent area
stained as previously reported (49).
v.

mRNA Analysis
To compare the effect of disuse atrophy on different fiber types, we analyzed three

different muscles known to have different fiber type compositions. Specifically, we analyzed the
Extensor Digitorum Longus (EDL, predominantly fast twitch fiber), Gastrocnemius (mixed fibers)
, soleus (predominantly slow twitch fibers) muscles. Muscles were homogenized in TriZOL
reagent to extract RNA. RNA was extracted and reverse transcribed into cDNA as previously
described (48, 50). cDNA was analyzed using SYBR Green primer pairs or Taqman probes as
appropriate using the -ΔΔCT method as we have previously described (48, 50, 51). All samples
were analyzed using a StepOne PCR instrument (ThermoFisher Scientific, Waltham, MA). SYBR
primers included: Pparα, Nrf2, Mfn1, Mfn2, Opa1, Drp1, Fis1, Mff, mtiF2, mtiF3, Taco1, Tufm,
Tfam, and Bnip3 (primer pairs have previously been reported(48). Taqman probes included: 18s
(Clone #Mm03928990_g1), Cox4 (Clone #mm01250094_m1), Pgc1α (Clone # mm01208835_m1
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), Lc3 (Clone # Mm00458725_g1) and p62 (Clone #Mm00448091_m1). All samples were
normalized to 18s values, which did not differ between groups.
vi.

Western Blot Analysis
Western blot analysis of the gastrocnemius and extensor digitorum longus (EDL) muscles

were completed as we have previously described (47, 48, 50). All membranes were imaged using
a LiCor Odyssey® Fc Imaging System and analyzed using ImageStudio Lite software (LiCor,
Lincoln, NE). For all membranes, one cohort of males (0hr, 24hr, 48hr, 72hr, and 168hr) and one
cohort of females (0hr, 24hr, 48hr, 72hr, and 168hr) was loaded on each membrane. To compare
samples across gels an internal control sample was loaded on each membrane and samples
were normalized to Ponceau S stain and the internal control. Antibodies included: COX‐IV (Cell
Signaling 4844S), PGC‐1α (Novus Biologicals, NBP1-04676SS), MFN1 (Santa Cruz sc‐50330),
MFN2 (Santa Cruz sc‐50331), OPA1 (Santa Cruz sc‐367890), DRP1 (Cell Signaling 14647), FIS1
(Novus NB100‐56646). BNIP3 (Cell Signaling 3769), LC3 (Cell Signaling 4108), p62 (Cell
Signaling 5114s). Western blot analysis was only performed in gastrocnemius and EDL tissues
due to tissue availability.
vii.

Statistical Analysis
Each sex was analyzed by a one-way ANOVA with in factor levels including hours of

disuse (0hrs, 24hrs, 48hrs, 72hrs, or 168hrs). When significant F ratios were found, a Tukey posthoc was used to delineate differences between groups. Additionally, in order to determine how
different measures of muscle metabolism and mitochondrial quality are altered during the
progression of disuse we utilized trend analysis as previously described and as we have
previously published (49). This analysis was used to determine overall patterns of the data that
may not reach pair-wise statistical significance and indirectly compare differential progressions of
disuse atrophy in males and females.
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d.

Results
i.

Lower body and tissue weights following hindlimb unloading in male and female mice.
Tissue weights from all animals are presented in Table 1. Both male and female animals

had lower bodyweight and muscle weights with hindlimb unloading. Males had lower bodyweight
with increased duration of unloading, with a linear decrease trend (p=0.010, Table 1) observed in
body weight across groups. Females had a quadratic trend for body weight (p=0.010, Table 1),
with a lower body weights in animals with longer durations of unloading that appeared to plateau
at 72hrs of disuse. In male mice, gastrocnemius muscle exhibited a linear trend, with increased
duration of hindlimb unloading corresponding to lower mass (p<0.001, Table 1), 48hr and 168hr
animals had ~12.1% and ~15.8% lower gastrocnemius weight compared to 0hr. Similarly, in
female gastrocnemius muscle, a linear trend was also noted (p<0.001, Table 1). With 48hr, 72hr,
and 168hr female animals having ~ 8.7%, ~15.0%, and ~16.9% lower gastrocnemius weights
compared to 0hr. In male soleus muscle, a linear trend was found (p<0.001, Table 1), with 48hr,
72hr and 168hr animals having ~14.0%, ~19.6%, and ~38.6% lower soleus muscle weights
compared to 0hr. In females, a linear trend was also found (p<0.001, Table 1), with 24hr, 48hr,
72hr, and 168hr animals having ~10.9%, ~17.9%, ~24.0%, and ~33.8% lower soleus muscle
weights compared to 0hr females. In male plantaris muscle, a linear trend was also noted
(p<0.001, Table 1), with 48hr, 72hr, and 168hr mice having ~11.1%, ~11.2%, and ~18.0% lower
plantaris weights compared to 0hr. Likewise, female mice demonstrated a linear trend (p<0.001,
Table 1), with 24hr, 48hr, 72hr, and 168hr animals having ~15.7%, ~16.5%, ~25.1%, and ~20.2%
lower plantaris weights compared to 0hr animals. In male tibialis anterior (TA) muscle, a linear
trend was also noted with duration of hindlimb unloading (p<0.001, Table 1), with 168hr animals
having ~13.4% lower TA weights compared to 0hr. In female TA muscle, a linear trend was also
noted (p=0.008, Table 1) with 48hr, 72hr and 168hr animals having ~9.1%, ~14.7%, and 11.8%
lower TA weights compared to 0hr. However, in both male and female mice there was no effect
of hindlimb unloading on EDL weights (p=0.334 and p=0.203 respectively). Of note, lower muscle
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weights were no significant between 0-24hrs in male mice; however, in female mice there were
statistically significant lower muscle weights within 24hrs of unloading. Graphical representation
of percent losses and muscle losses normalized to body weight at time of hindlimb unloading are
presented in Supplementary Figure 1.
ii.

Hindlimb unloading resulted in decreased muscle size in males and females.
Male and female cross sectional area for both SDH+ and SDH- fibers were averaged

within each animal and analyzed by one-way ANOVA and trend analysis. Males demonstrated a
linear decrease in SDH+ CSA (p<0.05, Figure 1A & 1H), which was also demonstrated in fiber
distributions of all muscle fibers (10,000 fibers, p<.0.05, Figure 1C &1H). Similarly, females
experienced a linear trend for lower CSA of SDH+ muscle fibers (p<0.05, Figure 1B & 1H) which
was evident in fiber distributions when pooling all analyzed muscle fibers (~10,000 fibers, Figure
1C & 1H). However, both males and females exhibited no statistical differences in CSA of SDHmuscle fibers at both the individual animal level (Figure 1B, p>0.05) and the individual fiber levels
(~8,000 and ~7,000 fibers, Figures 1E & 1F).

Additionally, male muscle glycogen content

measured by PAS demonstrated a cubic trend (p<0.0001, Figure 1G & 1H). 24 and 48hr unloaded
males had ~30% lower glycogen content, which then returned to control (0hr) levels in 72hr
animals. Then glycogen in 168hr was similar to 24 and 48hr animals (Figure 1G & 1H). However,
females overall had no statistical differences in glycogen content measured by PAS (Figure 1G &
1H, p>0.05). Cox4 mRNA content in the EDL was not different in any timepoints in males (p>0.05,
Supplementary Figure 2), whereas in females 48hr animals had ~65% greater Cox4 mRNA
content compared to 72hrs (p<0.05, Supplementary Figure 2). In males and females, there were
no differences in gastrocnemius Cox4 mRNA content across all time points (p>0.05,
Supplementary Figure 2). However, in the soleus muscle, there was a linear trend for decreased
Cox4 mRNA content (p<0.0001), with 168hr unloaded males having ~50-80% less Cox4 mRNA
content compared to 0, 24, and 48hr males. Contrastingly, females had a quadratic trend for Cox4
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mRNA content (p<0.006, Supplementary Figure 2), with a progressive decrease in Cox4 content
in 24, 48, and 72hrs of unloading which subsequently recovered to baseline levels by 168hrs of
unloading (Supplementary Figure 2). No differences in gastrocnemius (p=0.504 and p=0.520, for
EDL (p=0.955 and p=0.795) COX-IV protein in males or females were detected across groups
(Figure 1I and Supplementary Figure 2).
iii.

Hindlimb unloading appeared to exert dimorphic effects between males and females
In males, Red:Green ratio in pMitoTimer demonstrated a quadratic relationship (p<0.05)

with a peak in Red:Green ratio at 24 and 48hrs of disuse (~67% greater Red:Green Ratio, Figure
2A & 2E). Red: Green ratio then was 25% lower in 72 and 168hr animals, but still ~50% greater
than 0hrs animals (Figure 2A & 2E). However, in females a linear relationship was noted (p<0.05),
with significantly greater Red:Green ratio in pMitoTimer at 168hrs of disuse compared to 0hrs
(Figure 2A & 2E). Red puncta, a measure of degenerated mitochondria tagged for degeneration
(46), demonstrated alterations during the duration of unloading in both males and females. Males
had a quadratic trend, with 30-fold greater red puncta at 24 and 48 hrs of disuse, whereas females
did not have alterations in red puncta until 168hrs of disuse (p<0.05, Figure 2B & 2E). Of note, at
168hrs of disuse males had ~25 red puncta/image whereas females had ~10 red puncta/image.
Mitochondrial respiratory control ratio in the gastrocnemius muscle did not have any significant
trends or pairwise differences (p=0.951 Figure 2C). Similarly, male soleus muscle also did not
have any significant trends or pairwise differences (p= 0.782, Figure 2D). Due to COVID-19
global pandemic, we were not able to complete analysis on RCR in females or reactive oxygen
species in neither males or females
iv.

Measures of oxidative metabolism were altered with hindlimb unloading with
differential effects in males and females
In male EDL muscles there was a linear trend with lower Pparα mRNA content, with 48,

72 and 168hr males having ~50-70% lower mRNA content of Pparα (p<0.05, Figure 3A) However,
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in females there were no statistical differences in Pparα content (p>0.05). In male gastrocnemius
muscles, there was a significant linear trend for lower Pparα with longer durations of unloading
(p<0.0001, Figure 3B), with ~50% less Pparα content in 24, 48, 72 and 168hrs of unloading
compared to 0hrs. A similar pattern was noted in females, with a significant linear trend towards
lower Pparα content with longer durations of unloading (p<0.0001, Figure 3B). Additionally, in
male and female soleus muscles, Pparα content was ~75% lower in 24hrs animals and remained
lower in 48, 72 and 168hrs in both males and females (p<0.0001, Figure 3C).
In males, a cubic trend (p<0.0001) was noted in Nrf2 content in the EDL, with ~40%
greater Nrf2 content in 24 and 48hr males, compared to all other time points. A similar pattern
was noted in females, however the global F test did not reach statistical significance (p=0.06). In
male gastrocnemius muscle a quadratic trend in Nrf2 content was noted (p<0.0003, Figure 3E),
with a peaking of Nrf2 content in 48hrs unloaded males (2-fold greater content), then a
progressive decrease in Nrf2 content, with 168hrs males having ~50% less Nrf2 content
compared to 0hrs animals. However, in female gastrocnemius muscle, Nrf2 content was greater
in 24 and 48hr animals and remain elevated in 72hr and 168hr groups (p<0.05, Figure 3E). In
male soleus muscle a quadratic trend was noted (p<0.002, Figure 3F), with progressively greater
Nrf2 content that peaked in 72hrs animals (~2-fold greater compared to 0hrs), that then returned
to baseline in 168hrs animals. In females, there were no differences in Nrf2 content in any time
points (p=0.84, Figure 3F).
In males, there were no significant differences noted in Pgc1α mRNA content in the EDL
muscle (p=0.078, Figure 3G); however, in females, significant pairwise differences were noted in
48hr animals, with 48hr animals having ~3-fold greater Pgc1α compared to other group (p=0.002,
Figure 3G). In male gastrocnemius muscles a cubic trend was noted in Pgc1α content, with 24hr
males having lower Pgc1α, that then returned to baseline in 48 and 72hr animals, and then
became lower in 168hr animals (Figure 3H, p<0.005). Whereas in females, no differences in
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Pgc1α content were noted between any time points. In male soleus muscle there were no
differences in Pgc1α content noted between any groups (p=0.31, Figure 3I). However, in females
there was a quadratic trend noted (p<0.0001, Figure 3I), with 24hrs animals having ~75% less
Pgc1α content compared to 0hrs. In male and female EDL muscle, there were no significant
differences or pairwise comparisons in PGC1-α content (p=0.133 and 0.379 respectively Figure
3J and 3L). In male and female gastrocnemius muscle, there were no significant differences in
PGC1-α content (p=0.083 and p=0.204 respectively, Figure 3K and 3L).
v.

Markers of mitochondrial mRNA translation demonstrated muscle and sex specific
alterations during the duration of hindlimb unloading
We also measured markers of mitochondrial translation, which are mitochondrial DNA

encoded proteins imperative for oxidative phosphorylation (52). Some of our prior works suggest
muscle pathologies such as insulin resistance may affect mitochondrial translation (53), as such,
we sought to investigate if disuse atrophy affected markers of mitochondrial translation. In the
EDL muscle, there were no statistical differences noted in male mtiF2 content (p=0.166, Figure
4A). However, in female EDL muscles, a cubic trend (p<0.006, Figure 4A) was noted in mtiF2,
with 48hr females having ~7-fold more mtiF2 content compared to all other groups. In the
gastrocnemius muscle, a linear trend was noted in males, which corresponded to ~50% lower
mtiF2 content in 168hr males compared to 0hr males (p<0.006, Figure 4B). However, in female
gastrocnemius muscle, no significant trends or differences were detected (p=0.063, Figure 4B).
In the soleus muscle, both males and females exhibited lower mtiF2 content in all HU groups
compared to 0hrs control (p<0.006 and p<0.02 respectively, Figure 4C). Males had a negative
linear trend in mtiF2 which reached statistical significance within 24hrs of unloading (~70% lower
mtiF2 content in 24hrs compared to 0hrs). Whereas females demonstrated a quadratic trend, with
24hr and 48hr females having ~50% less mtiF2 content compared to 0hrs; however by 72hrs and
168hrs, there was no difference compared to 0hr female mice (Figure 4C).
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In the EDL muscle, no significant differences or trends were noted for mtifF3 in males
(p=0.16, Figure 4D). In female EDL muscles, a quadratic trend was noted in mtifF3 content,
whereby 48hr animals had ~5-fold greater mtifF3 content compared to all other groups (p<0.04,
Figure 4D). Similar to mtiF2, in male gastrocnemius muscle a significant linear trend was noted,
with 168hr males having ~20-40% less mtifF3 content compared to 0hr, 48hr and 72hr animals
(p<0.0001, Figure 4E). In female gastrocnemius muscle, a significant quadratic trend was noted
in mtifF3 (p<0.03, Figure 4E), whereby 48hr females had ~80% greater mtifF3 content compared
to 0hr and 168hr animals. In the soleus muscle, males had a linear decrease in mtifF3 content
(p<0.02, Figure 4F), with 24hrs and 168hrs animals having ~70% lower mtifF3 content compared
to 0hrs. Females had no statistical differences noted (p=0.867, Figure 4F) in mtifF3 content in
the soleus muscle.
Within the EDL muscle, males did not have any significant differences or trends noted in
Taco1 content (p=0.07, Figure 4G). In females, a cubic trend was noted (p<0.02, Figure 4G),
whereby 48hr females had 3-fold greater Taco1 content, which then bottomed out in 72hr animals,
and then began to slowly recover in 168hr animals. Within the gastrocnemius muscle, a significant
linear trend in males was noted in Taco1 content, whereby 24hr, 48hr, 72hr and 168hr animals
had ~30-60% less Taco1 content compared to 0hr animals (Figure 4H). Similarly, a significant
linear trend was also noted in female gastrocnemius muscle in Taco1 content; however pairwise
differences were only significant between 0hr and 168hr with 168hr animals having ~50% less
Taco1 content compared to 0hr (p<0.0008, Figure 4H). Within the soleus muscle, males had a
linear decrease in Taco1 content (p<0.005, Figure 4I), which reached statistical significance in
168hr males (~80% less content compared to 0hr, Figure 4I). Similarly, females had a linear
decrease in Taco1 content (p<0.005, Figure 4I); however 24hrs had ~50% lower Taco1 content,
which reached statistical significance and remained depressed in all experimental groups.
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In the EDL muscle, males did not have any significant differences or trends in Tufm content
(p=0.22, Figure 4J). However females had a cubic trend noted for Tufm content (p<0.005, Figure
4J). 24hr females had ~160-fold greater Tufm content compared to all other groups. Within the
gastrocnemius muscle, males had a significant quadratic trend noted in Tufm content (p<0.003,
Figure 4K), whereby 48hr animals had ~100-130% greater Tufm compared to 0hr, 24hr, 72hr and
168hr animals. However in female gastrocnemius muscle, no significant differences were noted
(p=0.10, Figure 4K). In the soleus muscle, males had linear decrease in Tufm content (p<0.007,
Figure 4L), with 24hr males having ~90% less Tufm content compared to 0hrs, which remained
depressed in all other experimental groups (Figure 4L). In females, a similar trend was noted
(p<0.03, Figure 4L), with 24hr females having ~50% lower Tufm content compared to 0hrs, which
remained depressed in all other experimental groups.
In male EDL muscle, no significant trends or differences were noted for Tfam (p=0.86,
Figure 4J). In the EDL muscle of females a significant F test was noted (p=0.03, Figure 4J),
however no significant trends were noted and the only significant pairwise differences were
between 72hrs and 168hrs (~1-fold). In the gastrocnemius muscle, males had a significant
quadratic trend noted in Tfam content (p<0.008, Figure 4N), with 48hr animals having ~75-135%
greater Tfam content compared to 0hr, 24hr, 72hr, and 168hr animals. Similarly, females also had
a significant quadratic trend noted in Tfam content (p<0.006, Figure 4N). However, contrasting to
males, 72hr animals had peak Tfam content, the differences between means were only significant
between 72hr and 168hr animals (~125% greater Tfam content in 72hr compared to 168hr
animals). In the soleus muscle, males had a significant cubic trend (p<0.0002, Figure 4O) in Tfam
content, with 24hr males having ~1.5-fold greater Tfam content compared to 0hr. Tfam content
then appeared to normalize to 0hr animals in 48hr, 72hr and 168hr animals. In females, no
significant trends or differences were noted in Tfam content (p=0.14, Figure 4O).
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vi.

Mitochondrial dynamics were markedly altered in both male and female mice during
the progression of hindlimb unloading
In the EDL muscle, there were no significant trends or differences noted in Mfn1 mRNA

content in males (p=0.06, Figure 5A). In female EDL muscle, although no significant trends were
noted (p=0.08-0.9), a significant global F test was observed (p<0.01), which corresponded to
significant pairwise differences between 48hr animals and 0hr animals (~3-fold greater Mfn1
content in 48hr animals compared to 0hr) and 48hr animals and 72hr animals (~4-fold greater
Mfn1 content in 48hr animals compared to 72hr) (Figure 5A). Within the gastrocnemius muscle,
males had a significant linear trend towards lowered Mfn1 with increased duration of unloading
(p<0.002, Figure 5B), though the only significant pairwise differences detected were between
168hr and 48hr males (~60% lower Mfn1 content in 168hr compared to 48hr). In female
gastrocnemius muscle no significant trends or differences were noted in Mfn1 content (p=0.11,
Figure 5B). In the soleus muscle, males did not have any significant trends or differences between
groups in Mfn1 content (p=0.28, Figure 5C). However, in females, a significant cubic trend
(p<0.006, Figure 5C) was noted with 72hr animals having ~3-fold greater Mfn1 content compared
to 24 and 48hr females, normalized back to 0hr animals in 168hr animals (Figure 5C). In male
EDL muscle, there was a significant trend for decreased MFN1 content with prolonged periods of
hindlimb unloading (p=0.010, Figure 5J and 5L); however, no pairwise differences reached
statistical significance. In female EDL muscle there was a significant linear trend for greater MFN1
content with increased duration of hindlimb unloading (p=0.003, Figure 5J & 5L); however no
pairwise differences reached statistical significance. In male gastrocnemius muscle no significant
pairwise differences or trends were noted in MFN1 content in either males (p=0.349) or females
(p=0.254, Figure 5K and 5L).
Within the EDL muscle, males had a significant cubic trend noted in Mfn2 content
(p<0.003, Figure 5D), with 24hr males having ~1.5-2-fold greater Mfn2 compared to all other
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groups. In females, although the global F test was significant (p=0.03), no significant trends were
noted (0.18-0.76) and the only pairwise differences noted were between 48hr and 72hr animals
(~2.7-fold greater in 48hr compared to 72hr, Figure 5D). Within male gastrocnemius muscle, a
significant global F test was noted in Mfn2 content (p=0.02, Figure 5E); however no significant
trends were noted. The only pairwise difference noted was between 24hr and 48hr animals (~50%
lower Mfn2 content in 24hr animals compared to 48hr). However, in female gastrocnemius
muscle, a significant cubic trend was noted in Mfn2 (p<0.0006, Figure 5E), whereby 72hr females
had 45-65% greater Mfn2 content compared to 24hr, 48hr and 168hr animals. No significant
differences were noted in Mfn2 content in the soleus muscle of either males or females (p=0.22
and p=0.28 respectively, Figure 5F). Within male EDL muscle, there was no significant trend or
pairwise differences in MFN2 content (p=0.409, Figure 5M and 5L). However, in female EDL
muscle, there was a significant linear trend for greater MFN2 content with longer durations of
hindlimb unloading (p=0.005, Figure 5M and 5L), with 168hr females having 1.5-fold greater
MFN2 compared to 24hr females. In addition, no differences were noted in MFN2 content in either
male (p=0.405) or female (p=0 450, Figure 5N and 5L) gastrocnemius muscle.
In male EDL muscle, no significant differences or trends were noted in Opa1 content
(p=0.07, Figure 5G). In females, no significant trends were noted (p=0.07-0.96); however a
significant global F test was noted (p=0.002, Figure 5G), which corresponded to ~5-7 fold
difference in 48hr animals compared all other experimental groups. Within the gastrocnemius
muscle of males, a significant linear trend was detected (p<0.0001, Figure 5H), with progressively
lower Opa1 content with greater duration of unloading. These differences reached statistical
significance between 0hr and 168hr animals, with 168hr animals having ~60% less Opa1 content
compared to 0hr animals. Contrastingly, in female gastrocnemius muscle, no significant trends or
differences were noted in Opa1 mRNA content (p=0.09, Figure 5H). In the soleus, a significant
linear trend was noted in Opa1 content in males (p=0.005, Figure 5I), with 168hr males having
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~75% lower Opa1 content compared to 0hr. Similarly, a significant linear decrease was noted in
females (p<0.03, Figure 5I). However, Opa1 content became lower at an earlier timepoint (~50%
decrease in 48hr, 72hr and 168hr animals). In male EDL muscle there was no differences in OPA1
content (p=0.483, Figure 5O and 5L). However, in female EDL muscle, there was a linear trend
(p=0.048, Figure 5O and 5L) with a progressive decrease in OPA1 with increased durations of
unloading. The only pairwise difference noted as between 0hr and 48hr, with 48hr animals having
~50% less OPA1 compared to 0hrs (Figure 5O and 5L). In male gastrocnemius muscle, no
differences or trends were noted in OPA1 content (p=0.142, Figure 5P and 5L). Similarly, females
also had no differences noted in gastrocnemius OPA1 content (p=0.895, Figure 5P and 5L).
In the EDL muscle, males had a significant linear trend noted in Drp1 content (p<0.011)
with greater durations of unloading corresponding to greater Drp1 (Figure 6A). The only significant
differences noted were between 48hr and 168hr animals (~1.7-fold greater Drp1 content in 168hr
animals). In female EDL muscle, a significant cubic trend was noted in Drp1 content (p<0.002),
whereby 24hr females had significantly greater Drp1 content (~70-fold) compared to all other
experimental groups (Figure 6A). With male gastrocnemius muscle, a significant linear decrease
in Drp1 content was noted (p<0.005, Figure 6B), with 24hr, 48hr, 72hr, and 168hr animals having
~40-55% less Drp1 content compared to 0hr. Contrastingly, in female gastrocnemius muscle, no
significant differences or trends were noted (p=0.30, Figure 6B). In the soleus, males
demonstrated a linear decrease in Drp1 content (p<0.02, Figure 6C), with significant differences
noted between 0hr and 24hr and 168hr animals (~50% lower Drp1 content). In females, a
quadratic trend was noted (p<0.0002) with 48hr females having the least Drp1 content (~70%
less compared to 0hr) , that then became greater in 72hr and 168hr animals; however it should
be noted that all differences between experimental groups and 0hr animals reached statistical
significance (Figure 6A). In both male and female EDL muscle, there were no significant trends
or pairwise difference in DRP1 (p=0.834 and p=0.772 respectively, Figure 6J & 6N). In both male
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and female gastrocnemius muscle, there were no significant differences or pairwise comparisons
in DRP1 content (p=0.804 and p=0.122 respectively, Figure 6L and 6N).
Within male EDL muscle, a quadratic trend was observed in Mff content (p<0.02, Figure
6D), whereby Mff appeared to gradually become greater in 24hr, 48h, and 72hr animals, then
became lower in 168hr animals (Figure 6D). The only significant pairwise difference noted was
between 48hr and 168hr animals (~2-fold less in 168hr animals, Figure 6D). However, in females
no significant trends or differences were observed in Mff content in the EDL (p=0.06, Figure 6D).
In male gastrocnemius muscle a significant cubic trend was noted in Mff content (p<0.05, Figure
6E), whereby 48hr males had ~65-90% greater Mff content compared to 0hr, 24hr, 72hr and 168hr
animals. Similarly, females also had a cubic trend noted in Mff content within the gastrocnemius
muscle (p<0.003, Figure 6E). However, the peak in Mff content in females presented in 72hr
animals, with ~80-90% greater Mff content in 72hr animals compared to 24hr, 48hr, and 168hr
animals. Within the soleus muscle of male mice, a cubic trend was noted in Mff content (p<0.0001,
Figure 6F), whereby 24hr animals had 1.5-fold more Mff content compared to 0hrs; Mff content
then became progressively less with longer durations of unloading (Figure 6F). In females a
significant linear trend was noted in Mff content (p<0.0005), with a gradual increase in Mff content
with increased unloading time (Figure 6F).
In male EDL muscle no significant differences or trends were observed in Fis1 content
(p=0.21, Figure 6G). However, in female EDL muscle, a significant quadratic trend was noted in
Fis1 content (p<0.02, Figure 6G). Specifically, 48hr females has significantly greater Fis1 content
compared to all other groups (~11-fold greater, Figure 6G). Within the gastrocnemius muscle of
males, a significant linear trend was detected in Fis1 (p<0.005, Figure 6H); however the only
pairwise differences noted were between 48hr and 168hr animals (~50% lower Fis1 content in
168hr compared to 48hr). Contrastingly, in female gastrocnemius muscle, a significant quadratic
trend was noted in Fis1 content (p<0.002, Figure 5R), with progressively greater Fis1 content in
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24hr, 48hr, and 72hr animals compared to 0hr (~60% greater Fis1 content in 72hr compared to
0hr), which then became less in 168hr animals (~70% less Fis1 content in 168hr compared to
72hr, Figure 6H). Within the soleus muscle of males, no significant differences or trends were
noted in Fis1 content (p=0.28, Figure 6I). Similarly, females also did not have any significant
differences or trends noted in Fis1 (p=0.25, Figure 6I). In both male and female EDL muscle
there were no significant trends or pairwise differences in FIS1 content (p=0.594 and p=0.191
respectively, Figure 6J & 6N). In male gastrocnemius muscle, there was a linear trend for
decreased FIS1 content with prolonged duration of unloading (p=0.002, Figure 6K & 6N), with
168hr males having ~73% less FIS1 content compared to 0hr animals. Conversely, in female
gastrocnemius muscle, a significant cubic trend was detected, with 72hr females having ~2-fold
greater FIS1 content compared to 0hr, 24hr, and 48hr animals (p=0.0015, Figure 6K & 6N).
vii.

Mitophagy demonstrated dimorphic responses between males and females
In male EDL muscle, a cubic trend was noted in Bnip3 content (p<0.0001, Figure 7A), with

24hr males having ~2-3 fold greater Bnip3 content compared to all other groups (Figure 7A).
Females also had a cubic trend noted (p<0.008, Figure 6A), with 48hr animals having ~11-12-fold
greater Bnip3 content compared to all other groups (Figure 7A). Within male gastrocnemius
muscle, a significant cubic trend was noted in Bnip3 content (p<0.0003, Figure 7B), with
progressively greater Bnip3 content in 24hr and 48hr animals, then lower Bnip3 content in 72hr
and 168hr animals (~75% greater Bnip3 content in 48hr animals compared to 72hr and 168hr).
However, in female gastrocnemius muscle, Bnip3 appeared to have more robust alterations with
hindlimb unloading, with a significant quadratic trend noted (p<0.0001, Figure 7B). Specifically,
48hr females had ~3-4.5-fold greater Bnip3 content compared to 0hr, 24hr, and 168hr animals.
Within male soleus muscle, Bnip3 demonstrated a linear decrease (p<0.01, Figure 7C). However,
within the global linear trend, 48hr males appeared have greater Bnip3 compared to other
experimental groups (Figure 7C). Contrastingly, females had a linear increase in Bnip3, with
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longer durations of unloading corresponding to greater Bnip3 content (Figure 7C). There were no
significant differences noted in BNIP3 content in either males or females (p=0.732 and p=0.852
respectively, Figure 7J and 7L). In male gastrocnemius muscle there were no significant trends
of pairwise differences detected in BNIP3 content (p=0.552, Figure 7K and 7L). However in
females, a significant quadratic trend was detected (p<0.001, Figure 7K and 7L), whereby 48hr
and 72hr animals had ~1.7-fold greater BNIP3 compared to 0hr and 168hr animals.
No significant differences or trends in Lc3 content were observed in male EDL muscle
(p=0.33, Figure 7D). However in female EDL muscle, a significant cubic trend was observed in
Lc3 content (p<0.003, Figure 7D), with 24hr females having ~13-fold greater Lc3 content than 0hr
and 72hr females. Within male gastrocnemius muscle, although a significant F test was noted in
Lc3 content (p<0.002, Figure 6E), no significant trends were detected. However 48hr males did
have pairwise differences noted between 24hr, 72hr, and 168hr animals (~50-80% greater Lc3
content in 48hr animals) (Figure 7E). Contrastingly, in female gastrocnemius muscle a quadratic
trend was detected (p<0.0001, Figure 7E), whereby Lc3 appeared to progressively become
greater in 24hr, 48hr, and 72 hr animals, then Lc3 content became lower in 168hr animals. 72hr
animals had ~1.2-2.5-fold greater Lc3 content compared to 0hr, 24hr, 48hr and 168hr animals
(Figure 7E). In the soleus muscle, males demonstrated a quadratic relationship with regards to
Lc3 content (p<0.05, Figure 7F) , with a 24hr males having ~90% less Lc3 content compared to
0hr. In female soleus muscle, Lc3 demonstrated a quadratic trend, with 24hr animals having ~50%
less Lc3 content that then began to increase in 48hr, 72hr, and 168hr animals (Figure 7F). In
males gastrocnemius muscle, a significant cubic trend (p=0.011, Figure 7N and 7L) was found in
LC3II/I ratio, with 24hr animals having ~13-15-fold greater LC3II/I ratio compared to 0hr and 168hr
animals. A similar pattern was noted in LC3II, however there was no statistical significance
(p=0.081, Supplementary Figure 3). In females, a cubic trend was also noted in LC3II/I content
(p=0.038, Figure 7N and 7L) with 24hr animals having ~6-fold greater LC3II/I content compared
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to 0hr animals. A similar pattern was noted in LC3II, however there was no statistical significance
(p=0.290, Supplementary Figure 3). With regard to total LC3 content, there were no significant
differences in total LC3 content noted in either males (p=0.116, Supplementary Figure 3) or
females (p=0.847, Supplementary Figure 3).
In male EDL muscle, a linear trend was observed in p62 content (p=0.0065, Figure 7G).
Whereby p62 content appeared to gradually become lower with longer durations of unloading.
However the only statistical difference noted was between 24hr and 168hr animals (~50% lower
p62 content in 168hr animals, Figure 7G). Contrastingly, in females a significant cubic trend was
noted in p62 content (p<0.002, Figure 7G). With 24 and 48hr animals ~20-40-fold more p62
content compared to 0hr animals, with no other pairwise differences noted. Within male
gastrocnemius muscle, a linear decrease in p62 content was detected (p<0.003, Figure 7H),
however the only pairwise difference noted was between 48hr and 168hr animals (~38% lower
p62 content in 168hr compared 48hr animals). In female gastrocnemius muscle, a quadratic trend
was noted (p<0.002, Figure 7H), with 48hr females having ~100% greater p62 content compared
to 0hr animals. No statistical differences were noted in p62 content in either male or female soleus
muscles (p=0.63 and p=0.58 respectively, Figure 7I). In male EDL muscle there was a significant
quadratic trend noted in p62 protein content (p=0.001, Figure 7O and 7L), with 48hr males having
~1.5-2-fold greater p62 protein content compared to 0hr, 24hr, and 168hr animals. In female EDL
muscle, there was also a quadratic trend noted in p62 content, with 72hr females having ~3-10fold greater p62 content compared to all other time points (p<0.001, Figure 7O and 7L). In male
gastrocnemius muscle there was a significant cubic trend in p62 protein content (p=0.003, Figure
7P and 7L). Specifically, 24hr animals had ~1.5-fold greater p62 content compared to 72hr and
168hr animals. In female gastrocnemius muscle, a significant quadratic trend was noted (p<0.001,
Figure 7P and 7L), with 72hr females having ~3-4-fold greater p62 content compared to 0hr and
168hr animals.
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e. Discussion
To our knowledge, this is one of the first studies to investigate mitochondrial aberrations
in both male and female mice during the early development and progression of disuse atrophy
using hindlimb unloading. We find that although muscle loss occurs relatively fast in both males
and females, certain aspects of mitochondrial quality control differ between males and females in
the progression and development of disuse-induced muscle atrophies. More so, differences also
appear to occur depending on the fiber type distribution of the muscle during disuse atrophies,
with oxidative muscles having the greatest aberrations compared to glycolytic muscles.
Importantly, many aberrations to mitochondrial quality control do not necessarily follow linear
increases or decreases, highlighting the importance of timing for future hindlimb unloading
interventions.
We find differences in phenotypic muscle loss occurs rapidly in both male and female
mice. This is particularly true in female mice, where 24hrs of hindlimb unloading was sufficient to
result in 5-10% loss in body, soleus and gastrocnemius weights, compared to 48hrs in male mice.
Accordingly, similar to prior works, we find robust muscle loss with hindlimb unloading in both
male and female mice, with oxidative muscles such as the soleus muscle being particularly
susceptible to these disuse-induced losses (9, 34, 54, 55). Of note, we observe signs of
mitochondrial degeneration, measured by pMitoTimer, in males in the early phases of unloading
that then appears to taper off with increased duration of unloading. Importantly, these aberrations
to mitochondrial quality occurred before the onset of detectible muscle loss in males. Conversely,
females had no alterations to pMitoTimer until 168hrs of disuse, long after muscle loss had
occurred. Recent works have begun to establish mitochondrial differences in males and females
(56-58); however, to our knowledge, this is one of the first studies to find sex-related differences
in mitochondrial health during the early phases of disuse atrophy. These findings suggest disuseinduced atrophy has sex-specific divergent effects on the mitochondrial quality and provide
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rational for future investigations of these mitochondria-related sex differences during muscle
atrophies.
Interestingly, we did not find any alterations in RCR, a measure of ATP production, in
either males or females in either gastrocnemius or soleus muscle across any of our time points,
strongly suggesting muscle loss during disuse atrophies is not directly attributable to alterations
in mitochondrial function and subsequent ATP production, at least in the early development of
disuse atrophies. However, this is perhaps unsurprising as our prior works have not demonstrated
reductions in RCR (in males) until 3-4weeks of cancer development and associated wasting (33),
which likely suggests that reductions in mitochondrial ATP production do not occur until well after
the initiation of muscle pathologies, if such reductions exist. More so, works specifically in disuse
atrophy have found robust mitochondrial aberrations at 7+ days of unloading (34, 59, 60). As
such, it is quite possible the duration of unloading in our study was not sufficient to result in
functional alterations to mitochondrial ATP production, implying mitochondria dysfunction as a
result of disuse-related muscle pathologies, not necessarily the cause.
One aspect of mitochondrial quality control that appeared consistently altered across the
muscle types, was mitochondrial translation. Mitochondrial translation refers to the mRNA
translation of the mitochondrial genome as well as other genes largely responsible for key aspects
of the electron transport system. Mitochondrial translation has recently become a highly
investigated area of research (for a more thorough review of the mitochondrial translation process
see reviews on the topic (61) and we have previously noted alterations to this process during
exercise and obesity (53). In the present study, we find alterations to mitochondrial translation
across the different muscle types; however, notably the most atrophy prone muscle (soleus)
appeared to have the most consistent and robust alterations in markers for mitochondrial
translation. These findings of reduced content of mitochondrial translation markers aligns with
prior works from our laboratory in hindlimb unloaded rats (59). While speculative, within highly
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oxidative fibers, reductions in mitochondrial translation may strongly influence initial muscle
wasting. Prior works have found mitochondrial translation tightly coordinated with mitochondrial
biogenesis and subsequent mitochondrial quality control (62). However, precise mechanisms
connecting mitochondrial translation to catabolic process has not been established and require
further investigation.

Interestingly, altered mitochondrial translation during disuse appeared

specific to the soleus muscle, providing evidence for differential effects of atrophy across fiber
types. These findings provide further rationale to investigate fiber-type specific interventions
during muscle pathologies to restore/rescue the most susceptible muscles during myopathies.
Although many aspects of mitochondrial dynamics appeared altered during the
progression of atrophy, these alterations did not appear to be consistent across muscle fiber
types. This contradicts prior works that have found alterations to the mitochondrial quality network
with disuse, such as increased markers of fusion and decreased markers of fission, with disuse
(59, 60). A potential explanation for these differences may be variance across studies in the
duration of unloading. Works finding differences in mitochondrial fusion as a consequence of
disuse atrophy have utilized 7-28 days for unloading interventions, as opposed to our 1-7 day
timeline. As such, it is possible that the 7 day timeline is not sufficient to result in aberrations to
mitochondrial fusion and suggest alterations to the mitochondrial network are more of a
consequence than cause of muscle atrophy during disuse. However, there did appear to be more
alterations in mitochondrial fission, particularly in females, whereby females had greater content
in many makers of mitochondria fission such as MFF and FIS1 across multiple muscles. We
suggest two possible interpretations of these alterations: 1. Pathological mitochondrial fission
whereby disuse results in increased fission, decreased networking of the mitochondria, and
increased prevalence of segregated unhealthy mitochondrial puncta or 2. Increased fission is
necessary for mitophagy and therefore the increased fission is to facilitate the increased
mitophagy. However, based on the current data we cannot draw strong conclusions on either of
these possibilities and these findings warrant further investigation, specifically in female subjects.
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Concurrent with dramatic muscle mass loss, females appeared to have robust changes in
moderators of autophagy and mitophagy, particularly at the mRNA level. These alterations appear
to coincide with prior works demonstrating increased autophagy and mitophagy in murine models
of disuse atrophy (63-65). However, to our knowledge, this is one of the first studies to report
substantial differences in Bnip3 responses between males and females during disuse atrophy.
Specifically, we find 4-10-fold increases in Bnip3 in female mice unloaded for 24-48hrs compared
to male mice which had marginal differences in Bnip3. Many prior works have found increases in
BNIP3 during the early phases of muscle atrophy (65-68), which then appears to reverse to have
decreased BNIP3 with prolonged durations (>2 weeks) of disuse (59, 69). Yet to our knowledge,
no study has compared the relative differences in mitophagy/autophagy induction in male and
female rodents during the early phases of disuse. Speculatively, in females, these comparatively
greater increases in mitophagy may serve as a protective factor for the muscle, whereby
increased mitophagy allows for early removal of unhealthy mitochondria and maintenance of a
healthy mitochondrial pool. This comparatively healthier mitochondrial pool may help maintain the
Red:Green ratio we noted in female pMitoTimer, with females not displaying greater Red:Green
ratio until 7 days of disuse. However, this explanation would warrant further investigations using
knockout models to validate this hypothesis. More so, as some have speculated that mitophagy
may be an important moderator of disuse atrophy (65-68), future works evaluating the potential
efficacy of mitophagy-centered interventions should be conducted in males and females, as these
interventions may interact differently between the sexes.
Additionally, it is also noteworthy that males and females appeared to have different
inductions of autophagy, specifically Lc3 and p62 during the initial days of disuse atrophy. Across
the EDL, gastrocnemius, and soleus muscle females appeared to have greater inductions of
autophagy. However, it is noteworthy that the soleus muscle comparatively had relatively modest
inductions to mitophagy/autophagy (particularly Bnip3 and p62) compared the EDL and
gastrocnemius muscles. Prior works have already established baseline autophagy to be greater
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in the oxidative soleus muscle (70). Speculatively, autophagy within the soleus muscle (in
particular female soleus) may reach a “ceiling effect” and as a result cannot increase autophagy
action compared to less oxidative muscles during pathological stimuli. This hypothesis generally
aligns with prior works finding females to have greater markers for autophagy compared to males
and greater autophagy in more oxidative muscles (70-73).

Previous works have clearly

established the role of autophagy on muscle loss during disuse atrophy using both male and
female models (74-76). However, to our knowledge this is the first time autophagy-related
alterations to demonstrate differential trajectories in males and females. Prior works in cancer
models have found sex-related differences in autophagy. Specifically, males exhibited greater
autophagy responses due to cardiac cachexia(77); however due to the different mechanisms of
atrophy between cancer and disuse it is difficult to make strong comparisons between studies.
It is notable that despite some robust alterations in many aspects of mitochondrial quality
control markers, we did not find any phenotypic alterations to the EDL across any time points.
This finding appears to suggest that significant aberrations to cellular signaling cascades can
occur within a tissue without overt changes in phenotypic outcomes to the tissue itself. The
potential disconnect between cellular signaling cascades and phenotypic outcomes warrants
consideration in future works investigating alterations to cellular signaling cascades during muscle
atrophies. We should note that in this study we have not directly assessed muscle contractile
function and changes observed here in cellular signaling may correlate to aspects of the
phenotype that are thus not measured here.
With some of the differences noted in males and females, it is impossible to discuss sexrelated differences in muscle atrophies without acknowledging the potential role of sex hormones.
For this study, we did not specifically control for the estrous cycle in the female mice. Although
there did not appear to be excessive variability in female compared to male mice, we cannot rule
out the possibility that sex hormones may have affected the results in ways that we cannot
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accurately predict. However, it is currently unclear how the estrous cycle directly affects muscle
wasting pathologies, as prior works

monitoring the estrous cycle in females during the

development of cancer cachexia found that the timeline for hormone-moderated differences in
females with and without estrous cycles is on the scale of weeks, not days (78, 79). As such, it is
not clear if differences in estrous cycle may affect outcomes in this study. Additionally, to our
knowledge, no study has directly investigated if hindlimb unloading itself is sufficient to induce
alterations in estrous cycle or testosterone in males, limiting our ability to draw strong inferences
on the influence of sex hormones on disuse muscle pathologies. Therefore, future works should
evaluate the potential role of sex hormones both on the development of disuse atrophies as well
as the sufficiency of disuse atrophy to cause aberrations to normal sex hormone secretion.
In conclusion, we find that even a relatively short bout of hindlimb unloading (24-48hrs) is
sufficient to result in muscle loss in both male and female mice as well as multiple aberrations to
mitochondrial quality control. We do note that at 7 days, many aspects of male and female atrophy
appear to “normalize” and future works should investigate if sex differences remain throughout
longer durations of disuse. This study provides a comprehensive evaluation of mitochondrial
alterations during the development and progression in disuse atrophy across multiple muscle
groups of varying fiber type in both males and females. These data should provide an
indispensable resource for the study of disuse-induced muscle atrophy.
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Figures

Figure 1: Muscle atrophy and metabolic alterations by muscle fiber type. A.)Cross sectional area
of SDH+ muscle fibers. B.) Cross sectional area of SDH- muscle fibers. C.) Muscle fiber cross
sectional area distributions in SDH+ fibers in female mice. D.) Muscle fiber cross sectional area
distributions in SDH+ fibers in male mice. E.) Muscle fiber cross sectional area distributions in
SDH- fibers in female mice. F.) Muscle fiber cross sectional area distributions in SDH- fibers in
male mice. G.) Periodic Acid Schiff (PAS) staining for glycogen content in males and females.
H.) Representative images for SDH and PAS staining in male and female mice. I.) Representative
images of COXIV immunoblotting, no differences were noted in COXIV content in gastrocnemius
or EDL muscle. Different letters indicate statistical differences at p<0.05. * indicates linear trend,
Ω indicates quadratic trend, # indicates cubic trend.
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Figure 2: Measures of mitochondrial health and function. A.) pMitotimer Red:Green ratio in males
and females. B.) Red puncta content in males and females. C.) Respiratory exchange ratio (RCR)
of state 3 and state 4 respiration in the gastrocnemius muscle in males and females D.) RCR in
the soleus muscle in males and females. E) Representative image of pMitoTimer. Different letters

indicate statistical differences at p<0.05. * indicates linear trend, Ω indicates quadratic trend, #
indicates cubic trend.
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Figure 3: mRNA markers of metabolism and mitochondrial biogenesis in the EDL, Gastrocnemius
and Soleus muscles. A.) Pparα mRNA content in the EDL muscle in males and females. B.) Pparα
mRNA content in the gastrocnemius muscle in males and females. C.) Pparα mRNA content in
the soleus muscle in males and females. D.) Nrf2 mRNA content in the EDL muscle in males and
females. E.) Nrf2 mRNA content in the gastrocnemius muscle in males and females. F.) Nrf2
mRNA content in the soleus muscle in males and females. G.) Pgc1α mRNA content in the EDL
muscle in males and females. H.) Pgc1α mRNA content in the gastrocnemius muscle in males
and females. I.) Pgc1α mRNA content in the soleus muscle in males and females. J.) PGC1α
protein content in the EDL muscle in males and females. K.) PGC1α protein content in the
gastrocnemius muscle in males and females. L.) Representative images from the EDL and
gastrocnemius muscles. Different letters indicate statistical differences at p<0.05. * indicates
linear trend, Ω indicates quadratic trend, # indicates cubic trend.
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Figure 4: mRNA content of markers of mitochondrial translation. A.) mtiF2 mRNA content in EDL
muscle in males and females. B.) mtiF2 mRNA content in gastrocnemius muscle in males and
females. C.) mtiF2 mRNA content in the soleus muscle in males and females. D.) mtiF3 mRNA
content in EDL muscle in males and females. E.) mtiF3 mRNA content in the gastrocnemius
muscle in males and females. F.) mtiF3 mRNA content in the soleus muscle in males and females.
G.) Taco1 mRNA content in the EDL muscle in males and females. H.) Taco1 mRNA content in
the gastrocnemius muscle in males and females. I.) Taco1 mRNA content in the soleus muscle
in males and females. J.) Tufm mRNA content in the EDL muscle in males and females. K.) Tufm
mRNA content in the gastrocnemius muscle in males and females. L.) Tufm mRNA content in the
soleus muscle in males and females. M.) Tfam mRNA content in the EDL muscle in males and
females. N.) Tfam mRNA content in the gastrocnemius muscle in males and females. O.) Tfam
mRNA content in the soleus muscle in males and females. Different letters indicate statistical
differences at p<0.05. * indicates linear trend, Ω indicates quadratic trend, # indicates cubic trend.
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Figure 5: mRNA and protein content of markers of mitochondrial fusion. A.) Mfn1 mRNA content
in the EDL muscle in males and females. B.) Mfn1 mRNA content in the gastrocnemius muscle
in males and females. C.) Mfn1 mRNA content in the soleus muscle in males and females. D.)
Mfn2 mRNA content in the EDL muscle in males and females. E.) Mfn2 mRNA content in the
gastrocnemius muscle in males and females. F.) Mfn2 mRNA content in the soleus muscle in
males and females. G.) Opa1 mRNA content in the EDL muscle in males and females. H.) Opa1
mRNA content in the gastrocnemius muscle in males and females. I.) Opa1 mRNA content in the
soleus muscle in males and females. J.) MFN1 protein content in the EDL muscle in males and
females. K.) MFN1 protein content in the gastrocnemius muscle in males and females. L.)
Representative images of Western Blot images in the EDL and gastrocnemius muscles. M.)
MFN2 protein content in the EDL muscle in males and females. N.) MFN2 protein content in the
gastrocnemius muscle in males and females. O.) OPA1 protein content in the EDL muscle in
males and females. P.) OPA1 protein content in the gastrocnemius muscle in males and females.
Different letters indicate statistical differences at p<0.05. * indicates linear trend, Ω indicates
quadratic trend, # indicates cubic trend.
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Figure 6: mRNA and protein content of markers of mitochondrial fission. A.) Drp1 mRNA content
in the EDL muscle in males and females. B.) Drp1 mRNA content in the gastrocnemius muscle in
males and females. C.) Drp1 mRNA content in the soleus muscle in males and females. D.) Mff
mRNA content in the EDL muscle in males and females. E.) Mff mRNA content in the
gastrocnemius muscle in males and females. F.) Mff mRNA content in the soleus muscle in males
and females. G.) Fis1 mRNA content in the EDL muscle in males and females. H.) Fis1 mRNA
content in the gastrocnemius muscle in males and females. I.) Fis1 mRNA content in the soleus
muscle in males and females. J.) FIS1 protein content in the EDL muscle in males and females.
K.) FIS1 protein content in the gastrocnemius muscle in males and females. L.) DRP1 protein
content in the EDL muscle in males and females. M.) DRP1 protein content in the gastrocnemius
muscle in males and females. N.) Representative images of Western Blot images from the EDL
and gastrocnemius. Different letters indicate statistical differences at p<0.05. * indicates linear
trend, Ω indicates quadratic trend, # indicates cubic trend.
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Figure 7: mRNA and protein content of markers of mitophagy and autophagy. A.) Bnip3 mRNA
content in the EDL muscle in males and females. B.) Bnip3 mRNA content in the gastrocnemius
muscle in males and females. C.) Bnip3 mRNA content in the soleus muscle in males and
females. D.) Lc3 mRNA content in the EDL muscle in males and females. E.) Lc3 mRNA content
in the gastrocnemius muscle in males and females. F.) Lc3 mRNA content in the soleus muscle
in males and females. G.) p62 mRNA content in the EDL muscle in males and females. H.) p62
mRNA content in the gastrocnemius muscle in males and females. I.) p62 mRNA content in the
soleus muscle in males and females. J.) BNIP3 protein content in the EDL muscle in males and
females. K.) BNIP3 protein content in the gastrocnemius muscle in males and females. L.)
Representative images of Western Blot images for EDL and gastrocnemius muscles. M.) LC3II/I
protein content in the EDL muscle in males and females. N.) LC3II/I protein content in the
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gastrocnemius muscle in males and females. O.) p62 protein content in the EDL muscle in males
and females. P.) p62 protein content in the gastrocnemius muscle in males and females.
Representative images of Western Blot images. Different letters indicate statistical differences at
p<0.05. * indicates linear trend, Ω indicates quadratic trend, # indicates cubic trend.
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Supplementary Figure 1: Graphical Representation of tissue weights. A.) Tissue weights
normalized to hang weight in males. B.) Tissue weights normalized to hang weight in females. C.)
Percent tissue weight loss in males. D.) Percent tissue weight loss in females.

103

Supplementary Figure 2: Cox4 data. A.) Cox4 mRNA content in the EDL of male and female
mice. B.) Cox4 mRNA content in the gastrocnemius of male and female mice. C.) Cox4 mRNA
content in the soleus of male and female mice. D.) COXIV protein content in the EDL of male and
female mice. E.) COXIV protein content in the gastrocnemius of male and female mice.
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Supplementary Figure 3: LC3 content in EDL and gastrocnemius muscle. A.) LC3II content in
the EDL muscle. B.) LC3II content in the gastrocnemius muscle. C.) LC3Total content in the EDL
muscle. D.) LC3Total content in the gastrocnemius muscle.
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g. Tables
Table 1
0hrs
24hrs
48hrs
72hrs
168hr
23.10 +
22.12 +
21.18 +
21.89 +
21.23 +
0.52a
0.23a,b
0.33b
0.46a,b
0.45b
FemalesΩ
20.00 +
18.37 +
18.97 +
17.60 +
18.49 +
0.04a
0.37a,b
0.51a,b
0.60b
0.22a
Gastrocnemius Males*
117.92 +
119.68 +
103.81 +
108.24 +
99.37 +
(mg)
3.93a
2.2a,b
2.14b
2.39a,b
2.41b
Females*
91.19 +
85.14 +
82.94 +
76.81 +
75.80 +
1.88a
1.53a
1.65b
1.92b
1.54b
Soleus (mg)
Males*
8.31 +
8.67 +
7.15 +
6.68 +
5.10 +
0.36a
0.38a
0.32b
0.17b
0.32c
Females*
7.49 +
6.67 +
6.15 +
5.69 +
4.96 +
0.26a
0.19b
0.71b
0.31b,c
0.27c
Plantaris (mg)
Males*
16.24 +
17.03 +
14.43 +
14.41 +
13.32 +
0.41a
0.68a
0.33b
0.54b
0.31b
Females*
13.13 +
11.06 +
10.96 +
9.84 +
10.47 +
0.63a
0.24b
0.34b
0.49b
0.23b
Tibialis Anterior Males*
41.43 +
44.46 +
40.03 +
40.03 +
35.88 +
(mg)
1.17a,b
0.84b
0.59a
0.59a
1.06b
Females*
33.59 +
30.74 +
30.52 +
28.66 +
29.62 +
0.86a
0.73a,b
0.82b
0.67b
1.05b
Extensor
Males
9.66 +
9.87 +
9.33 +
9.14 +
8.95 +
Digitorum
0.47
0.36
0.15
0.34
0.26
Longus (mg)
Females
7.72 +
7.46 +
7.03 +
6.57 +
7.19 +
0.45
0.13
0.31
0.34
0.51
Tissue weights from the present study. Data are presented as Mean + SEM. Different letters
indicate statistical differences at p<0.05. * indicates linear trend, Ω indicates quadratic trend, #
indicates cubic trend.
Bodyweight (g)

Males*
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Chapter V: Manuscript from Specific Aim II
Altering aspects of mitochondrial quality to improve musculoskeletal outcomes in disuse
atrophy
Megan E. Rosa-Caldwell, Nicholas P. Greene
Formatted for Submission to The Journal of Cachexia, Sarcopenia, and Muscle
a. Abstract
Muscle atrophy is a significant moderator for disease prognosis; as such, interventions to mitigate
disuse-induced muscle loss are imperative to improve clinical interventions. Mitochondrial
deteriorations may underlie disuse-induced myopathies; therefore, improving mitochondrial
quality may be an enticing therapeutic intervention. However, different mitochondrial-based
treatments may have divergent impacts on the prognosis of disuse atrophy. Therefore, the
purpose of this study was to investigate different mitochondria-centered interventions during
disuse atrophy in hindlimb unloaded male and female mice. Methods: Male and female mice
overexpressing PGC-1α (PGC-1α) or mitochondrially targeted catalase (MCAT) and their
respective wildtype (WT) littermate controls were hindlimb unloaded for 7 days to induce disuse
atrophy or allowed normal ambulatory activity (cage control). After designated interventions,
animals were euthanized and tissues collected for measures of mitochondrial quality control and
protein turnover. Results: While PGC-1α overexpression mitigated ubiquitin-proteasome
activation (Murf1 and Atrogin mRNA content), this did not correspond to phenotypic protections
from disuse-induced atrophy. Yet, PGC-1α mice appeared to have greater autophagy induction
with disuse compared to WT. In MCAT mice, females had a mitigated response to disuse atrophy;
however, this effect was not noted in males. Despite these phenotypic differences, there were no
clear cellular signaling differences between MCAT hindlimb unloaded females and MCAT fully
loaded females. Conclusion: PGC-1α overexpression does not protect against phenotypic
alterations during disuse atrophy, despite mitigating some catabolic pathways. However,
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increased mitochondrially-targeted catalase activity appears to blunt disuse atrophy with in highly
oxidative muscles in female mice.
b. Introduction
Skeletal muscle atrophy is a significant predictor of mortality and morbidity across a variety
of pathologies such as cancer, HIV/AIDs, chronic heart failure, renal failure and intensive care
unit (ICU) hospital stays (1, 2). While it is well understood that muscle wasting across these
pathologies is detrimental to patient outcomes, effective treatments to mitigate muscle loss have
yet to be developed. This may be due in part to divergent mechanisms contributing to this muscle
loss, with some muscle pathologies appearing to be more inflammation dependent (e.g. cancer
cachexia) (3-6), whereas others appear to be inflammation independent (such as disuse atrophy
(7). However, one commonality across the various muscle atrophies is the development of
mitochondrial aberrations such as increased reactive oxygen species production, decreased ATP
production, and decreased mitochondrial quality control (8-11). These mitochondrial aberrations
suggest the plausibility of a conserved mechanism for the development of muscle atrophies and
the potential for a conserved therapy to mitigate muscle pathologies.
Mitochondrial quality is comprised of multiple features such as: ATP production,
respiratory control ratio, mitochondrial biogenesis, mitochondrial dynamics, mitochondrialautophagy (mitophagy) and translation of mitochondrially encoded proteins (12, 13).
Deteriorations in any one of these aspects may influence mitochondrial quality and subsequent
muscle health. Recent works have investigated the sufficiency of increasing aspects of
mitochondrial quality as treatments for muscle wasting, specifically disuse muscle atrophy (1416). Multiples studies have found increasing mitochondrial content using a transgenic model
(PGC1α) sufficient to maintain cross sectional area of muscle fibers during disuse (14-16). This
may suggest increasing mitochondrial content itself may be sufficient to protect muscle against
disuse atrophy; however, this has yet to result in meaningful interventions. As such, it is unclear
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if these muscle mass protections were specifically due to enhanced mitochondrial content or
increases in other aspects of mitochondrial quality. Additionally, prior works have suggested
excessive reactive oxygen species (ROS) production may be the initiating factor in the
development of muscle wasting (8). Therefore, enhancing ROS neutralizing systems may also be
an efficient modality for preventing muscle atrophies. However, a direct comparison of different
mitochondrial-related treatments for disuse muscle atrophy has yet to described in the scientific
literature.
Many studies investigating potential treatments for disuse atrophy have predominantly
utilized male organisms (14-19). This discrepancy in representation between sexes in pre-clinical
research may partially account for lack of effective therapeutics in clinical studies. Specific to
disuse atrophy, females appear to exhibit differing clinical outcomes compared to males, with
females having greater decrements to muscular strength compared to males with ICU-associated
muscle weakness (20, 21). More so, data from our laboratory suggests different mitochondrial
deteriorations between males and females in the development of disuse atrophy using a hindlimb
unloading model (Chapter 3). Overall suggesting that etiologies may differ between the sexes and
potential therapeutic options should be investigated in both male and female models.
Therefore, the purpose of this study was to investigate the sufficiency of increasing
mitochondrial quality through multiple quality control pathways in a mouse model of disuse
atrophy in both males and females. Specifically, we investigated if genetic overexpression of
PGC-1α (increasing mitochondrial content) or increased mitochondrially targeted catalase
(MCAT; increasing ROS handling capacities specifically at the mitochondria) would provide
protections against disuse atrophy in male and female mice.
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c. Methods
i.

Animal Interventions

Breeding/Genotyping:
All animal protocols were approved by the University of Arkansas Institutional Animal Care
and Use Committee (Protocol numbers 17022 & 17089). Breeder mice for both muscle creatine
kinase PGC1-α and MCAT colonies were purchased from Jackson Laboratories (Bar Harbor, ME,
Stock# 008231 and Stock# 016197 respectively). 3 weeks after birth mice were genotyped for
either PGC-1α or MCAT overexpression through PCR as we have previously described (22). After
genotyping, animals were allocated to either CON or HU conditions (described below). For the
PGC1α colony, a total of 72 animals were used and analyzed for data. The samples sizes for
individual groups are depicted in Table 1. However, for the MCAT colony, due to breeding
limitations, a total sample size of 44 was achieved, with the smallest group containing 3 animals
(MCAT-HU Males). Sample sizes for the MCAT portion are depicted in Table 2.
Experimental Design
At 8 weeks of age animals underwent transfection with pMitoTimer in the flexor digitorum
brevis (FDB) muscle as we have previously described (more thoroughly described below) (8).
After two weeks of recovery, animals were then randomly allocated to hindlimb unloading (HU) or
weight bearing control (CON) groups. Animals were hindlimb unloaded for 7 days to induce disuse
atrophy. CON animals were allowed to freely move about their cages. This length of disuse has
been shown to induce disuse atrophy in both male and female models (15, 23-34). After disuse
or control interventions, animals were euthanized and tissues collected for further analysis.
ii.

pMitoTimer Electroporation and Analysis
Briefly, animals were anesthetized with 2% isoflurane mixed with oxygen. Upon

anesthesia, 10 µL of 0.36 mg/ml of hyaluronidase dissolved in sterile saline was injected into the
right FDB of each mouse. One hour post hyaluronidase injection, animals were re-anesthetized
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and the right FDBs were injected with 20 µg of pMitoTimer (Addgene, Watertown, MA, Cat#
#52659) dissolved in 10 µL sterile saline. After 15 minutes of recovery, the FDB underwent
electroporation with 10 pulses at 75 V/cm, 1Hz and 20ms/pulse. pMitoTimer analysis was
completed as we have previously described (8). At tissue harvest, FDBs were removed and fixed
in 4% paraformaldehyde (PFA): Phosphate Buffered Saline (PBS) solution for 20 minutes then
rinsed in PBS for 5 minutes. After washing in PBS, FDBs were carefully spread flat on gelatin
coated microscope slides using forceps. FDBs were mounted with 10% glycerol:PBS solution and
a standard microscope cover plate. FDBs were imaged with FITC and TRIC filters using carefully
controlled exposure times as we have previously described (8). FITC and TRIC images were
analyzed using Cell Profiler and Matlab software (generous gift of Dr. Z. Yan) as we have
previously described. Images were quantified for Red/Green ratio and Red Puncta, measuring
mitochondrial stress (greater red fluorescent indicative of greater mitochondrial stress) and
degenerated mitochondria (red fluorescent signal without any green, suggestive of completely
degenerated mitochondria tagged for mitophagy). Approximately 3 images were measured per
animal with outcome variables averaged within each animal.
iii.

Histological Analysis
During tissue harvest plantaris muscles were frozen in Optimal Cutting Temperature

(OCT) medium. Later, 10µm cross sections plantaris muscles were cut with a Leica CM1860
cryostat microtome and stained for Hemotoxylin and Eosin (H&E) staining as previously described
(35). Muscle fiber cross sectional area (CSA) was measured for ~100 fibers per animal. Fiber
CSA was analyzed both through averaging the CSAs within each animal.
iv.

mRNA Analysis
mRNA from the gastrocnemius muscle (PGC1α and MCAT colonies) and soleus muscle

(MCAT) were isolated and reversed transcribed to cDNA using commercial kits as previously
described (22, 36). The gastrocnemius muscle was chosen as a mixed fiber muscle (37), that
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would allow us to investigate disuse atrophy in a muscle that experiences disuse atrophy but is
not the most susceptible to disuse atrophy. The soleus was utilized based on phenotypic evidence
in suggesting protections to soleus muscle mass in MCAT mice (more thoroughly described in
the results section). Taqman probes or Primers were used as appropriate to amplify cDNA for
genes related to protein turnover and mitochondrial quality control as previously described (22,
36). cDNA was quantified using the

-ΔΔ

Ct method and a QuantStudio3 PCR instrument

(ThermoFisher Scientific, Waltham, MA) similar to what we have previously described (22, 36).
SYBR primers included: Pparα, Mfn1, Mfn2, Opa1, Drp1, Fis1, Mff, and Bnip3 (primer pairs have
previously been reported(22). Taqman probes included: 18s (Clone #Mm03928990_g1), Cox4
(Clone #Mm01250094_m1), Pgc1α (Clone #Mm01208835_m1), Lc3 (Clone #Mm00458725_g1),
Redd1 (Clone #Mm00512504_g1), Deptor (Clone #Mm01195339_m1), Catalase (Clone
#Mm00437992_m1), Atrogin (Clone #Mm00499523_m1), Murf1 (Clone #Mm01185221_m1),
Pax7 (Clone #Mm01354484_m1) and p62 (Clone #Mm00448091_m1). All samples were
normalized to 18s, which did not differ between groups.
v.

Immunoblotting
Immunoblotting of proteins related to muscle protein turnover and mitochondrial quality

control were measured as we have previously described (22, 36). Immunoblots were imaged with
Li-Cor Odyssey Fc System (Lincoln, NE) and quantified with Image Studio Software (Li-Cor,
Lincoln, NE). Antibodies included: PGC-1α (Novus Biologicals, NBP1-04676SS), p62 (Cell
Signaling, 5114s), LC3 (Cell Signaling, 4108).
vi.

Statistics
Each transgenic colony and sex were analyzed by paired 2 X 2 ANOVA analysis.

Independent factors within each sex included presence of transgenic gene (WT v. PGC or MCAT)
and hindlimb unloading intervention (CON v. HU). Sex was not a statistical factor due to the
excessive comparisons that would result in a 2X2X2 ANOVA that would not provide meaningful
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information. Instead, the inclusion of males and females was to investigate if these responses
differ between sexes and provide physiological plausibility for future works to either combine
sexes for analysis or separate sexes and directly compare males and females statistically. When
significant F ratios were found a Tukey post hoc was used to compare differences between
means. However, based on visual inspection of the data, some outcome variables were analyzed
by T-tests between percent difference from genotype and sex control (e.g. comparing percent
body weight loss in WT females compared to MCAT females). This was completed as an
additional analysis upon visual inspection of the data that suggested MCAT mice had smaller
absolute masses compared to WT in cage control conditions. Significance was denoted at p<0.05.
d. Results
i.

Confirmation of transgenic models
Both male and female PGC1α transgenic mice had ~13-fold greater Pgc1α mRNA content

compared to WT (p<0.001, Supplementary Figure 1A, B, & 1C). More so, male and females also
had ~2.5-fold and ~5-fold greater PGC1α protein compared to WT (p=0.029 and p=0.011
respectively Supplementary Figure 1D & 1E). Similarly, both male and female PGC1α transgenic
mice had ~4-fold and ~1.5-fold greater Cox4 mRNA content compared to WT (p=0.01 and p=0.02
respectively, Supplementary Figure 1F & 1G). MCAT transgenic mice had ~50% greater catalase
content, which was confirmed in both the gastrocnemius and soleus muscle (p=0.005 and
p=0.024, Supplementary Figure 1H, I, & J). Due to sample size limitations WT and transgenic
animals were combined for a single T-test for confirmation of genotype.
ii. PGC1α overexpression did not protect against disuse-induced atrophy
Overall, there were no significant interactions between PGC1α overexpression and HU.
Hindlimb unloading resulted in ~9% (~2.5 g) lower bodyweights compared to control in male mice
(p=0.001, Figure 1A). Female HU mice also had a ~5% (~1.0 g) lower bodyweight compared to
CON (p=0.021, Figure 1B). Male HU mice had ~30% lower soleus (3.6 mg, p<0.001), ~23% lower
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plantaris (5.0 mg, p<0.001), ~18% lower gastrocnemius (26.0 mg, p<0.001) and 15% lower tibialis
anterior (8.7 mg, p<0.001) weights compared to CON mice (Figure 1C, 1E, 1G, & 1K). Similarly,
female HU mice had ~28% smaller soleus (2.5 mg, p<0.001), ~16% smaller plantaris (2.3 mg,
p<0.001), ~15% smaller gastrocnemius (14.6 mg, p<0.001) and ~10% smaller tibialis anterior (4.2
mg, p<0.001) weights compared to CON mice (Figure 1D, 1F, 1H, 1J). Interestingly, in female
mice there was a main effect of genotype, with PGC1α transgenic mice having ~9% greater tibialis
anterior weights (3.4 mg, p=0.008) compared to WT mice (Figure 1J). There was no effect of HU
in male or female on EDL mass (mice (p=0.10 and p=0.16 respectively, Figure 1K and 1L).
Additionally, HU mice had ~38% and ~50% less gonadal fat (139.8 mg and 104.4 mg, p<0.001)
in male and female mice respectively (data not shown).
Within the plantaris muscle, HU males had ~21% lower CSA compared to CON mice, with
no effect of genotype (1106 µm2 v. 850 µm2, p=0.001, Figure 1M). In female mice, HU also had a
~13% lower cross sectional area compared to control mice (846 µm2 v. 722 µm2, p=0.029, Figure
1N). However, in females an effect of genotype on cross sectional area was noted, with PGC1α
transgenic mice having ~22% greater cross sectional area compared to WT mice (890 µm2 v. 722
µm2, p<0.001, Figure 1N).
iii.

In PGC1α mice, mitochondrial stress had divergent responses between males and
females
In males, there was no effect of genotype (p=0.238) or hindlimb unloading (p=0.987) on

Red/Green Ratio of pMitoTimer (Figure 2A & 2E). However in females, there was an interaction
between genotype and hindlimb unloading (p=0.003). Specifically, WT-HU animals had 46%
greater Red/Green Ratios compared to PGC1α-HU animals (Figure 2B & 2F). With regards to
Red Puncta, no statistical differences were noted in males (Figure 2C & 2E). However, in females
a main effect of Red Puncta approached statistical significance (p=0.09, Figure 2D & 2F), with
HU animals having ~50% greater Red Puncta compared to CON.
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iv.

Catabolic signaling was differentially affected in WT compared to PGC1α mice by
HU.
In males, an effect of intervention was noted in Lc3 mRNA content, with HU mice having

1.8-fold greater Lc3 mRNA content compared to CON mice (p=0.01, Figure 3A), with no effect of
genotype. Similarly, in females, HU animals had 3-fold greater Lc3 mRNA content compared to
CON (p=0.0008, Figure 3B), with no effect of genotype. In males, there was a main effect for total
LC3 protein content (p=0.040, Figure 3C &3I), whereby PGC1α males had ~75% greater LC3
content compared to WT. In females, an interaction was noted (Figure 3D & 3I, p=0.025), whereby
PGC1α-HU animals had ~3-fold greater LC3 protein content compared to all other groups.
Additional LC3 quantification (LC3II and LC3II/I ratio can be found in Supplementary Figure 3.
Males had a main effect for greater LC3II/I ratio, whereas females did not. Both males and females
had greater LC3II content; however this only reached significance in females). In males, main
effects of genotype and intervention were found in p62 mRNA content, with HU mice having ~75%
greater p62 mRNA content compared to CON (p=0.03, Figure 3E) and PGC1α animals having
~75% less p62 mRNA content compared to WT (p=0.02, Figure 3E). In females, an effect of
treatment was found, with HU mice having ~65% greater p62 mRNA content compared to CON
(p=0.01, Figure 3F). The effect of genotype in females did not reach statistical significance
(p=0.071), however a mean difference of 50% lower p62 mRNA content was observed in female
PGC1α animals compared to WT (Figure 3F). With regards to p62 protein content, in males a
main effect of intervention was noted (p=0.035, Figure 3G & 3I), with HU males having ~50% less
p62 protein content compared to CON. More so, in females, main effects of genotype (p=0.021)
and intervention (p=0.041) were detected in p62 protein content (Figure 3H). In females, HU mice
had ~75% greater p62 protein content compared to CON, and PGC1α females had ~75% less
p62 protein content compared to WT (Figure 3H & 3I). In males, an interaction was noted in
Atrogin mRNA content, with WT-HU mice having ~3-fold greater Atrogin mRNA content compared
to all other groups (p=0.02, Figure 3J). Similarly, in females, an interaction in Atrogin mRNA
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content was also noted, with WT-HU mice having ~3.5 fold greater Atrogin mRNA content
compared to all other groups (p=0.02, Figure 3K). In males, an interaction was noted in Murf
mRNA content, with WT-HU mice having ~2.5-fold greater Murf mRNA content compared to all
other groups (p=0.002, Figure 3L). Females had similar patterns to Murf mRNA content, with
WT-HU mice having 3-fold greater Murf mRNA content compared to all other groups; however,
the interaction did not reach statistical significance (p=0.08, Figure 3M). Females also had an
effect of genotype on Murf mRNA content with PGC1α animals having ~70% less Murf mRNA
content compared to WT mice (p=0.02, Figure 3M).
v.

Anabolic signaling was not affected by genotype following HU.
In males, Igf1 mRNA content demonstrated an effect of intervention, with HU animals

having ~50% lower Igf1 mRNA content compared to CON (p=0.003, Figure 4A). Similarly, in
females, an effect of intervention was also noted in Igf1 mRNA content, with HU animals
demonstrating ~30% less Igf1 mRNA compared to CON (p=0.04, Figure 4B). In males, Pax7
mRNA content demonstrated an effect of intervention, with HU animals having ~40% greater Pax7
mRNA content comparted to CON (p=0.0082, Figure 4C). However in females, there was no
effect of genotype or intervention noted in Pax7 mRNA content (p=0.92 and p=0.11 respectively,
Figure 4D). In males, Redd1 mRNA (an inhibitor of mTOR signaling) was ~2.8-fold greater in
PGC1α animals compared to WT (p=0.004, Figure 4E). Male HU animals had mean greater
Redd1 mRNA content (~2-fold greater); however this difference did not reach statistical
significance (p=0.06). In females, no effect of genotype or intervention were noted in Redd1
mRNA content (p=0.95 and 0.32 respectively, Figure 4F).
vi.

Mitochondrial dynamics appeared influenced by genotype but not intervention
With regards to Mfn1 mRNA content, in males, an interaction was noted between

genotype and hindlimb unloading (p=0.031). Specifically, PGC1α-CON mice had 100-250%
greater Mfn1 mRNA content than WT-CON, WT-HU and PGC1α-CON mice (Figure 5A).
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However, in female mice, main effects of genotype (p=0.025) and treatment (p=0.038) were noted
in Mfn1 mRNA content. Specifically, female PGC1α mice had ~2.5-fold greater Mfn1 mRNA
content compared to WT (Figure 5B). Additionally, female HU mice had 1.5-fold greater Mfn1
mRNA content compared to CON (Figure 5B). In males, only an effect of genotype was noted in
Mfn2 mRNA content (p=0.026), with PGC1α mice having double Mfn2 mRNA content compared
to CON mice (Figure 5C). A similar effect was noted in females (main effect of genotype p=0.054,
Figure DF). In males, main effects of both genotype (p<0.001) and HU were noted (p=0.007) in
Opa1 mRNA content (Figure 5E). Male PGC1α transgenic mice had 2.5-fold greater Opa1 mRNA
content compared to WT and HU mice had ~50% less Opa1 mRNA content compared to CON
mice (Figure 5E). Whereas in female mice, there was no effect of unloading on Opa1 mRNA
content (p=0.352). However an interaction between genotype and intervention was noted
(p=0.018), whereby PGC1α-CON mice had ~2.5-fold greater Opa1 mRNA content compared to
WT-CON female mice (Figure 5F).
In males, Mff mRNA content was not affected by either genotype (p=0.469) or hindlimb
unloading (p=0.805, Figure 5G). Yet in females, a main effect of HU was found (p=0.028), with
HU animals having ~2-fold greater Mff mRNA content compared to CON (Figure 5H). In males, a
robust effect of genotype was noted in Drp1 mRNA content (p=0.001), with PGC1α mice having
~3.5-fold greater Drp1 mRNA content compared to WT (Figure 5I). Whereas in females, an effect
of HU was noted (p=0.045), with HU animals having ~50% less Drp1 mRNA content compared
to CON (Figure 5J). In males, Fis1 mRNA, a marker of mitochondrial fission, demonstrated a
significant interaction (p=0.021); however no Tukey-adjusted comparisons resulted in significant
pair-wise differences (Figure 5K). In females, a significant main effect of genotype was found in
Fis1 mRNA content (p=0.023), with PGC1α mice having ~30% less Fis1 mRNA content compared
to WT (Figure 5L).
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vii.

Mitophagy and fat oxidation demonstrated sex-related differences
In males, an interaction in Bnip3 mRNA content was noted (p=0.005), however no Tukey-

adjusted pairwise comparisons reached statistical significance (p=0.12-0.99, Figure 6A).
However, in females an effect of intervention was noted, with HU animals having 1.8-fold greater
Bnip3 mRNA content compared to CON (p=0.008, Figure 6B). In males a main effect of HU was
noted in Pparα mRNA content (p=0.007, Figure 6C), which HU animals having ~50% less Pparα
mRNA content compared to CON. In females, an effect of genotype was noted (p<0.0001, Figure
6D) with ~4-fold greater Pparα mRNA content in PGC1α mice compared to WT.
viii.

MCAT Bodyweight and Cross Sectional Area
Across both males and females, there were significant differences detected in muscle

mass, with HU groups having ~7-35% lower gastrocnemius, plantaris, soleus, and tibialis anterior
weights (Supplementary Figure 4). However, upon visual inspection of the data, MCAT females
had lower body and muscle weights in between CON groups which were not robust enough to
correspond to a main effect of genotype. As such, we assessed CON groups by T-test observing
significantly attenuated tissue weight differences in MCAT-HU compared to WT-HU. Therefore,
we further analyzed muscle and body weight data in HU animals as percent difference from within
genotype CON and compared percent differences between WT-HU and MCAT-HU through an
unpaired T-test. Through this analysis we noted MCAT females tended to have attenuated
differences in muscle size compared to WT. Specifically, MCAT females had smaller differences
between HU and CON with regard to bodyweight (~10% lower mass in WT v. ~3% lower mass in
MCAT), soleus mass(~40% lower mass in WT v. ~20% lower mass in MCAT) and tibialis anterior
mass(~20% lower mass in WT v. ~10% lower mass in MCAT) compared to WT (p=0.012—
p=0.003, Figure 7A). However, in males there were no differences between MCAT-HU and WTHU mice in percent differences from CON (Figure 7B). In plantaris CSA, there was a main effect
of HU males and females (p=0.044 and p=0.050 respectively,

Figure 7C and Figure 7D)
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Although not significant, a similar pattern of MCAT females maintaining plantaris cross sectional
area also appeared (Figure 7D). Based on these findings, we opted to utilize the soleus muscle
as the primary tissue for cell signaling analysis as this tissue appeared to have the greatest
protections in the MCAT females compared to WT females. Due to the limited tissue availability
of the soleus (~10-14 mg of total tissue), Real Time PCR analysis of genes related to
musculoskeletal health were analyzed as opposed to immunoblot because more targets could be
analyzed.
ix.

In MCAT mice, mitochondrial stress had divergent responses between males and
females
In males, there were no statistical differences in Red/Green ratio across groups (p=0.24,

Figure 8A & 8E). However, in females, an interaction was noted in Red/Green Ratio (p=0.04,
Figure 8B & 8F), with MCAT-CON animals having ~6-fold greater Red/Green ratio compared to
WT-CON and WT-HU (Figure 8B & 8F). No significant differences were noted in number of red
puncta in either males (p=0.30, Figure 8C & 8E) or females (p=0.24, Figure 8D and 8F).
x.

Mediators of protein catabolism in MCAT mice did not suggest protections against
HU
Due to the observation that there appeared to be phenotypic differences in the response

to HU between males and females, for mRNA analysis, we compared mRNA responses of WT
and MCAT soleus muscle to HU (some genes were additionally analyzed in the gastrocnemius
and can be found in Supplementary Figure 5). Additionally, as a supplementary analysis, we also
compared contents of mRNAs in WT-CON and MCAT-HU animals. All analysis was performed
with T-tests. In males, MCAT-HU mice had 33% greater Atrogin mRNA compared to WT-HU
(p=0.046, Figure 9A), with no differences noted between WT-CON and MCAT-CON animals
(p=0.68). In females, there was no difference in Atrogin mRNA content between WT-HU and
MCAT-HU mice (p=0.37, Figure 9B). Additionally, there was no difference between WT-CON and
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MCAT-CON animals (p=0.40). In males, MCAT-HU mice had ~50% greater MurF1 mRNA content
compared to WT-HU (p=0.001, Figure 9C), though there was no difference between WT-CON
and HU-CON animals (p=0.17, Figure 9C). However in females, there was no difference noted in
MurF1 mRNA content (p=0.68). In males, there were no differences in Lc3 mRNA content
between WT-HU and MCAT-HU animals (p=0.41), more so there were no differences in Lc3
mRNA content between WT-CON and MCAT-CON animals (p=0.42, Figure 9E). Similarly, in
females there were no difference in Lc3 mRNA content between WT-HU and MCAT-HU animals
(p=0.81) or WT-CON and MCAT-CON animals (p=0.85, Figure 9F). In males, MCAT-HU mice
had ~35% greater p62 mRNA content compared to WT-HU mice (p=0.048, Figure 9G), with no
differences noted between WT-CON and MCAT-CON mice (p=0.97, Figure 9G). However, in
females, there were no differences noted in p62 mRNA content between either WT-HU and
MCAT-HU (p=0.76) or WT-CON and MCAT-CON (p=0.55, Figure 9H).
xi.

Mediators of protein anabolism did not appear to differ between WT and MCAT mice
In males, there were no differences in Igf1 mRNA content between either WT-HU and

MCAT-HU (p=0.67) or WT-CON and MCAT-CON mice (p=0.32, Figure 10A). Correspondingly,
in females, there were no differences in Igf1 mRNA content between either WT-HU and MCATHU (p=0.63) or WT-CON and MCAT-CON mice (p=0.32). Additionally, in males there were no
differences in Deptor mRNA content between either WT-HU and MCAT-HU (p=0.84) or WT-CON
and MCAT-CON mice (p=0.51, Figure 10C). Similarly, in females there were no differences in
Deptor mRNA content between either WT-HU and MCAT-HU (p=0.63) or WT-CON and MCATCON mice (p=0.32, Figure 10D). In males, there was no difference in Redd1 mRNA content
between either WT-HU and MCAT-HU (p=0.22) or WT-CON and MCAT-CON (p=0.27, Figure
10E). I). In females, MCAT-HU mice had ~2-fold greater Redd1 mRNA content compared to WTHU (p=0.013, Figure 10F). However, there were no statistical differences between female WTCON and MCAT-CON (p=0.015, Figure 10F).

127
xii.

Mitochondrial dynamics did not greater differ between MCAT and WT mice
In the males there were no differences noted in Mfn1 mRNA between either WT-HU and

MCAT-HU (p=0.35) or WT-CON and MCAT-CON (p=0.975, Figure 11A). Likewise, in females
there was no difference noted in Mfn1 mRNA between either WT-HU and MCAT-HU (p=0.28) or
WT-CON and MCAT-CON mice (p=0.35, Figure 11B). With regards to Mfn2, mRNA content there
were no differences between male HU (p=0.967) or CON mice (p=0.41, Figure 11C).
Contrastingly, in female mice, MCAT-HU mice had ~50% lower Mfn2 mRNA content compared
to WT-HU (p=0.014, Figure 11D). However, there were no differences between female WT-CON
and MCAT-CON mice in Mfn2 mRNA content (p=0.16, Figure 11D). Although not statistically
significant, there was a mean difference in Opa1 mRNA content between male MCAT-HU
compared to WT-HU mice that approached statistical significance (p=0.08, Figure 11E). However,
no differences were noted between male WT-CON and MCAT-CON groups (p=0.61, Figure 11E).
In females, there were no differences in Opa1 mRNA content between either WT-HU and MCATHU (p=0.15) or WT-CON and MCAT-CON mice (p=0.11, Figure 11F).
In males there was no difference in Mff mRNA content between either WT-HU and MCATHU (p=0.54) or WT-CON and MCAT-CON (p=0.31, Figure 11A). However, in females MCAT-HU
mice had ~33% less Mff mRNA content compared to WT-HU mice (p=0.041, Figure 11H).
Interestingly, female MCAT-CON mice had ~2-fold greater Mff mRNA content compared to WTCON (p=0.006, Figure 11H). In males and females, no differences were noted in Fis1 mRNA
content between either WT-HU and MCAT-HU (p=0.82 and p=0.90) or WT-CON and MCAT-CON
mice (p=0.97 and p=0.35, Figures 11I and 11J respectively). In males, there were no differences
in Drp1 mRNA content between either WT-HU and MCAT-HU (p=0.80) or WT-CON and MCATCON mice (p=0.30, Figure 11K). Contrastingly, in female HU mice, MCAT-HU had ~3.5-fold
greater Drp1 mRNA content compared to WT-HU (p=0.03), with no differences noted between
WT-CON and MCAT-CON animals (p=0.99, Figure 11L).
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xiii.

Mitophagy in MCAT mice did not appear to differ from WT
In males, there were no differences in Pparα content between either WT-HU and MCAT-

HU (p=0.19) or WT-CON and MCAT-CON mice (p=0.29, Figure 12A). Contrastingly, in females,
MCAT-HU mice had ~33% less Pparα mRNA content compared to WT-HU (p=0.02, Figure 12B).
Interestingly, female MCAT-CON mice had ~2-fold greater Pparα mRNA content compared to
WT-CON (p=0.03, Figure 12B). In males and females, there was a mean difference in Bnip3
mRNA content between WT-HU and MCAT-HU mice that approached statistical significance (~2
fold greater Bnip3 mRNA content, p=0.08 and p=0.08 respectively, Figure 12C & 12D), with no
differences noted between MCAT-CON and WT-CON (p=0.88 and p=0.31 respectively, Figure
12C and 12D).
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e. Discussion
To our knowledge, this is one of the first studies to compare mitochondrially-targeted
genetic interventions in the prevention or attenuation for disuse-induced atrophy. Phenotypically,
we find no differences in musculoskeletal outcomes between WT and PGC1α mice; however,
these musculoskeletal aberrations appear to be moderated by different catabolic pathways. More
so, while MCAT transgenic males showed no protection from disuse atrophy, MCAT females
appeared to blunt disuse-induced muscle atrophy, with particular protection in the soleus muscle.
Yet, the precise mechanism for these protections remains uncertain. Taken together, these data
appear to suggest mitochondrial interventions to mitigate or prevent disuse atrophy may be more
nuanced than previously believed.
Similar to prior reports, we find overexpression of PGC1α sufficient to mitigate induction
of the ubiquitin proteasome system (14-16, 33, 38-40). However, compared to other works we do
not find genetic overexpression of PGC1α to protect against disuse atrophy regarding either
muscle mass or muscle cross-sectional area. There are a few potential reasons for these
differences in findings. Prior works that have found PGC1α effective for disuse atrophy have used
relatively older mice (24 weeks of age compared to 10 weeks of age in our study (15, 16)) or
have used more aggressive interventions such as denervation (38). Therefore, it is possible that
the efficacy of greater PGC1α is dependent on age of the animal. For example, other transgenic
models have demonstrated divergent efficacy for mitigating muscle loss depending on the age of
the organism (41). As such, it is plausible that the different results for PGC1α efficacy could be
partially attributed to interactions between PGC1α signaling cascades and the age of the
organism. Conversely, other research has found local transfection of PGC1α sufficient to alter
cellular signaling cascades associated with atrophy (similar to our findings); however, these
differences in cellular signaling cascades were not sufficient to mitigate aging-induced atrophy
(42). Moreover, regarding denervation-induced atrophy, potential differences may be attributed to
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subtle differences in cellular signaling cascades specific to denervation compared to disuse
atrophy. For example, recent works have found denervation and disuse to modify slightly different
atrogenes (43). Although both disuse and denervation have extremely similar cellular signaling
cascades, these modest differences between the two models may partially explain differences
noted between our study and previous research (38). Yet, other works have found PGC1α
knockout animals to protect against disuse-induce muscle atrophy (44). It seems unlikely that
both increased PGC1α and decreased PGC1α can equally protect against disuse atrophy,
suggesting at minimum the interactions between PGC1α and musculoskeletal health are more
complicated than previously described. Regardless, our data suggest that promotion of greater
mitochondrial content, via PGC1α, is insufficient to protect against disuse-induced atrophy.
While PGC1α appears sufficient to blunt the ubiquitin-proteasome responses to atrophy,
this does not seem to be the case with other catabolic pathways, notably autophagy. In fact, our
data tends to suggest that autophagy induction, particularly LC3 protein content may be the
driving catabolic pathway in PGC1α mice. For example, we observed strong main effects or
interactions for LC3 protein content in hindlimb unloaded males and females. This finding aligns
with prior works from our group and others demonstrating PGC1α to drive LC3 content (22, 45).
Of note, females comparatively exhibited greater markers of autophagy induction compared to
males at both the RNA and protein level (~3-fold greater LC3 content in HU females compared to
~50% greater LC content in males). Females are generally thought to have greater mitochondrial
content (46, 47) and presumably PGC1α. As PGC1α is known to partially mediate autophagy (22,
45), these differences in markers of autophagy may be partially mediated by sex-specific
differences in mitochondrial density. Sex differences in mitochondrial biogenesis and subsequent
autophagy appear to agree with other research finding potential sex differences in catabolic
signaling cascades (48, 49), and may suggest the potential need for therapeutics tailored to sexspecific responses to atrophy. Yet, these studies on sex differences during disuse atrophy are still
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in the relatively early stages and more works are needed to in preclinical models to fully
characterize sex differences in disuse atrophy.
While we did not note any phenotypic protections against disuse atrophy in PGC1α mice,
we did see a protection in female MCAT mice. It is possible that MCAT protections are specific to
females, though we should acknowledge the limited sample size in males restricts our ability to
infer strong conclusions on the potential protective role of additional catalase in males. However,
there is plausible evidence to suggest that females may be more responsive to ROS-specific
interventions. For example, females are known to have greater mitochondrial content compared
to males (46, 47) and mitochondria are primary reactive oxygen species (ROS) generation sites
within the cell (50). Therefore, it is plausible that females may have greater capacity to generate
ROS during myopathies, particularly in mitochondrially-dense muscles such as the soleus.
Correspondingly, because of this potential for greater ROS generation, females may be more
responsive to mitochondria-related treatments to mitigate ROS generation. This would align with
our data finding female MCATs having robust protections from disuse atrophy in the soleus
muscle. However, we recognize this hypothesis requires further validation.
Specific to MCAT itself, prior works have found MCAT mice to protect against other
musculoskeletal pathologies such as insulin resistance, cardiomyopathies and aging-induced
muscle loss (41, 51-54). Though there has been controversy within the scientific literature on
MCAT’s efficacy for muscle pathologies (55, 56). These protections are thought to be at least
partially due to MCAT’s control over oxidative phosphorylation (57). As previously mentioned,
different transgenic strains appear to interact differently depending on the age of the model
organism. This appears to also be true with MCAT mice. For example, MCAT appears protective
for cardiomyopathies in older mice, but not younger mice (41). Therefore, it is plausible that
because of the age of our mice, we are not maximizing the potential therapeutic potential of
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increased mitochondrial catalase and we may have seen greater protections in older animals.
Yet, this hypothesis would require further investigation.
While we noted MCAT females to have some phenotypic protection from disuse atrophy,
we did not find any robust cellular signaling cascade differences between WT and MCAT that
would clearly account for phenotypic differences noted between WT and MCAT female mice. In
fact, if anything, MCAT mice appeared to have augmented atrophic signaling compared to WT.
This was noted in Atrogin (males), MurF1 (males), and p62 (males). Due to catalase’s role as
ROS scavenger, it is likely that any protections from MCAT were due to functional differences in
mitochondrial function and subsequent ROS emission and/or neutralization. Unfortunately,
methodological limitations of this study did not allow for measurement of these particular
variables. As such, future works investigating therapeutic potential of catalase-based
interventions should likely focus more on functional outcomes as opposed to cellular signaling
outcomes. More so, while these differences in catabolic signaling do not necessarily explain
phenotypic protections to muscle size, they do highlight signaling differences between males and
females within this particular strain of mice and emphasize the need to investigate muscle
pathologies and subsequent interventions in both males and females.
In conclusion, we find overexpression of PGC1α insufficient to protect against disuse
muscle atrophy; however increased mitochondrially targeted catalase appears sufficient to
mitigate muscle atrophy, yet this effect may be sex specific. Hindlimb unloading resulted in similar
muscle losses in both PGC1α and WT animals despite PGC1α animals having substantially less
ubiquitin-proteasome activation. However, PGC1α hindlimb unloaded animals appear to more
heavily rely on autophagy-mediated catabolism compared to the ubiquitin-proteasome system.
Conversely, we find overexpression of mitochondrially targeted catalase was sufficient to mitigate
disuse response in female mice. This effect appeared more robust in oxidative muscles such as
the soleus. As oxidative fibers are more susceptible to disuse atrophy (7), catalase based
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therapies may provide the greatest opportunity to protect the most susceptible fibers during the
development of disuse atrophies. However, more works are clearly needed to further understand
the potential sex and age interactions with catalase during disuse muscle pathologies.
Regardless, these findings further support the necessity of investigating potential muscle
therapeutics in both male and female models.
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f.

Tables

Table 1: Representation of sample size for each group for the PGC1α portion of this study.
CON
Male
Female
WT
PGC1α
WT
PGC1α
9
9
8
9

HU
Male
WT
PGC1α
10
9

WT
9

Female
PGC1α
9

Table 2: Representation of sample size for each group for the MCAT portion of this study.
CON
Male
WT
8

MCAT
4

HU
Female
WT
MCAT
5
6

Male
WT
7

MCAT
3

WT
6

Female
MCAT
6
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g. Figures

Figure 1: Muscle weights and cross sectional area for males and females from PGC1α colony
portion of this study. A: Bodyweights for males. B: Bodyweights for females. C: Soleus mass for
males. D: Soleus mass for females. E: Plantaris mass for males. F: Plantaris mass for females.
G: Gastrocnemius mass for males. H: Gastrocnemius mass for females. I: Tibialis Anterior (TA)
mass for males. J: Tibialis Anterior (TA) mass for females. K: Extensor Digitorum Longus (EDL)
mass for males. L: Extensor Digitorum Longus (EDL) mass for females. M: Cross sectional area
(CSA) quantification and representative images for males. N: Cross sectional area (CSA)
quantification and representative images for females. * denotes Tukey-adjusted p<0.05. All CSA
images were taken at 20X magnification.
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Figure 2: pMitotimer from males and females from the PGC1α portion of this study. A: Red/Green
ratio in males. B: Red/Green ratio in females. C: Red puncta in males. D: Red puncta in females.
E: Representative images of pMitoTimer in males. F: Representative images of pMitoTimer in
females.
* denotes a Tukey-adjusted p<0.05. pMitotimer images were taken at 100X
magnification

137

Figure 3: mRNA and protein content of moderators of autophagy and ubiquitin-proteasome
catabolism. A: Lc3 mRNA content in males. B: Lc3 mRNA content in females. C: Total LC3
protein content in males. D: Total LC3 protein content in females. E: p62 mRNA content in males.
F: p62 mRNA content in females. G: p62 protein content in males. H: p62 protein content in
females. I: Representative image of immunoblotting targets. J: Atrogin mRNA content in males.
K: Atrogin mRNA content in females. L: MurF1 mRNA content in males. M: MurF1 mRNA content
in females. * denotes Tukey-adjusted p<0.05.
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Figure 4: mRNA content of moderators of protein/muscle anabolism. A: Igf1 mRNA content in
males. B: Igf1 mRNA content in females. C: Pax7 mRNA content in males. D: Pax7 mRNA
content in females. E: Redd1 mRNA content in males. F: Redd1 mRNA content in females. *
denotes Tukey-adjusted p<0.05.
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Figure 5: mRNA content of moderators of mitochondrial fusion and fission. A: Mfn1 mRNA
content in males. B: Mfn1 mRNA content in females. C: Mfn2 mRNA content in males. D: Mfn2
mRNA content in females. E: Opa1 mRNA content in males. F: Opa1 mRNA content in females.
G: Mff mRNA content in males. H: Mff mRNA content in females. I: Drp1 mRNA content in males.
J: Drp1 mRNA content in females. K: Fis1 mRNA content in males. L: Fis1 mRNA content in
females. * denotes Tukey-adjusted p<0.05.
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Figure 6: mRNA content of markers of mitophagy and fatty acid oxidation in PGC1α mice. A:
Bnip3 mRNA content in males. B: Bnip3 mRNA content in females. C: Pparα mRNA content in
males. D: Pparα mRNA content in females. * denotes Tukey-adjusted p<0.05.
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Figure 7: Percent difference of muscle losses in MCAT male and female mice. A: Percent
difference tissue loss in female hindlimb unloaded mice. B: Percent difference tissue loss in male
hindlimb unloaded mice. C: Cross sectional area (CSA) and associated representative images in
males. D: Cross sectional area (CSA) and associated images in females. * denotes Tukeyadjusted p<0.05.
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Figure 8: pMitotimer from males and females from the MCAT portion of this study. A: Red/Green
ratio in males. B: Red/Green ratio in females. C: Red puncta in males. D: Red puncta in females.
E: Representative images of pMitoTimer in males. F: Representative images of pMitoTimer in
females. * denotes a Tukey-adjusted p<0.05. pMitotimer images were taken at 100X
magnification
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Figure 9: mRNA content from the soleus muscle in MCAT and WT mice. A: Atrogin mRNA
response and basal content in males. B: Atrogin mRNA response and basal content in females.
C: Murf1 mRNA response and basal content in males. D: Murf1 mRNA response and basal
content in females. E: Lc3 mRNA response and basal content in males. F: Lc3 mRNA response
and basal content in females. G: p62 mRNA response and basal content in males. H: p62 mRNA
response and basal content in females. Larger graphs are the responses of WT-HU and MCATHU, with the inset graph containing comparisons between WT-CON and MCAT-CON. To
demonstrate responses compared to control, 1 (indicating the within genotype basal levels) is
graphed. * = p<0.05 from a Students T-test between genotypes.
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Figure 10: mRNA content of moderators of protein anabolism the soleus of MCAT mice. A: Igf1
mRNA content in males. B: Igf1 mRNA content in females. C: Deptor mRNA content in males.
D: Deptor mRNA content in females. E: Redd1 mRNA content in males. F: Redd1 mRNA content
in females. Larger graphs are the responses of WT-HU and MCAT-HU, with the inset graph
containing comparisons between WT-CON and MCAT-CON. To demonstrate responses
compared to control, 1 (indicating the within genotype basal levels) is graphed. * = p<0.05 from a
Students T-test between genotypes.
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Figure 11: mRNA content of markers of mitochondrial fusion and fission in the soleus of MCAT
mice. A: Mfn1 mRNA content in males. B: Mfn1 mRNA content in females. C: Mfn2 mRNA content
in males. D: Mfn2 mRNA content in females. E: Opa1 mRNA content in males. F: Opa1 mRNA
content in females. G: Mff mRNA content in males. H: Mff mRNA content in females. I: Fis1
mRNA content in males. J: Fis1 mRNA content in females. K: Drp1 mRNA content in males. L:
Drp1 mRNA content in females. Larger graphs are the responses of WT-HU and MCAT-HU, with
the inset graph containing comparisons between WT-CON and MCAT-CON. To demonstrate
responses compared to control, 1 (indicating the within genotype basal levels) is graphed. * =
p<0.05 from a Student’s T-test between genotypes.
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Figure 12: mRNA content of markers of mitophagy and fatty acid oxidation in the soleus muscle
of MCAT mice. A: Pparα mRNA content in males. B: Pparα mRNA content in females. C: Bnip3
mRNA content in males. D: Bnip3 mRNA content in females. Larger graphs are the responses of
WT-HU and MCAT-HU, with the inset graph containing comparisons between WT-CON and
MCAT-CON. To demonstrate responses compared to control, 1 (indicating the within genotype
basal levels) is graphed. * = p<0.05 from a Student’s T-test between genotypes.
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Supplementary Figure 1: Confirmation of genotype for both PGC1α and MCAT colonies. A:
Representative images from genotyping of PGC1α mice using ethidium bromide gels. B: Pgc1α
mRNA content in males. C: Pgc1α mRNA content in females. D: PGC1-α protein content in males.
E: PGC1-α protein content in females. F: Cox4 mRNA content in males. G: Cox4 mRNA content
in females. H: Representative images from genotyping of MCAT mice using ethidium bromide
gels. I: Catalase mRNA content in the gastrocnemius muscle of male and female mice. J:
Catalase mRNA content in the soleus muscle of male and female mice. * denotes p<0.05.
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Supplementary Figure 2: Additional quantification of LC3 protein. A: LC3II/I protein ratio in male
PGC1α mice. B: LC3II/I protein ratio in female PGC1α mice. C: LC3II protein content in male
PGC1α mice. D: LC3II protein content in female PGC1α mice.
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Supplementary Figure 3: Percent difference between WT-HU and PGC1α-HU animals. A:
Males percent difference from CON. B: Females percent difference from CON.

150

Supplementary Figure 4: Raw Tissue weights from MCAT portion of the study. A.) Bodyweights
in males. B.) Bodyweights in females. C.) Gastrocnemius weights in males. D.) Gastrocnemius
weights in females. E.) Plantaris weights in males. F.) Plantaris weights in females. G.) Soleus
weights in males. H.) Soleus weights in females. I.) Tibialis anterior weights in males. K.) Tibialis
anterior weights in females. * = Tukey adjusted p < 0.05.
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Supplementary Figure 5: Selected mRNA contents for the gastrocnemius of MCAT mice. A:
Murf1 mRNA content in males. B: Murf1 mRNA content in females. C: Atrogin mRNA content in
males. D: Atrogin mRNA content in females. E: p62 mRNA content in males. F: p62 mRNA
content in females. G: Lc3 mRNA content in males. H: Lc3 mRNA content in females.
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Differential effects of sex hormones during in vitro models of muscle atrophy
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a. Abstract
Muscle atrophy can have significant implications for quality of life and mortality across a variety
of pathologies. Recently, there have been increased emphases on the need to more thoroughly
study differential and conserved mechanisms in male and female physiology during the
development and progression of muscle atrophies. One relatively identifiable difference between
males and females that may influence muscle physiology is circulating sex hormones. Therefore,
the purpose of this study was to investigate the effects of different sex hormones, testosterone,
estrogen, progesterone and estrogen combined with progesterone on myotube health during
different in vitro models of atrophy. Both dexamethasone (DEXA) and Lewis Lung Carcinoma
(LLC) conditioned media (LCM) were sufficient to result in ~25-30% lower myotube diameter.
Treatment with 200ng/dL of testosterone or 60pg/mL of estrogen was sufficient to help maintain
myotube diameter in dexamethasone treated myotubes. However 30ng/mL of progesterone or
combining estrogen and progesterone did not protect myotube diameter during dexamethasoneinduced atrophy. Conversely, in LLC conditioned media, all sex hormones treatments were
sufficient to mitigate LLC-induced atrophy to myotubes. Different hormones activated different
catabolic and anabolic signaling cascades. Taken together, these results demonstrate divergent
mechanisms for hormonal protections of muscle quality during myopathies. More so, these
protective mechanisms (or lack thereof) also vary depending on the atrophic pathology.
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b. Introduction
Musculoskeletal health is imperative for quality of life and longevity across a variety of
pathologies (1-4). Because of this relationship between muscle size and health outcomes, there
is a significant body of research on mechanisms and potential interventions for muscle wasting
within the scientific literature (5-7). However, a noted shortcoming of many prior works on muscle
atrophy involves the primary use of male models (5, 6). While these studies have greatly furthered
our understanding of mechanisms contributing to muscle loss across various pathologies, the
question remains if these mechanisms are conserved between males and females. Recent works
have begun to establish sex-related differences in muscle physiology as well as responses to
muscle atrophy (5, 8-10). As such, a more thorough understanding of differential and conserved
mechanisms in males and females during atrophic pathologies are necessary for the development
of effective clinical interventions.
One relatively distinct difference between males and females that may contribute to
differential responses to muscle atrophy is differences in circulating sex-related hormones such
as testosterone, estrogen and progesterone. Prior works have found hormonal interactions to
influence muscle health (5, 11-18). However hormonal mechanisms contributing to muscle size
appear to vary depending on the atrophic stimulus (19). For example, testosterone
supplementation has been found to improve muscle mass and quality of life in patients with cancer
cachexia, sarcopenia or spinal cord injuries (17, 18, 20). However, in some models of
glucocorticoid-induced atrophy and disuse atrophy testosterone supplementation is not sufficient
to protect against atrophy (21-23).

Overall, the aggregate of these studies suggests

testosterone’s efficacy is strongly dependent on the atrophic model. Interestingly, recent works
suggest testosterone-mediated alterations to muscle quality may be partially mediated by
protecting mitochondrial turnover and subsequent mitochondrial quality mitochondrial turnover
(24). As mitochondrial quality is generally considered important for muscle size and health (25-
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28), testosterone may have therapeutic potential for mitochondrially-related myopathies.
However, this mitochondrial quality-testosterone axis during muscle atrophy has not been
thoroughly investigated and warrants further study.
Estrogen is broadly considered the hallmark female sex hormone. Generally, estrogen is
considered protective for muscle health (29), with loss of estrogen through ovariectomy resulting
in decreased muscle size (30, 31) or delayed recovery from muscle atrophy (32, 33). Aligning with
this body of work, estrogen-based therapies have shown promise in some models of muscle
atrophy such as muscular dystrophy (34, 35). More so, estrogen promotes mitochondrial function,
which is believed to moderate muscle quality in females (36). Taken together, the scientific
literature implies estrogen is an important regulator of musculoskeletal wellbeing, at least in
female models. In addition to estrogen, progesterone is a significant hormone in the female
menstrual (human)/estrous (rodent) cycle. However, compared to estrogen, there is substantially
less literature on progesterone and muscle health. Yet, progesterone appears to be an important
moderator of many myopathies (37-39). Specifically, progesterone signaling appears to be a
robust moderator of neurological-musculoskeletal interactions. For example, progesterone-based
treatments are actively being investigated for neurological diseases such as amyotrophic lateral
sclerosis (ALS) (37-39). Additionally, recent evidence has suggested a progesterone-specific
receptor on the mitochondrial membrane (40, 41), suggesting progesterone may directly influence
mitochondrial quality and function. As mitochondrial quality is generally considered an important
moderator of muscle quality; these works suggest progesterone may be a largely uninvestigated
contributor to muscle health.
An interesting limitation of the scientific literature is the isolation of estrogen in many preclinical and in vitro studies. To our knowledge there are no studies in vitro investigating how
combined estrogen and progesterone affect muscle quality, specifically during atrophic
pathologies. In particular, studies using ovariectomy interventions typically generalize the effects
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of ovariectomy to estrogen action alone (11, 12, 14, 30, 32, 33, 42). This generalization omits the
possibility that some interactions may in part be mediated by progesterone action. More so, this
generalization omits the potential interactions between estrogen and progesterone. In a whole
organism, neither estrogen nor progesterone act in a vacuum; they both peak at approximately
the same point in the estrous/menstrual cycle (43-46) and are both eliminated after an
ovariectomy. As such, the interaction of progesterone and muscle health represents a sizeable
hole in our understanding of female sex hormones and muscle physiology. Therefore, the purpose
of this study was to compare hormonal effects on myotube diameter, measures of protein
anabolism and catabolism, as well as and markers for mitochondrial quality across multiple in
vitro models of muscle atrophy
c. Methods
i.

Cell Culture Media
All experiments were completed with C2C12 myoblasts (ATCC, Cat# CRL-1772). Cells

were plated in 6-well plates or specialized cell chamber units (Strex USA, San Diego, California,
STB-CH-04). Cells were grown in media containing, DMEM (ThermoFisher Scientific, Cat#
11960051) 20% Fetal bovine serum (ThermoFisher Scientific, Cat# 16000044) and 1% penicillinstreptomycin (ThermoFisher Scientific Cat# 15070063). After cells reached ~70-80% confluence,
cells were then differentiated with media containing 2% Hormone-free Fetal Bovine Serum
(ThermoFisher

Scientific,

Cat#

12676029),

1%

penicillin-streptomycin,

5%

HEPES

(ThermoFisher Scientific, Cat # 15630080), and 0.2% Insulin-Transferrin solution (ThermoFisher
Scientific, Cat# 41400045) Cells differentiated for ~5 days, at which point experiments were
begun.
ii.

Hormone treatments
All hormone treatments were completed in serum free DMEM media supplemented with

1% penicillin streptomyocin solution. Testosterone (Millipore Sigma, Cat# T1500-1G) was diluted
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to 200ng/dL for all experiments. This concentration corresponds to the upper range for
bioavailable testosterone in men (47). Bioavailable testosterone concentrations were used as
opposed to total testosterone (which are generally ~5 times greater), because in males a large
majority of testosterone is bound to sex hormone binding globulin (SHBG)(47). Testosterone that
is bound to SHBG is generally considered inactive (47). As such, using the bioavailable
concentrations likely better represents physiologically relevant testosterone levels. Estrogen
(Millipore Sigma, Cat# E3301-1G) was diluted to a concentration of 60pg/mL corresponding to
peak estrogen concentrations noted in the proestrus phase of the estrous cycle in female mice
(43-46). Progesterone (Millipore Sigma, Cat# P8783-1G) was diluted to a concentration of 30
ng/mL corresponding to peak progesterone concentrations noted during the proestrus phase of
the estrous cycle (43-46). For treatments containing both estrogen and progesterone, estrogen
and progesterone were combined at 60pg/mL and 30 pg/mL respectively.
iii.

Dexamethasone Treatment
To test the effects of hormones on glucocorticoid included muscle wasting we incubated

myotubes in dexamethasone (DEXA). Dexamethasone (Alfa Aesar, CAT# a17590) was dissolved
ethanol then diluted to 100ng/mL in cell culture media for all experiments. Ethanol was used as a
vehicle control for dexamethasone experiments. Once myotubes were differentiated, myotubes
treated with either control, dexamethasone supplemented media (DEXA), dexamethasone
supplemented media + testosterone (200ng/dL), dexamethasone supplemented media +
estrogen (60pg/mL), dexamethasone supplemented media + progesterone (30ng/mL),
dexamethasone supplemented media + estrogen + progesterone(60pg/mL and 30ng/mL). Cells
were incubated for 24 hours and then analyzed for myotube diameter, mitochondrial polarization,
mRNA analysis of genes related to protein anabolism and catabolism.

162
iv.

Lewis Lung Carcinoma Media Treatment
Treatment of cells with Lewis Lung Carcinoma (LLC) conditioned media (LCM) was

performed as previously described, with minor modifications (48, 49). Briefly, C2C12 or LLC cells
at ~100% confluence were incubated in 20% FBS growth media. After 24hrs of incubation, media
was collected and filtered. Media was then diluted with serum free DMEM cell culture media
supplemented with 1% penicillin-streptomycin to a final concentration of 30% conditioned media
and 70% serum free DMEM. C2C12 conditioned media, prepared in the same manner, served as
a control for these experiments. LCM was then supplemented with either testosterone (200ng/dL),
estrogen (60pg/mL), progesterone (30ng/mL) or estrogen and progesterone combined (60pg/mL
and 30ng/mL). Conditioned media was placed on differentiated myotubes and incubated for
24hrs. Myotubes were then analyzed for myotube diameter, mitochondrial polarization, and
mRNA analysis of genes related to protein turnover.
v.

“Disuse” Atrophy Treatment
Due to COVID-19 induced limitations to research, the disuse treatment was not able to be

completed. However, this protocol was proposed to simulate disuse atrophy. To simulate disuse
atrophy in vitro, a specialized cell stretch and electrical stimulation system was utilized (C-Stretch,
Ion Optix, Westwood, MA). After ~5 days of differentiation in specialized cell chamber units (Strex
USA, San Diego, California, STB-CH-04), myotubes would have been placed in the specialized
C-Stretch instrument. Myotubes would then be stimulated at 11.5 V for 2 ms pulses and 1Hz.
Concurrently, myotubes would also undergo 5% stretch and relaxation cycles. These stimulation
and stretch cycles were designed to simulate “healthy muscle” in vitro. This protocol was chosen
as a generally low frequency protocol that elicits adaptations without large hypertrophic
adaptations (50, 51). 5% stretch was chosen as a low intensity intervention that produces modest
gains in myotube size (52-54), without significant damage that occurs at higher intensity (such as
10%) stretch protocols (54). 24hrs was chosen because prior research has found 24hrs of either
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stretch or stimulation to induce measurable adaptations in vitro (50, 51, 53, 55). After 24hrs,
stimulation would have been halted, and myotubes (other than control myotubes) would have
been allowed to atrophy to simulate disuse atrophy in vitro. Control myotubes would have
continued stimulation for an additional 24hrs. At the initiation of atrophy, cells would have been
treated with hormones including testosterone (200ng/dL), estrogen (60pg/mL), progesterone
(30ng/mL) or estrogen combined with progesterone (60pg/mL and 30ng/mL). After 24hrs of
“disuse”, myotubes would have been analyzed for myotube diameter, mitochondrial polarization,
and mRNA content of genes related to protein turnover. While this particular protocol was not able
to be completed, pilot studies suggest this protocol was sufficient to induce myotube atrophy in
vitro (Supplementary Figure 1).
vi.

JC1 staining
JC1 fluorescent dye was used as a measure of mitochondrial polarization. JC1 dye

(ThermoFisher, Cat# T3168)

was diluted to 2 µg/mL in cell growth media. After atrophic

treatments, myotubes were rinsed with phosphate buffered saline (PBS). Myotubes were then
incubated in JC1 dye for 30 minutes. After 30 minutes of JC1 incubation, JC1 dye was removed
and myotubes were rinsed with PBS and imaged using a Nikon Ti‐S inverted epiflourescent
microscope (Melville, NY) equipped with FITC and TRITC filters and associated software (NISElements Basic Research, Nikon, Melville, NY). JC1 was quantified as the ratio of red:green
fluorescence, where a greater red:green ratio was indicative of greater mitochondrial polarization.
vii.

SunSET Analysis of Protein Synthesis
SunSET analysis was completed as previously described (49, 56, 57). Briefly, a working

concentration of puromycin (75mM, VWR, Cat# 80054-140 ) was diluted to 1 µM using serum
free cell culture media. After atrophic interventions, puromycin solution was placed on myotubes
and allowed to incubate for 30 min. Myotubes were then harvested using protein homogenization
buffer (recipe previously described elsewhere (58)). Samples were then loaded into ~10% SDS‐
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polyacrylamide gel (PAGE) and transferred onto PDVF membranes. Membranes were blocked
using LiCor Intercept blocking buffer (LiCor, Lincoln, NE, Cat# 927-60001) and incubated in
puromycin primary antibody (MilliporeSigma, Burlington, MA, Cat# MABE343) diluted 1:20,000
in blocking buffer. After ~24hrs of primary incubation, membranes were washed with Tris Buffered
Saline and incubated in puromycin secondary (Jackson ImmunoResearch Labs, West Grove, PA,
Cat# 115-035-206) diluted to 1:20,000 for ~90 minutes. Membranes were then incubated with
WesternSuren PREMIUM Chemiluminescent Substrate (LiCor, Cat# 926-95000) and imaged
using LiCor Odyssey Fc Imaging system. Because puromycin becomes incorporated into proteins
as they are being transcribed during the 30min incubation period, greater puromycin content was
interpreted as greater protein synthesis rates (57, 59).
viii.

mRNA Analysis
After atrophic interventions cells were harvested with 1 mL of Trizol to harvest RNA. RNA

was isolated was we have previously described (58, 60). Once RNA was isolated, cDNA was
synthesized using commercial reagents (SuperScript™ VILO™ Master Mix, Cat# 11755050,
ThermoFisher Scientific,). cDNA was analyzed using SYBR primers or Taqman probes as
appropriate using a QuantStudio 3 Realtime PCR instrument (ThermoFisher Scientific, Waltham,
MA). SYBR primer sequences have been published previously (58). Primers included: Bnip3,
Drp1, Fis1, Mff, Mfn1, Mfn2, and Opa1. Taqman probes included: 18s (Clone #Mm03928990_g1),
Pgc1α

(Clone

#Mm01208835_m1),

Lc3

(Clone

#Mm00458725_g1),

Redd1

(Clone

#Mm00512504_g1), Deptor (Clone #Mm01195339_m1), Atrogin (Clone #Mm00499523_m1),
Murf1

(Clone

#Mm01185221_m1),

p62

(Clone

#Mm00448091_m1),

NfKB

(Clone

#Mm00476361_m1), Foxo3 (Clone #Mm01185722_m1), MyoD (Clone #Mm00440387_m1),
MyoG

(Clone

#Mm00446194_m1),

Igf1

(Clone

#Mm00439560_m1),

Tgfβ

(Clone

#

Mm01178820_m1), Tnfα (Clone # Mm00443258_m1). All samples were normalized to 18s
values, which did not differ between groups.
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ix.

Statistical Analysis
For all experiments, the independent factor was atrophic intervention (DEXA or LCM) with

levels of treatments including Vehicle (positive control), atrophic treatment (negative control),
atrophic treatment + testosterone, atrophic treatment + estrogen, atrophic treatment +
progesterone, atrophic treatment + estrogen + progesterone. Because of the many groups
involved in each experiment, a global ANOVA and subsequent F test would not be appropriate
due to excessive comparisons. A typical ANOVA with pairwise comparisons for 6 groups would
entail 15 pairwise comparisons and dramatically expand Type I error rate. To maintain statistical
power we utilized a compressed ANOVA model to answer two primary hypothesis. The two
primary hypotheses tested were 1.) Do experimental conditions differ from control conditions and
2.) Do hormone treated myotubes differ from myotubes treated with an atrophic stimulus. Within
each hypothesis, the ANOVA model was condensed to contain only the number of pre-planned
comparisons of interest (adjusted F test). If the adjusted F test was significant, then pre-planned
comparisons were evaluated for significant differences between groups. P values were adjusted
with a Holm’s correction, with p<0.05 considered statistically significant for phenotypic data
(myotube diameter, mitochondrial polarization, and puromycin) and p<0.10 considered significant
for mRNA data. The more liberal p value was chosen for mRNA data due to limitations in sample
size and the exploratory nature of this study. This statistical analysis allowed us to investigate
how hormones may influence myotube responses to atrophic stimuli while still appropriately
managing the Type I error rate. All statistics were completed using SAS statistical software.
Comparisons of interest for Hypothesis 1 were:
1. Control v. atrophic condition
2. Control v. Testosterone treatment
3. Control v. Estrogen treatment
4. Control v. Progesterone treatment
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5. Control v. Progesterone and Estrogen treatment
Comparisons of interest for Hypothesis 2 were:
1. Atrophic condition v. Testosterone treatment
2. Atrophic condition v. Estrogen treatment
3. Atrophic condition v. Progesterone treatment
4. Atrophic condition v. Progesterone and Estrogen treatment
d. Results
i.

DEXA-induced atrophy results in decreased myotube size, which is protected by
testosterone or estrogen, but not progesterone
To test the effects of hormones on glucocorticoid included muscle wasting, we incubated

myotubes in serum free DMEM containing 100 nM dexamethasone (DEXA) dissolved in 100%
ethanol. After 24 hrs of incubation, dexamethasone-treated cells had ~37% smaller myotube
diameter compared to vehicle-treated control myotubes (p<0.0001, Figure 1A). However,
testosterone supplemented media was not different from CON myotubes (p=0.088, Figure 1A).
More so, testosterone treated myotubes were ~36% larger than DEXA treated tubes (p<0.0001,
Figure 1A).

While estrogen treated myotubes were statistically smaller than CON myotubes

(~12%, p=0.025, Figure 1A), they also had ~37% larger myotubes compared DEXA treated cells
(p<0.0001, Figure 1A). Progesterone and progesterone combined with estrogen were ~25%
smaller compared to CON (p<0.0001, and p<0.0001 respectively, Figure 1A) and not statistically
different from DEXA treated myotubes (p=0.129, and p=0.129 respectively).
Based on these findings we opted to investigate potential cellular signaling mechanisms
that may be contributing to these phenotypic differences in myotube size. Cells from two separate
experiments were harvested (4 wells/condition) and analyzed for mRNA of cellular cascades
related to protein anabolism and catabolism. Although the adjusted F test was not significant
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(p=0.178), Atrogin mRNA was ~8-fold greater in dexamethasone treated cells, which approached
statistical significance (p=0.087, Figure 1B). Testosterone and estrogen treatment appeared to
blunt the induction of Atrogin compared to CON, (p=0.260 and p=0.260 respectively); however
testosterone and estrogen treated cells were not statistically different from DEXA treated cells
(p=1.00 and p=1.00 respectively, Figure 1B). Whereas progesterone and estrogen combined with
progesterone were not statistically different from either CON (p=0.141 and p=0.131 respectively)
or DEXA (p=1.00 and p=1.00 respectively) Atrogin mRNA content compared to CON (p=0.047
and p=0.033 respectively, Figure 1B). With regards to MuRF1 mRNA content, DEXA cells were
from any groups; however there was a mean difference of ~2-fold greater MuRF1 mRNA content
in DEXA (p=0.31, Figure 1B). Neither testosterone nor estrogen were different from CON with
regards to MuRF1 mRNA content (p=0.378, and p=0.378) or DEXA treated cells (p=1.00 and
p=1.00 respectively); however, progesterone treated cells had ~3-fold greater MuRF1 mRNA
content compared to CON (p=0.054, Figure 1B) and was not different compared to DEXA treated
myotubes (p=1.00). Progesterone combined with estrogen was not statistically different from
CON (p=0.311) or DEXA (p=1.00, Figure 1B).
DEXA did not impact Lc3 mRNA compared to CON (p=0.211, Figure 1B). Yet,
testosterone, estrogen and progesterone treatments all resulted in ~50% greater Lc3 mRNA
content (p=0.022, p=0.032, p=0.018 respectively, Figure 1B). However combined estrogen and
progesterone was not different from CON (p=0.212, Figure 1B). No hormone treated cells were
different from DEXA (p=0.284, Figure 1B). p62 mRNA content was ~50% greater in DEXA treated
myotubes (p=0.083, Figure 1B), though hormone treatments did not statistically impact p62
mRNA content p=0.27-1.00, Figure 1B). Additionally p62 mRNA content was no different between
DEXA and testosterone, progesterone and progesterone combined with estrogen (p=0.1730.513, Figure 1B). However, estrogen treated cells had ~50% less p62 mRNA content compared
to DEXA treated myotubes (p=0.066, Figure 1B).
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DEXA treated myotubes had ~4-fold greater Deptor mRNA content compared to CON
(p=0.0003). All hormone treated cells had ~3-fold greater Deptor mRNA compared to CON
(p=0.0002-p=0.008, Figure 1C). Although no hormone treatments were statistically different from
DEXA (p=0.351), hormone treatment did appear to blunt Deptor mRNA induction (Figure 1C).
In DEXA treated myotubes, Redd1 mRNA was ~5-fold greater in DEXA treated cells
(p<0.018, Figure 1C). All hormone treated cells also had ~5-6-fold greater Redd1 mRNA content
compared to CON (p=0.002-p=0.018, Figure 1C). None of the hormone treated cells were
different from DEX treated cells (p=0.451, Figure 1C). Neither DEXA (p=0.701) or hormone
(p=0.586) treatment affected Nfkb mRNA content (Figure 1C). DEXA treatment resulted in ~3.5fold greater Foxo3 mRNA content (p=0.023, Figure 1C). Testosterone and Estrogen treated cells
were not statistically different from CON myotube in Foxo3 mRNA content (p=0.151, p=0.151,
Figure 1C). However, progesterone and progesterone combined with estrogen still had ~2-fold
greater Foxo3 mRNA content compared to CON (p=0.062 and p=0.057 respectively, Figure 1C).
ii.

Estrogen treated myotubes had greater protein synthesis compared to control
myotubes
DEXA treatment did not affect puromycin incorporation (p=0.28); however, estrogen

treatment resulted in ~75% greater protein synthesis measured by puromycin incorporation
(p=0.022, Figure 2A and 2B). Although DEXA itself did not appear to affect MyoD mRNA content,
(p=0.626, Figure 2C) hormone treatment, including estrogen, progesterone and estrogen
combined with progesterone was associated with lower MyoD mRNA content compared to control
(~50% lower MyoD mRNA content, p=0.024, p=0.050, and p=0.050 respectively). More so, all
hormone treated myotubes (testosterone, estrogen, progesterone and estrogen combined with
progesterone) all had 30-50% lower MyD content compared to DEXA treated myotubes (p=0.006p=0.023, Figure 2C). DEXA treatment resulted ~50% greater MyoG mRNA content compared to
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CON (p=0.031, Figure 2C). Hormone treatments appeared to mitigate this induction in MyoG
mRNA (p=0.39-0.49, Figure 2C).
iii.

DEXA treatment resulted in aberrations to mitochondrial signaling, without clear
functional differences
DEXA treatment did not result in aberrations to mitochondrial polarization measured by

JC1 (p=0.298,Figure 3A). More so, no hormone treated tubes were different from DEXA (p=0.195,
Figure 3A). DEXA treatment resulted in ~3-fold greater Pgc1α mRNA content compared to CON
(p=0.031, Figure 3B). Hormone treatments were not statistically different from CON (p=0.21-1.00,
Figure 3B). More so, estrogen, progesterone and estrogen combined with progesterone all had
50-80% less Pgc1α mRNA content compared to DEXA, yet testosterone treatment was not
statistically different from DEXA (p=0.368, Figure 3B). There were no differences between any
interventions and Bnip3 mRNA content (p=~0.42, Figure 3B). DEXA treated myotubes had ~30%
less Opa1 mRNA content compared to CON (p=0.025, Figure 3B). Hormone treated myotubes
(testosterone, estrogen, progesterone, estrogen combined with progesterone) had ~60-90% less
Opa1 mRNA content compared to CON (p<0.0001, Figure 3B). More so, hormone treated
myotubes had ~30-50% lower Opa1 mRNA content compared to DEXA treated myotubes
(p=0.0001-0.019, Figure 3B). DEXA and hormone treatments resulted in ~80% less Fis1 mRNA
content compared to CON (p<0.0001 for all comparisons Figure 3B). Additionally, no hormone
treated myotubes were different for DEXA with regard to Fis1 mRNA content (p=0.94, Figure 3B).
iv.

LCM induced atrophy of myotubes which appeared protected by all hormone
treatments
LCM resulted in ~25% lower myotube diameter compared to CON myotubes (p<0.0001,

Figure 4A). Testosterone treated tubes were not statistically different from CON (p=0.21, Figure
4A).

Estrogen, progesterone and estrogen and progesterone combined had ~9% smaller

myotube diameter compared to CON (p=0.0872, p=0.0872, and p=0.0872). Moreover,
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testosterone treated myotubes were ~23% larger compared to LCM-treated myotubes (p=0.0004,
Figure 4A). Additionally Estrogen, progesterone and estrogen and progesterone combined had
~20% larger myotube diameter compared to LCM myotubes (p=0.0003, p=0.0003, p=0.0003,
Figure 4A)
v.

LCM and hormone treatment resulted in some alterations to moderations of muscle
catabolism
Due to the limited sample size for LLC experiments (n=2/group), inferential statistics were

not necessarily appropriate for RNA data. As such, data will only be discussed as mean
differences, with the acknowledgement that future works will need to further validate these
findings. MyoG mRNA content was ~25% greater in LCM myotubes (Figure 5A).
testosterone or estrogen

appeared to influence this response (Figure 5A).

Neither
However,

progesterone appeared to result in 25% lower MyoG mRNA compared to the LCM myotubes
(Figure 5A). MyoD mRNA content did not appear influenced by LCM, testosterone, or estrogen
(Figure 5A). However, progesterone appeared to result in a mean decrease in MyoD mRNA
content. LCM appeared to result in modest greater Igf1 mRNA content compared to CON (Figure
5A). Whereas, Igf1 mRNA content was greater in testosterone or estrogen treated myotubes
(~50% greater Igf1 mRNA content, Figure 5A). Progesterone and estrogen combined with
progesterone appeared to blunt this greater Igf1 mRNA content (Figure 5A)
LCM resulted in ~30% greater Atrogin mRNA content compared to CON (Figure 5B).
Interestingly, testosterone resulted in ~3-fold greater Atrogin mRNA content compared to CON
(Figure 5B). A similar pattern was noted in progesterone and estrogen combined with
progesterone (~3-4 fold greater Atrogin mRNA content compared to CON, Figure 5B). However,
estrogen treatment did not result in exacerbated Atrogin mRNA content (Figure 5B). Neither LCM
nor hormone treatment appeared to influence Murf1 mRNA content (Figure 5B). While LCM itself
did not appear to result in greater Lc3 mRNA content (Figure 5B). LCM appeared to result in
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~50% greater p62 mRNA content compared to CON (Figure 5B). However hormone treatment in
general did not appear to influence p62 mRNA content (Figure 5B).
vi.

Sex hormones appear to moderate moderators of protein synthesis during LCMinduced atrophy
LCM itself did not appear to influence Redd1 mRNA content (Figure 6A); however

testosterone appeared to result in ~50% greater Redd1 mRNA content (Figure 6A). Estrogen
treatment did not influence Redd1 mRNA content, but progesterone and estrogen combined with
progesterone appeared to result in ~50% greater Redd1 mRNA content (Figure 6A). Similarly,
Deptor mRNA did not have inductions as a result of LCM. (Figure 6A). However, testosterone,
progesterone and progesterone combined with estrogen treatment resulted in ~3-fold greater
Deptor mRNA content (Figure 6A). Estrogen treatment did not appear to alter Deptor mRNA
content (Figure 6A).
Neither LCM nor hormone treatment appeared to impact Nfkb mRNA content (Figure 6B).
LCM treatment did not appear to alter Tgfβ mRNA content (Figure 6B). However, testosterone,
progesterone and estrogen combined with progesterone appeared to result in ~40% less Tgfβ
mRNA content. LCM and hormone treatment appeared to result in ~40-90% reduced Tnfα mRNA
content (Figure 6B). LCM resulted in ~30% greater Foxo3 mRNA content (Figure 6B); yet,
testosterone, progesterone, and progesterone combined with estrogen resulted in ~3-fold greater
Foxo3 mRNA content compared to CON (Figure 6B). Estrogen appeared to blunt this response
in Foxo3 mRNA content (Figure 6B). Both LCM and hormone treatments appeared to result in
~40% lower Il6 mRNA content (Figure 6B).
vii.

LCM did not appear to greatly influence mitochondrial turnover
There were no differences noted in JC1 polarization between any interventions and CON

(p=0.384) or hormone interventions and DEXA (p=0.347, Figure 7A). LCM induced greater Pgc1α
mRNA (~40%), in testosterone treated cells there was a 4-fold greater Pgc1α content compared
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to CON (Figure 7B). Estrogen did not result in any alterations to Pgc1α mRNA content but
progesterone also resulted in a 4-fold greater Pgc1α mRNA content. Neither LCM nor hormone
treatment appeared to influence Cox4 mRNA content (Figure 7B) . LCM treatment resulted in
~30% greater Bnip3 mRNA content compared to CON. Testosterone appeared to result in
additional Bnip3 mRNA content (~50% greater Bnip3 mRNA content compared to CON).
However, both estrogen and progesterone treatment appeared to blunt these alterations to Bnip3
mRNA (Figure 7B).
viii.

LCM resulted in aberrations to mitochondrial dynamics, some sex hormones
appeared to protect against some of these alterations
LCM resulted in ~4-fold greater Mfn1 mRNA content compared to CON. Additionally,

testosterone appeared to augment this response with ~6-fold greater Mfn1 mRNA content
compared to CON (Figure 8A). Estrogen, progesterone, and combined estrogen and
progesterone did not appear to have a strong inductions in Mfn1 (Figure 8A). LCM media resulted
in ~2-fold greater Mfn2 mRNA content compared to CON (Figure 8A). Testosterone did not
appear to influence this response (Figure 8A). However, estrogen, progesterone and combined
estrogen and progesterone had ~80% lower Mfn2 mRNA content compared to CON (Figure 8A).
Overall, neither LCM or hormones did not appear to influence Opa1 content (Figure 8A).
LCM did not appear to greatly influence Fis1 mRNA content (Figure 8B). Additionally,
testosterone did not appear to influence Fis1 mRNA content (Figure 8B). However, estrogen and
progesterone appeared to greatly reduce Fis1 content (Figure 8B). Mff mRNA content did not
appear impacted by LCM (Figure 8B); however testosterone did appear to impact Mff mRNA
content, with ~2-fold greater Mff mRNA content (Figure 6A). More so, estrogen, progesterone and
estrogen and progesterone appeared to result in ~50-80% less Mff mRNA content (Figure 8B).
Finally, LCM treatment resulted in ~3.5-fold greater Drp1 mRNA content compared to CON wells.
However, all the sex hormones appeared to protect against Drp1 mRNA induction (Figure 8B).
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e. Discussion
To our knowledge, this is one of the first studies investigating hormonal influences on
models of muscle atrophy in vitro. We find either testosterone or estrogen sufficient to mitigate
phenotypic aberrations to muscle health during different pathologies. However, progesterone or
progesterone combined with estrogen appears to have divergent effects on myotube diameter
depending on the precise stimuli. To our knowledge, this is one the first studies to compare the
individual and combined effects of progesterone and estrogen. These findings may have
significant implications for future research investigating the role of sex hormones on muscle
pathologies.
Similar to prior reports (61-63), we find dexamethasone sufficient to result in reduced
myotube diameter compared to vehicle control. Additionally, we find testosterone sufficient to
blunt dexamethasone-induced atrophy also agreeing with prior works (61, 64). Previous works
have found testosterone sufficient to blunt many moderators of protein catabolism such as Foxo3
and Murf1 (61), and inflammation such as Nfkb (18, 20). While in this particular study we did not
find dexamethasone induction of Nfkb, we do find strong inductions of atrophic moderators
Atrogin, Murf1 (though not statistically significant), and Foxo3. Testosterone mitigated these
aberrations, which appeared to blunt phenotypic myotube atrophy. Conversely, we find
dexamethasone increased inhibitors of protein synthesis (Redd1 and Deptor) and decreases
moderators of protein synthesis (Igf1) which testosterone was not sufficient to mitigate. Overall
these results imply testosterone mitigates glucocorticoid-induced atrophy through attenuating
atrophic signaling cascades. Conversely, we find estrogen to moderate not only atrophic
programming during glucocorticoid-induced atrophy, but we also find estrogen sufficient to induce
anabolic programing. More so, these protections are specific to estrogen and some of these
protections are ablated with the inclusion of progesterone. For example, we find estrogen itself is
sufficient to blunt Atrogin and Foxo3 induction with dexamethasone treatment; yet, when estrogen
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is combined with progesterone these protections are lost. Similarly, we find estrogen sufficient to
increase protein synthesis measured by SuNSET technique during dexamethasone induced
atrophy. However, when combined with progesterone this increase in protein synthesis is ablated.
Taken together, these results suggest hormone-mediated protections against myopathies have
protective impacts; however, these protections occur through different mechanisms. Testosterone
appears to primarily mitigate catabolic pathways, whereas estrogen acts through both increasing
anabolic programing and decreasing catabolic programing. Conversely, when combined with
progesterone, many of estrogen’s protective mechanisms are lost. To our knowledge, this is one
of the first studies to report divergent mechanisms between estrogen and progesterone during
glucocorticoid-induced atrophy and these findings warrant more investigation in the future.
Surprisingly, LLC conditioned media did not result in an increased inflammatory phenotype
in myotubes. This may be partially attributed to small sample sizes in each group; therefore this
experiment needs further replication for final validations. However, similar to prior works (49), we
find LCM sufficient to result in ~25% lower myotube diameter compared to control myotubes. This
myotube atrophy was attenuated by testosterone, estrogen, and progesterone combined with
estrogen. However, similar to dexamethasone-induced atrophy, the different sex hormones seem
to influence different anabolic/catabolic cascades. Counterintuitively, testosterone increased
atrophic pathways such as Atrogin, p62, Lc3 as well as protein inhibitory pathways Redd1 and
Deptor. However, testosterone also increased Igf1 content, generally implying that testosterone
treatment may protect myotube size through Igf1 signaling mechanisms. Interestingly,
testosterone treatment appears sufficient for myotube protection despite induction of catabolic
signaling cascades. Conversely, in estrogen and progesterone treated myotubes, we noted a
protection of myotube diameter with both hormones. Similar to dexamethasone-induced atrophy,
estrogen blunted Atrogin and Foxo3 induction, which likely contributed to some protections we
noted in myotube diameter. Yet, in progesterone incubated myotubes, we did not see these same
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protections, instead progesterone treated myotubes had greater Pgc1α content. Because Pgc1α
is associated with various signaling cascades related to mitochondrial and muscle quality (25, 26,
58), this Pgc1α induction may have been sufficient to protect myotube diameter.
It is interesting to note that both testosterone and progesterone appeared sufficient to
increase Pgc1α content. To our knowledge, only one other study has reported this finding using
in vitro methodologies (64). Other works have found removal of testosterone by castration to affect
the Pgc1α signaling cascade and subsequent mitochondrial biogenesis (65). Testosterone
mediated Pgc1α induction also appeared to correspond with alterations to various aspects of
mitochondrial quality control, in particular mitochondrial dynamics. Our laboratory has previously
shown Pgc1α to moderate many facets of mitochondrial quality control, including mitochondrial
dynamics (58). More so, it is generally well established that mitochondrial quality is imperative for
overall muscle quality (25). Therefore, it is possible that both testosterone and progesterone exert
protections from atrophic pathologies through Pgc1α activity and subsequent improvements to
mitochondrial quality control mechanisms. This hypothesis would align with recent works
suggesting a progesterone-mitochondrial quality connection (40, 41, 66). However, these
observations need to be further examined to validate this hypothesis.
We should note that while progesterone did not attenuate catabolic pathways within the
myotubes during DEXA-induced atrophy, this should not necessarily be interpreted as
progesterone being pathological for musculoskeletal health. While our data tends to suggest
progesterone may not directly contribute to protections during myopathies, other data clearly
demonstrates progesterone’s potential role for overall musculoskeletal health. For example,
research has demonstrated that progesterone action can strongly influence neurological health
(37, 38, 67). Neurological quality and function significantly influences overall musculoskeletal
health (68, 69); therefore, it is plausible that while progesterone may not directly benefit muscle
size, progesterone may indirectly influence muscle health through neurological mechanisms.
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In conclusion, this study provides some early evidences for differential regulation of
anabolic and catabolic processes between different sex hormones. Specifically, this study
demonstrates divergent regulation between female sex hormones estrogen and progesterone,
depending on the atrophic pathology. As such, future works investigating sex as a biological
variable should further investigate using in vitro methods to more thoroughly elucidate specific
actions of estrogen and progesterone in relation musculoskeletal and overall health.
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f.

Figures

Figure 1: Myotube diameter and moderators of protein catabolism and protein anabolism. A:
Myotube diameter from dexamethasone and hormone treatment as well as representative image.
B: mRNA content of moderators of protein catabolism with dexamethasone or hormone
treatment. C: mRNA content of inhibitors of protein anabolism and inflammation signaling with
dexamethasone and hormone treatment. Green * indicates statistical difference between CON,
red * indicates statistical differences between DEXA.
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Figure 2: Myotube protein synthesis. A: Protein synthesis measured by SuNSET technique after
dexamethasone and hormone treatment. B: Representative puromycin (SuNSET) blots after
dexamethasone and hormone treatment. C: mRNA content of moderators of myotube
differentiation after dexamethasone and hormone treatment. Green * indicates statistical
difference between CON, red * indicates statistical differences between DEXA.
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Figure 3: Measures of mitochondrial quality control with dexamethasone and hormone treatment.
A: Mitochondrial polarization measured though JC1 with dexamethasone and hormone treatment.
B: mRNA content of moderators of mitochondrial quality control with dexamethasone and
hormone treatment. Green * indicates statistical difference between CON, red * indicates
statistical differences between DEXA.

180

Figure 4A: Myotube diameter in LLC conditioned and hormone treated myotubes. Green *
indicates statistical difference between CON, red * indicates statistical differences between
DEXA.
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Figure 5: mRNA content of moderators of myotube anabolism. A: mRNA content of moderators
of myotube differentiation in LLC conditioned and hormone treated myotubes. B: mRNA content
of protein catabolism in LLC conditioned and hormone treated myotubes. N=2/group, as such, no
inferential statistics were analyzed on these data.
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Figure 6: mRNA content of inhibitors of protein synthesis and inflammation. A: mRNA content of
inhibitors of protein synthesis in LLC conditioned and hormone treated myotubes. B: mRNA
content of inflammation in LLC conditioned and hormone treated myotubes. N=2/group, as such,
no inferential statistics were analyzed on these data.
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Figure 7: Measures of mitochondrial quality control with LCM and hormone treatment. A:
Mitochondrial polarization measured though JC1 with LCM and hormone treatment. B: mRNA
content of moderators of mitochondrial quality control with LCM and hormone treatment.
N=2/group, as such, no inferential statistics were analyzed on these data.
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Figure 8: mRNA content of moderators of mitochondrial fusion and fission in LLC conditioned
and hormone treated myotubes. A: mRNA content of moderators of mitochondrial fusion in LLC
conditioned and hormone treated myotubes. B: mRNA content of moderators of mitochondrial
fission in LLC conditioned and hormone treated myotubes. N=2/group, as such, no inferential
statistics were analyzed on these data.
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Supplementary Figure 1: Myotube diameter data from myotubes pre-electrical stimulation and
stretch (Pre-Stretch), those same myotubes immediately after 24hrs of electrical stimulation at
11.5 V for 2 ms pulses and 1Hz as well as 5% stretch and relaxation cycles (Post-Stretch) and
finally cells the same myotubes that had stimulation and stretch halted to induce “atrophy” (PostAtrophy).

186
g. References
1.
Arthur ST, Van Doren BA, Roy D, Noone JM, Zacherle E, Blanchette CM. Cachexia among
US cancer patients. J Med Econ. 2016;19(9):874-80.
2.
Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms
and promising therapies. Nat Rev Drug Discov. 2015;14(1):58-74.
3.
Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently
diagnosed incurable cancer: a systematic review. Support Care Cancer. 2006;14(10):999-1011.
4.
Ali NA, O'Brien JM, Jr., Hoffmann SP, Phillips G, Garland A, Finley JC, et al. Acquired
weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med.
2008;178(3):261-8.
5.
Rosa-Caldwell ME, Greene NP. Muscle metabolism and atrophy: let’s talk about sex. Biol
Sex Differ. 2019;10.
6.
ME R-C, DK F, TA W, NP G. Muscle Alterations in the Development and Progression of
Cancer-Induced Muscle Atrophy: A Review. Journal of applied physiology (Bethesda, Md : 1985).
2020;128(1).
7.
Gao Y, Arfat Y, Wang H, Goswami N. Muscle Atrophy Induced by Mechanical Unloading:
Mechanisms and Potential Countermeasures. Front Physiol. 2018;9.
8.
Anderson LJ, Liu H, Garcia JM. Sex Differences in Muscle Wasting. Adv Exp Med Biol.
2017;1043:153-97.
9.
Canon ME, Crimmins EM. Sex differences in the association between muscle quality,
inflammatory markers, and cognitive decline. J Nutr Health Aging. 2011;15(8):695-8.
10.
Colom B, Oliver J, Garcia-Palmer FJ. Sexual Dimorphism in the Alterations of Cardiac
Muscle Mitochondrial Bioenergetics Associated to the Ageing Process. J Gerontol A Biol Sci Med
Sci. 2015;70(11):1360-9.
11.
Kawano S, Kanda K, Ohmori S, Izumi R, Yasukawa K, Murata Y, et al. Effect of estrogen
on the development of disuse atrophy of bone and muscle induced by tail-supension in rats.
Environ Med. 1997;41(2):89-92.
12.
Enns DL, Tiidus PM. Estrogen influences satellite cell activation and proliferation following
downhill running in rats. J Appl Physiol (1985). 2008;104(2):347-53.
13.
Capllonch-Amer G, Sbert-Roig M, Galmes-Pascual BM, Proenza AM, Llado I, Gianotti M,
et al. Estradiol stimulates mitochondrial biogenesis and adiponectin expression in skeletal muscle.
J Endocrinol. 2014;221(3):391-403.

187
14.
Cavalcanti-de-Albuquerque JP, Salvador IC, Martins EL, Jardim-Messeder D, Werneckde-Castro JP, Galina A, et al. Role of estrogen on skeletal muscle mitochondrial function in
ovariectomized rats: a time course study in different fiber types. J Appl Physiol (1985).
2014;116(7):779-89.
15.
M B, B P, M P, D A, I G, G E, et al. Urinary Sex Steroid and Glucocorticoid Hormones Are
Associated With Muscle Mass and Strength in Healthy Adults. The Journal of clinical
endocrinology and metabolism. 2019;104(6).
16.
Cobo G, gabriela.cobo@ki.se, Gallar P, Di Gioia C, García Lacalle C, Camacho R, et al.
Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness
in men undergoing haemodialysis. Nefrología (English Edition). 2020;37(1):54-60.
17.
ME H, AS G. Testosterone and Resistance Training Improve Muscle Quality in Spinal
Cord Injury. Medicine and science in sports and exercise. 2019;51(8).
18.
Urban RJ, Dillon EL, Choudhary S, Zhao Y, Horstman AM, Tilton RG, et al. Translational
Studies in Older Men Using Testosterone to Treat Sarcopenia. Trans Am Clin Climatol Assoc.
2014;125:27-44.
19.
J S, S M-S, S W, C S, K S. Stimulation of Both Estrogen and Androgen Receptors
Maintains Skeletal Muscle Mass in Gonadectomized Male Mice but Mainly via Different Pathways.
Journal of molecular endocrinology. 2010;45(1).
20.
Wright TJ, Dillon EL, Durham WJ, Chamberlain A, Randolph KM, Danesi C, et al. A
randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J
Cachexia Sarcopenia Muscle. 2018;9(3):482-96.
21.
Harjola V, Jankala H, Harkonen M. Myosin heavy chain mRNA and protein distribution in
immobilized rat skeletal muscle are not affected by testosterone status. Acta Physiol Scand.
2000;169(4):277-82.
22.
De Naeyer H, Lamon S, Russell AP, Everaert I, De Spaey A, Jamart C, et al. Effects of
tail suspension on serum testosterone and molecular targets regulating muscle mass. Muscle
Nerve. 2015;52(2):278-88.
23.
Wu Y, Collier L, Pan J, Qin W, Bauman WA, Cardozo CP. Testosterone reduced
methylprednisolone-induced muscle atrophy in spinal cord-injured rats. Spinal Cord.
2011;50(1):57-62.
24.
ML R, JL S, BS G. Increased Mitochondrial Turnover in the Skeletal Muscle of Fasted,
Castrated Mice Is Related to the Magnitude of Autophagy Activation and Muscle Atrophy.
Molecular and cellular endocrinology. 2018;473.
25.
Yan Z, Lira VA, Greene NP. Exercise training-induced regulation of mitochondrial quality.
Exerc Sport Sci Rev. 2012;40(3):159-64.

188
26.
Argiles JM, Lopez-Soriano FJ, Busquets S. Muscle wasting in cancer: the role of
mitochondria. Curr Opin Clin Nutr Metab Care. 2015;18(3):221-5.
27.
Ding H, Zhang ZY, Zhang JW, Zhang Y. Role of mitochondrial quality control in exerciseinduced health adaptation. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2013;29(6):543-53.
28.
Vitorino R, Moreira-Gonçalves D, Ferreira R. Mitochondrial plasticity in cancer-related
muscle wasting: potential approaches for its management. Curr Opin Clin Nutr Metab Care.
2015;18(3):226-33.
29.
Parr MK, Zhao P, Haupt O, Ngueu ST, Hengevoss J, Fritzemeier KH, et al. Estrogen
receptor beta is involved in skeletal muscle hypertrophy induced by the phytoecdysteroid
ecdysterone. Mol Nutr Food Res. 2014;58(9):1861-72.
30.
Y K, Y O. Estrogens Maintain Skeletal Muscle and Satellite Cell Functions. The Journal of
endocrinology. 2016;229(3).
31.
MR B, GE S, LM T, FC F, MF R, MM D, et al. Resistance Training and Ovariectomy:
Antagonic Effects in Mitochondrial Biogenesis Markers in Rat Skeletal Muscle. International
journal of sports medicine. 2016;37(11).
32.
McClung JM, Davis JM, Wilson MA, Goldsmith EC, Carson JA. Estrogen status and
skeletal muscle recovery from disuse atrophy. J Appl Physiol (1985). 2006;100(6):2012-23.
33.
M S, AM F, M B, EE S. Ovariectomy Prevents the Recovery of Atrophied Gastrocnemius
Skeletal Muscle Mass. Journal of applied physiology (Bethesda, Md : 1985). 2006;100(1).
34.
Teveroni E, Pellegrino M, Sacconi S, Calandra P, Cascino I, Farioli-Vecchioli S, et al.
Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by
antagonizing DUX4 activity. J Clin Invest. 2017;127(4):1531-45.
35.
Matsakas A, Yadav V, Lorca S, Narkar V. Muscle ERRgamma mitigates Duchenne
muscular dystrophy via metabolic and angiogenic reprogramming. Faseb j. 2013;27(10):4004-16.
36.
Velarde MC. Pleiotropic actions of estrogen: a mitochondrial matter. Physiol Genomics.
2013;45(3):106-9.
37.
G G-M, M M, A L, L G, A L, P R, et al. Comparative Effects of Progesterone and the
Synthetic Progestin Norethindrone on Neuroprotection in a Model of Spontaneous Motoneuron
Degeneration. The Journal of steroid biochemistry and molecular biology. 2019;192.
38.
M M, LI G, MS K, A L, G G-M, M S, et al. Protective Effects of the Neurosteroid
Allopregnanolone in a Mouse Model of Spontaneous Motoneuron Degeneration. The Journal of
steroid biochemistry and molecular biology. 2017;174.

189
39.
MC GD, L G, S G, F S, F L, R G, et al. Progesterone Modulates Brain-Derived
Neurotrophic Factor and Choline Acetyltransferase in Degenerating Wobbler Motoneurons.
Experimental neurology. 2007;203(2).
40.
Dai Q, Shah AA, Garde RV, Yonish BA, Zhang L, Medvitz NA, et al. A truncated
progesterone receptor (PR-M) localizes to the mitochondrion and controls cellular respiration. Mol
Endocrinol. 2013;27(5):741-53.
41.
Feng Q, Crochet JR, Dai Q, Leppert PC, Price TM. Expression of a mitochondrial
progesterone receptor (PR-M) in leiomyomata and association with increased mitochondrial
membrane potential. J Clin Endocrinol Metab. 2014;99(3):E390-9.
42.
Brown M, Foley A, Ferreria JA. Ovariectomy, hindlimb unweighting, and recovery effects
on skeletal muscle in adult rats. Aviat Space Environ Med. 2005;76(11):1012-8.
43.
Smith MS, Freeman ME, Neill JD. The control of progesterone secretion during the estrous
cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated
with rescue of the corpus luteum of pseudopregnancy. Endocrinology. 1975;96(1):219-26.
44.
Kramer PR, Bellinger LL. The Effects of Cycling Levels of 17β-Estradiol and Progesterone
on the Magnitude of Temporomandibular Joint-Induced Nociception. Endocrinology.
2009;150(8):3680-9.
45.
Butcher RL, Collins WE, Fugo NW. Plasma concentration of LH, FSH, prolactin,
progesterone and estradiol-17beta throughout the 4-day estrous cycle of the rat. Endocrinology.
1974;94(6):1704-8.
46.
Butcher RL, Inskeep EK, Pope RS. Plasma concentrations of estradiol produced with two
delivery systems in ovariectomized rats. Proc Soc Exp Biol Med. 1978;158(3):475-7.
47.
Krakowsky Y, Grober ED. Testosterone Deficiency - Establishing A Biochemical
Diagnosis. EJIFCC. 2015;26(2):105-13.
48.
Puppa MJ, Gao S, Narsale AA, Carson JA. Skeletal muscle glycoprotein 130's role in
Lewis lung carcinoma-induced cachexia. Faseb j. 2014;28(2):998-1009.
49.
Brown JL, Lee DE, Rosa-Caldwell ME, Brown LA, Perry RA, Haynie WS, et al. Protein
imbalance in the development of skeletal muscle wasting in tumour-bearing mice. J Cachexia
Sarcopenia Muscle. 2018.
50.
Evers-van Gogh IJ, Alex S, Stienstra R, Brenkman AB, Kersten S, Kalkhoven E. Electric
Pulse Stimulation of Myotubes as an In Vitro Exercise Model: Cell-Mediated and Non-CellMediated Effects. Sci Rep. 2015;5:10944.
51.
Lambernd S, Taube A, Schober A, Platzbecker B, Gorgens SW, Schlich R, et al.
Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting proinflammatory signalling pathways. Diabetologia. 2012;55(4):1128-39.

190
52.
Carson JA, Booth FW. Effect of serum and mechanical stretch on skeletal alpha-actin
gene regulation in cultured primary muscle cells. Am J Physiol. 1998;275(6):C1438-48.
53.
Gao S, Carson JA. Lewis lung carcinoma regulation of mechanical stretch-induced protein
synthesis in cultured myotubes. Am J Physiol Cell Physiol. 2016;310(1):C66-79.
54.
Simpson DG, Majeski M, Borg TK, Terracio L. Regulation of cardiac myocyte protein
turnover and myofibrillar structure in vitro by specific directions of stretch. Circ Res.
1999;85(10):e59-69.
55.
Vandenburgh H, Kaufman S. In vitro model for stretch-induced hypertrophy of skeletal
muscle. Science. 1979;203(4377):265-8.
56.
Lee DE, Brown JL, Rosa ME, Brown LA, Perry RA, Wiggs MP, et al. microRNA-16 Is
Downregulated During Insulin Resistance and Controls Skeletal Muscle Protein Accretion. J Cell
Biochem. 2015.
57.
Goodman CA, Mabrey DM, Frey JW, Miu MH, Schmidt EK, Pierre P, et al. Novel insights
into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in
vivo technique. FASEB J. 2011;25(3):1028-39.
58.
Greene NP, Lee DE, Brown JL, Rosa ME, Brown LA, Perry RAJ, et al. Mitochondrial
quality control, driven by PGC-1α, is dysregulated by Western Diet-induced obesity and partially
restored by moderate physical activity in mice. Physiological Reports. 2015;3:e12470.
59.
Goodman CA, Hornberger TA. Measuring protein synthesis with SUnSET: a valid
alternative to traditional techniques? Exerc Sport Sci Rev. 2013;41(2):107-15.
60.
Rosa-Caldwell ME, Lee DE, Brown JL, Brown LA, Perry JRA, Greene ES, et al. Moderate
Physical Activity Promotes Basal Hepatic Autophagy in Diet-Induced Obese Mice. Applied
Physiology, Nutrition, and Metabolism. 2016.
61.
Zhao W, Pan J, Zhao Z, Wu Y, Bauman WA, Cardozo CP. Testosterone protects against
dexamethasone-induced muscle atrophy, protein degradation and MAFbx upregulation. J Steroid
Biochem Mol Biol. 2008;110(1-2):125-9.
62.
Qiu J, Wang L, Wang Y, Zhang Q, Ma W, Fang Q, et al. MicroRNA351 targeting TRAF6
alleviates dexamethasone-induced myotube atrophy. J Thorac Dis. 2018;10(11):6238-46.
63.
Y Y, Y K, Y S, Y Y, H A. Glabridin Inhibits Dexamethasone-Induced Muscle Atrophy.
Archives of biochemistry and biophysics. 2019;664.
64.
W Q, J P, Y W, WA B, C C. Protection Against Dexamethasone-Induced Muscle Atrophy
Is Related to Modulation by Testosterone of FOXO1 and PGC-1α. Biochemical and biophysical
research communications. 2010;403(3-4).

191
65.
C L, J M, J Z, H Z, Y Z, J Q, et al. Testosterone Deficiency Caused by Castration Modulates
Mitochondrial Biogenesis Through the AR/PGC1α/TFAM Pathway. Frontiers in genetics. 2019;10.
66.
Bottje W, Kong BW, Reverter A, Waardenberg AJ, Lassiter K, Hudson NJ. Progesterone
signalling in broiler skeletal muscle is associated with divergent feed efficiency. BMC Syst Biol.
2017;11(1):29.
67.
Gonzalez Deniselle MC, Garay L, Meyer M, Gargiulo-Monachelli G, Labombarda F,
Gonzalez S, et al. Experimental and clinical evidence for the protective role of progesterone in
motoneuron degeneration and neuroinflammation. Horm Mol Biol Clin Investig. 2011;7(3):403-11.
68.
Kwon H, Di Cristina JF, Rutkove SB, Sanchez B. Recording characteristics of electrical
impedance-electromyography needle electrodes. Physiol Meas. 2018;39(5):055005.
69.
S V, SB R. Neurophysiological Biomarkers in Amyotrophic Lateral Sclerosis. Current
opinion in neurology. 2018;31(5).

192
Chapter VII: Conclusions
This dissertation investigated mitochondrial underpinnings of disuse atrophy and how
biological sex may influence mitochondrial aberrations during disuse atrophy. I find that males
and females appear to exhibit different mitochondrial mechanisms during the progression and
development of disuse atrophy, and that females appear more responsive to mitochondriallytargeted interventions. Finally, I find sex hormones may moderate the development of muscle
atrophies, though these protections act through different mechanisms; however, interactions
between estrogen and progesterone in relation to muscle health may be more complicated than
previously thought. These are the first series of studies to investigate the development and
progression of muscle atrophy in both males and females. Based on these series of studies, future
studies should seek to more thoroughly elucidate the complex interactions between hormonal
status and muscle atrophy. In particular, more works are needed to fully understand the
interactions between estrogen and progesterone and musculoskeletal health.
a. Mitochondrial degeneration varies depending on muscle fiber composition and
biological sex (Chapter 4)
In this study I investigated the progression of disuse atrophy across multiple muscles in
male and female mice for 24-168 hrs. From this experiment I find females tend to experience
disuse-induced muscle loss faster compared to males. However, sex differences in the
aberrations to mitochondrial health (measured by pMitoTimer) and various markers of
mitochondrial quality control (in particular BNIP3) demonstrate clear differences between males
and females during the progression of disuse atrophy. These results strongly suggest different
mitochondrial mechanisms during muscle atrophies between males and females. More so,
various aspects of mitochondrial quality control are altered across different muscle fiber
contributions. These studies provide preliminary evidence for sex differences in mitochondrial
deterioration during disuse atrophy.
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b. Increased mitochondrial content does not protect against disuse atrophy, whereas
increasing mitochondrial antioxidant capacity may protect muscle mass in females
(Chapter 5)
In this study I investigated the potential efficacy of mitochondrial-based therapies for
mitigating disuse atrophy in males and females. From this research, I demonstrate that increasing
mitochondrial content through greater PGC1α is sufficient to blunt ubiquitin-proteasome induction
during disuse. However, despite diminished activation of the ubiquitin-proteasome system,
greater PGC1α does not protect against or limit the progression of disuse atrophy in males or
females. Given PGC1α content was not altered during unloading (Chapter 3), this was not
necessarily a surprising result. Conversely, increasing mitochondrially targeted catalase appears
to protect muscle mass during disuse in females, particularly in the atrophy-prone soleus muscle.
Taken together these results support the hypothesis that mitochondria-based interventions may
protect against disuse atrophy, particularly interventions that mitigate potential damage caused
by reactive oxygen species, yet the efficacy of these interventions may be sex specific.
c. Sex hormones may moderate muscle protections during atrophic conditions; however,
these protections vary between atrophic models (Chapter 6)
In this study I investigated in vitro how sex hormones may moderate or protect against
different atrophic pathologies. While simulating disuse was not possible due to technical
difficulties and the global COVID-19 pandemic, I was still able to simulate glucocorticoid-induced
and cancer-induced muscle atrophy in vitro. I find that testosterone and estrogen are sufficient to
mitigate muscle losses during both dexamethasone and cachexia myopathies. Yet, the inclusion
of progesterone with estrogen results in more complex interactions. For example, estrogen and
progesterone combined do not mitigate dexamethasone-induced myotube atrophy myotubes yet
do mitigate cachexia-induced atrophy. More so, signaling cascades between traditionally “male”
hormones (e.g. testosterone) and traditionally “female” hormones (e.g. estrogen and
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progesterone) appear to exert protective effects through divergent signaling cascades.
Regardless, to my knowledge, this is the first study to investigate the combined effects of estrogen
and progesterone, a more appropriate recapitulation of circulating hormonal status in females.
Because estrogen and progesterone appear to exert divergent effects on skeletal muscle more
research is necessary to more fully elucidate complex hormonal interactions during myopathies.
d. Limitations and Delimitations
There are a few limitations not only inherent to these study designs but also the global
overall situation that limits some interpretations of these data. As all research utilized pre-clinical
models (e.g. mice and cells), it is possible that there are some inherent differences between our
model organisms and humans that we could not account for in these studies. Additionally, there
are some limitations due to the current global pandemic of COVID-19. Because of laboratory
shutdowns it was not possible to finish some analysis. Notably, there is no hormone data in
relation to disuse specific atrophy, the primary research topic of the dissertation. And the
cachexia-induced muscle atrophy was limited by sample size. However, based on the current
study there is plausible evidence that there are sex differences in the development and
progression of disuse atrophy AND our in vitro evidence in other models of atrophy appears to
suggest hormones may in part moderate muscle atrophy during myopathies.
Regarding delimitations, this study is strengthened by the use of multiple separate animal
studies to study disuse atrophy. The conserved findings we noted across all animal studies
provides robust evidence for some mitochondrial aberrations during disuse atrophy as well as sex
differences in the etiology of the disuse atrophy. More so, the use of in vitro models allows for the
precise investigation of hormonal interactions on atrophic pathologies.
e. Final Thoughts
In conclusion, these studies establish sex-related differences in the etiology of muscle
atrophy. More so, mitochondria-specific treatments may have differential efficacy between males
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and females. Finally, muscle atrophies appear to be partially moderated by sex hormones;
however, through different cellular signaling cascades. These studies provide some of the early
evidences for sex-based differences in disuse myopathies. More so, these studies emphasize the
need to investigate biomedical pathologies in both male and female models in order to develop
effective therapeutics for both males and females. These studies provide invaluable evidence for
why muscle biologists must begin “talk[ing] about sex”.
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197
ii.

Appendix A.ii

198
iii.

Appendix A.iii

199
iv.

Appendix A.iv

200
v.

Appendix A.v

201
b. Protocols
i.

IMML Protocol – Hindlimb suspension.

Purpose: Construct cage for the modeling of disuse atrophy in mice
Cage Construction
Drill small holes throughout the length of the rubber stoppers (hole size will vary depending on
width of rod) . Slide the smaller rubber (3) stopper onto the smooth rod (1). Next put the swivel
eye pulley (4) on the smooth rod. Slide another small rubber stopper (3) onto the smooth rod. The
swivel eye pulley should be in between 2 rubber stoppers. Place 1 beam clamp (5) onto the side
of the cage. Put the end of the smooth rod through the beam clamp. Place the other beam clamp
onto the opposite side of the cage and slide the other end of the smooth rod through that beam
clamp. Orientate the beam clamps so that they are in the center of the cage and tighten both
beam clamps. Place the large rubber stoppers onto the ends of the smooth rod to prevent it from
moving. After cage is assembled add in chicken wire bottom to allow for mice to grip and move
about the cage.
Pieces required
Rat Cage (dimensions)
1. 3/16” smooth rod – Lowe’s Hillman
2. 2 #2 rubber stoppers – Lowe’s Hillman product number 881323 (13/16 X 5/8 X 1)
3. 2 #7 rubber stoppers – Low’s Hillman product number 881325 (1-7/16 X 1-3/16 X 1)
4. 1 Swivel eye pulley – Grainger product 1RCE6
5. 2 Beam clamps – Grainger product 6PFR4
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Tail suspension
Supplies Needed (pictures of supplies below) :
Supply

Supplier

Reorder Number

Tensoplast Tape

BSN Medical

02168-00

Benzoin Swabsticks

PDI Medical

S42450

Betadine Swabsticks

Purdue Products

67618-153-01

Fishing line

NA

NA

Fishing hooks

NA

NA

Scissors

NA

NA

Small Bungees

NA

NA

Water bottle for mice with lid

NA

NA

Pre-assembled cage(s) (see
above)

NA

NA

An old glove box to put
mouse in while wrapping tails

NA

NA

Hair dryer

NA

NA

Small ethanol wipes
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Tensoplast Tape

Small Bungees and a fishing hook

Betadine
Swabstick

Water bottle for mice
with lid

Fishing line

Benzoin Swabstick
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Protocol:
1. Weigh each mouse before wrapping to get baseline weight
2. Cut out tape for each mouse. Each mouse will require: (see Fig 1 & 2)
a. A large tail wrapping piece (~2in X ~3in)
b. A fishing hook piece→ make by pinching the middle of tape while leaving the ends
unpinched
c. Sticking tape (2 pieces)
Fig1
b
a

Fig2
B (different
angle)

c
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3. Place mouse in box, hold onto tail throughout the duration of the tail cleaning and
wrapping.
4. Open the ethanol wipes (1 wipe/mouse) and swabstick packs that will be used (1 stick can
be used for up to 2 mice)
5. Sterilize the mouse’s tail. First wipe the tail with an ethanol wipe. Then use the betadine
stick to further sterilize the tail. The entire tail should be covered.
6. Make the mouse tail sticky using the benzoin solution (should make the tail a yellowish
color). After coating the tail in a layer of benzoin, use the hair dryer (set to low) to dry the
benzoin on the tail (this helps make the tail more sticky). Repeat benzoin drying cycle 2-3
more times. The tail should feel slightly sticky. Because the tail needs to be held onto
throughout this, gloves may become extra sticky and may need to be replaced between
animals.
7. Begin the tail wrapping. The shorter edge of the large wrapping tape should run parallel
to the mouse tail. Be sure the tape is far enough from the anus to allow for pooping (about
Fig 3
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the length of a pinky nail between anus and beginning of tape).
8. Then place the hook piece parallel to the tail, ensuring the flat edges wrap around the tail.
9. Finally, use the anchoring tape to anchor the hook piece to the rest of the tail. See Fig 3
for example of how tail should be wrapped.
10. After the tail has been wrapped place animal back in cage. Wrap tails of all remaining
mice.
11. When ready to hindlimb unload, insert the fishing hook through the loop made in the tail
wrap; then place mouse in assembled cage.
12. Cut a piece of fishing line ~12-14in long
13. Thread the fishing line through both the hook and the pully. Begin to knot the strings and
tighten. As you tighten the knot/thread, the mouse’s hindlimbs will begin to rise. Raise the
mouse until it is at approximately 30-45 degree angle. Tighten the knot and cut the extra
thread. See Figure 4 for example of threading and tying. See Fig 5 for how mouse should
look.

Fig 4
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Fig 5

14. Add the water bottle to the cage. The water bottle generally holds best when it is about
half full of water. Using a bungee cord (the red and green ones tend to work best), attach
the bottle to the corner of the cage. Be sure to ensure that there is not excessive water
dripping from the bottle as this can flood the cage.
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NO
!

15. Weigh food and spread pellets throughout the cage. Do not put the pellets all in the same
place as mice will try to make a food mountain for their legs. Usually ~30 grams is
sufficient.
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ii.

Periodic Acid-Schiff Staining Protocol

Purpose: To stain histology sections for glycogen content.
Reagents Needed:
Reagent

Supplier

Catalog Number

Schiff Reagent (stored in 4
degree)

EMD Millipore

1090330500

Periodic Acid (solid)

VWR

JTT146-3

Chloroform*

VWR

BDH83627.400

Glacial Acetic Acid*

VWR

BDH3092-500MLP

Ethanol

VWR

BDH1158-4LP

Xylenes*

VWR

BDH1170-4LG

Permount Mounting Media

Fisher Scientific

SP15-500

* Highly dangerous chemicals, use appropriate personal protection (e.g. gloves, masks etc.)
Supplies Needed:
•

Slide jars

•

Slide holders

•

Slide holder dipper

•

Slides with tissue sections cut to 8 -10 um

•

Cover glass for slides

•

Clear nail polish

Solution Recipes:
Carroy’s Fixative (200 mL)
•

120 mL of Ethanol

•

60 mL of Chloroform

•

20 mL of Glacial Acetic Acid
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•

Mix solutions together, store in glass bottle
* Contains very dangerous chemicals, this solution should be mixed in the hood.

0.5% Periodic Acid Solution (200 mL)
•

1 gram of Periodic Acid

•

Dissolve in 200 mL of DH2O
* This solution should be made fresh for every stain

35% Ethanol (200 mL)
•

70 mL Ethanol

•

130 mL dH2O

•

Mix solutions together, store in glass bottle

50% Ethanol (200 mL)
•

100 mL Ethanol

•

100 mL dH2O

•

Mix solutions together, store in glass bottle

75% Ethanol (200 mL)
•

150 mL Ethanol

•

50 mL dH2O

•

Mix solutions together, store in glass bottle

Protocol
1. Take slides out of -80 degree freezer, allow to air dry 5-10min
2. Place slides in Carroy’s fixative for 10min
3. Rinse with H2O for ~2min (running tap water)
4. Place slides in 0.5% Periodic Acid solution for 10 min
5. Rinse with H2O ~3min (running tap water)
6. Place slides in Schiff reagent for 10 min
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7. Rinse with H2O ~3min (running tap water)
8. Rinse slides in Ethanol solutions (3-4 dips) starting with 35% Ethanol solution, then 50%
Ethanol Solution, then 75% Ethanol solution, then 100% Ethanol solution, then a
separate/different 100% Ethanol solution.
9. Rinse in Xylenes
10. Mount with ~10uL permount, a cover glass and clear nail polish on the corners of the
cover glass.

glycogen
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iii.

Myotube Diameter

Purpose: To measure Myotube diameter for in vitro experiments involving anabolic or catabolic
stimuli

1. Open NIS BR software (there are a few icons with NIS)
2. Select the correct Driver (default should be Nikon DS-U3) click “okay”

3.
4. Check the correct microscope is “talking” to the software.
a. Click “Acquire” from top menu bar, drop down menu will appear
b. Click “Select Nikon DS-U3”, a pop up will appear

c. From the pop up, choose the correct microscope (the epiflourescent scope is the
top option from the left column, the bright light scope is on the bottom).
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d. Click “ok”
5. Select the appropriate objective and/or filters from the top bar

6. With microscope on, click the “live” button
a pop up with the image should appear
7. To take a picture, click the “camera” button
8. To save the picture, click “save” from the “File”
drop down menu, another pop up will appear,
ensure the optics matches the objective you took
the photo (e.g. the picture was taken with the
10X, 40X or 100X objective)
9. Take as many pictures as necessary.
10. When ready to analyze myotube diameter reopen the images to be analyzed
11. If the “Annotations and Measurements” are not present, bring them up
a. Click “View” from top menu bar
b. From the drop down menu click “Analysis
Controls”
c. From the secondary drop down menu click
“Annotations and Measurements”
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12. Click “length” button for two points from Annotations and Measurements
13. Begin tracking diameters on myotubes (1-3 lines/tube depending if diameter changes
down the length of the tube). While
doing this the “Annotations and
Measurements” box will update with
measurements.

14. When you are done measuring for a particular
image/group, click the “export” button from the
“Annotations and Measurements” Box. This
will export the data to a new excel spread
sheet with the tab titled “length”
When ready to measure again, click “clear”
button on “Annotations and Measurements” box. A warning box will pop up, click “Yes”. Start
over as step 12 as needed.
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iv.

JC1 Staining Protocol

Purpose: A fluorescent dye used in live cells to measure mitochondrial membrane potential.
*Note: this stain needs to be completed at the end of the cell experiment.
More information can be found at: https://www.thermofisher.com
Reagents Needed:
Regent

Supplier

Catalog Number

JC1 dye

ThermoFisher

T3168

Fetal Bovine Serum

ThermoFisher

16000044

DMEM

ThermoFisher

11965092

Penicillin / Streptomycin

ThermoFisher

10378016

Cell Grade PBS

ThermoFisher

10010031

DMSO (Dimethyl sulfoxide)

Alfa Aesar

43998

Growth Media

Equipment/Supplies Needed:
• Fluorescent Microscope with FITC and TRITC Filters and associated computer software
•

Cells (myoblasts or myotubes) to stain

•

Falcon Tubes (for mixing JC1 solution)

•

Pipettes (p1000, p10 and p200)

•

Serological Pipettes (for pipetting ~10mL)

Protocol A: Rehydrating JC1
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1. JC1 comes as a powdered dye, rehydrate in DMSO at a concentration of 1-5mg/mL.
Tubes should be protected from light at this point. There are currently tubes in the -20
cell culture fridge pre-diluted to 1mg/mL.
Protocol B: Calculate concentration of JC1 per well and make JC1 solution (these should be
made in the cell culture hood to ensure sterility)
1. The optimal JC1 concentration can vary, but typically 1ug/mL is sufficient for myoblasts
and 2 ug/mL for myotubes.
Example Calculation for cell experiment with 6 wells of myoblasts (need 6mL of solution
)
1ug/mL * 1mL/well= 1ug/well
From a solution that is already diluted to 1mg/ml → 1uL of JC1 / mL of DMEM
For a 6 well plate: 6 uL diluted in 6 mL of Growth media mixed in a falcon tube (for
myotubes double the amount of JC1)
Protocol C: Cell Experiment
1. To begin experiment, warm cell media for ~20 min in water bath
2. Open cell hood and place cells in cell culture hood (keeping in mind sterile technique)
3. Removed current media on cells
4. Rinse cells 3 times using sterile cell culture grade PBS
5. Pipette 1mL of JC1 solution into each well
6. Incubate 30 min
7. Remove JC1 solution
8. Rinse cells 3 times with sterile cell culture grade PBS
9. Image Cells
Protocol D: Imaging Cells
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1. Open Nikon software
2. Select the correct Driver (default should be Nikon DS-U3) click “okay”

3. Check the correct microscope is “talking” to the software.
a. Click “Acquire”
from top menu
bar, drop
down menu will
appear
b. Click “Select
Nikon DS-U3”,
a pop up will appear
c. From the pop up, choose the correct microscope (the epiflourescent scope is the
top option from the left column, the bright light scope is on the bottom).
d. Click “ok”
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4. Select the appropriate objective and/or filters from the top bar (FITC and TRITC)

5. With microscope on, click the “live” button

a pop up with the image should

appear
6. To take a picture, click the “camera” button
7. After taking a picture in either the FITC or TRITC filters switch to ensure each picture
has a FITC and TRITC version.
8. To overlay the pictures, pull the FITC or TRITC tab from either image (bottom left of
image) pull and place on the other image. This should result in an image with both FITC
and TRITC images overlaid on each other.
9. To save the picture, click “save” from the “File” drop down menu, another pop up will
appear, ensure the optics matches the objective you took the photo (e.g. the picture was
taken with the 10X, 40X or 100X objective) BE SURE TO SAVE THE FILE AS AN .ND2
FILE !!! IF IT IS NOT SAVED AS AN .ND2 FILE IT CANNOT BE ANALYZED!!
10. Take as many pictures as necessary.

Below are example images from both myoblasts and myotubes. Greater Red/Green
ratios are indicative of greater mitochondrial polarization. Red/Green ratios can be
calculated using MitoTimer analysis protocol.
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